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SUMMARY
The eye is a complex organ involved in the input pathway of circadian entrainment. 
Non-image forming, irradiance-dependent responses mediated by the human eye 
include synchronisation of the circadian axis and suppression of pineal melatonin 
production. Light exposure at night causes an acute suppression of melatonin levels. 
In humans the photoreceptors mediating this and other circadian responses to light 
are not known. Identification of a photopigment requires an investigation of the 
spectral sensitivity (action spectrum) of the light-dependent response.
The aim of this thesis was to construct an action spectrum for light-induced 
melatonin suppression. Melatonin suppression was quantified in 22 volunteers in 215 
light exposure trials using monochromatic light (30 minute pulse administered at 
circadian time (CT) 16-18) of different wavelengths (Imax 424, 456, 472, 496, 520 
and 548 nm) and irradiances (0.7-65.0 pW/cm^). At each wavelength, suppression of 
plasma melatonin increased with increasing irradiance. Irradiance response curves 
(IRCs) were fitted and the generated half-maximal responses (IR50) were corrected 
for lens filtering and used to construct an action spectrum.
The resulting action spectrum showed unique short-wavelength sensitivity very 
different to the classical scotopic and photopic visual systems. The lack of fit 
(R^<0.1) of the action spectrum with the published rod and cone absorption spectra 
precluded these photoreceptors firom having a major role. Cryptochromes 1 and 2 
also had a poor fit to the data. Fitting a series of Dartnall nomograms generated for 
rhodopsin-based photopigments showed that rhodopsin templates between Imax 457- 
462 nm fit the lens corrected data well (R^ > 0.73). Of these, the best fit was to the 
rhodopsin template with Xmax 459 nm (R^ = 0.74).
The findings demonstrate that short wavelength light is the most effective at 
suppressing melatonin and this sensitivity is clearly not matched to the spectral 
sensitivities of the known retinal photoreceptors that mediate human vision. As well 
as providing evidence for a novel photoreceptor system in humans, these data will 
allow optimisation of the spectral composition of light needed to manipulate the 
circadian axis.
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CHAPTER 1 
INTRODUCTION
21
1.1 CIRCADIAN RHYTHMS
Biological rhythms in man are endogenously generated with different periodicities. 
The most predominant biological rhythms are circadian (about a day). The function 
of the circadian system is to provide temporal organisation to physiological 
processes. Circadian rhythms are generated by a central pacemaker in the 
hypothalamic suprachiasmatic nuclei (SCN). Although these rhythms are 
endogenously generated they are entrained by the light dark cycle. In the absence of 
a light/dark cycle and all other time cues, circadian rhythms persist but free run with 
different periodicities. In humans free running rhythms usually have a period longer 
than 24 h. As the natural day is 24 h these rhythms are synchronised to 24 h daily by 
the environmental light/dark cycle and the exact period of the rhythms is set by 
environmental events.
Light is the major zeitgeher responsible for the entrainment of circadian rhythms. 
Environmental light entrains SCN activity to the 24 h day by acting on retinal 
photoreceptors from which a signal is transmitted to the SCN via the 
retinohypothalamic tract (RHT). This photic entrainment pathway is anatomically 
distinct from that responsible for vision. However, the photoreceptors responsible for 
circadian resetting and entrainment remain unknown.
This persistence of rhythmic oscillations of hormones, activity, and sleep/wake cycle 
is indicative of an internal rhythm generating clock. It is important that this clock be 
entrained with environmental conditions so that the correct biological response 
occurs at the correct time of day and year. There are three essential components of 
the circadian system, an input pathway to entrain the rhythm that is generated by a 
central pacemaker and output pathways for expression of the rhythms (Figure 1.1).
Light via the eye is the major entrainment pathway and removal of the eye leads to a 
loss of all rhythmicity in mammals (Nelson and Zucker, 1981; Foster and Provencio, 
1991) and humans (Lockley et al., 1998). The SCN contains the circadian oscillator, 
which is entrained by the daily resetting of the pacemaker according to the light/dark 
cycle. As well as entraining circadian rhythms such as the melatonin rhythm to the
22
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24 h day, light also has acute effects such as suppression of nocturnal plasma 
melatonin and alerting effects.
This chapter will review the effects of light on the circadian system in humans in 
particular on the melatonin rhythm. The melatonin rhythm is used as a marker of the 
phase of the internal biological clock and factors affecting this rhythm will be 
described. The light-induced suppression of melatonin has been used as a model to 
investigate the integrity of the light input pathway. In the present study it has been 
used to determine indirectly the spectral characteristics of the photoreceptors 
mediating the light induced suppression of melatonin, by construction of an action 
spectrum to this light dependent response. The study of circadian photoreception has 
recently been an area of intense interest. The discovery of novel photoreceptors and 
their functional characterisation will also be reviewed.
1.2 THE COMPONENTS OF THE CIRCADIAN SYSTEM
1.2.1 The Eye
The human eye is capable of detecting photic stimuli in the visible range of 
wavelengths (400-750 nm). The eye can detect brightness and wavelength. Light 
enters the eye via the pupil, which is surrounded by the iris. The iris contains both 
circular and radial smooth muscles, which alter the amount of light entering the 
pupil. The cornea focuses the light initially, and then on entering the eye the lens in 
the posterior chamber focuses the light on the retina. The retina contains the 
photoreceptive cells, the rods and cones. The photoreceptors transform the light into 
neural signals and the output signal is carried to the brain by the axons of retinal 
ganglion cells, which travel via the optic nerve to the visual areas of the brain.
This visual pathway also carries information to other areas of the brain, which are not 
involved in vision. The RHT carries light information to the SCN in the 
hypothalamus. Another retinal projection is to the pretectum. This pathway activates 
neurones in the Edinger-Westphal nucleus and this causes pupillary constriction and 
the pupillary light reflex.
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1.2.2 The Suprachiasmatic Nucleus
The SCN is composed of a pair of ovoid nuclei located in the anterior hypothalamus 
sitting just above the optic chiasm and lateral to the third ventricle in all mammals 
(Klein et al., 1991). It is the SCN, which is capable of independent oscillations and 
circadian rhythmicity. Evidence for this is provided by SCN lesioning experiments 
that result in a loss of circadian rhythmicity in the corticosterone rhythm (Moore and 
Eichler, 1972) activity and drinking rhythms (Stephan and Zucker, 1972) and the N- 
acetyltransferase (NAT) activity rhythm (Moore and Klein, 1974) and consequently 
the melatonin production rhythm.
Rhythmicity is controlled primarily by the SCN, as neonatal ablation of the SCN 
permanently abolishes circadian rhythms in drinking behaviour and locomotor 
activity in rats, suggesting that no other areas of the brain take over its function 
(Mosko and Moore, 1979). These animals are still active, produce hormones and eat 
and drink but they lose their temporal organisation.
Further evidence for the involvement of the SCN in circadian rhythm generation is 
provided by experiments in which embryonic SCN were transplanted to SCN 
lesioned rats resulting in a restoration of rhythmicity (Lehman et al., 1987). Later 
experiments of this kind illustrated that the host takes on the period characteristics of 
the donor (Ralph et al., 1990).
The first experiments to demonstrate that the SCN itself can express circadian 
rhythms showed higher metabolic activity during the light phase of the light/dark 
cycle by measuring the uptake of "^^ C labelled 2-deoxyglucose in vivo (Schwartz and 
Gainer, 1977). The higher metabolic activity during the day is consistent with studies 
by Inouye and Kawamura (1979). They demonstrated that SCN neurones generated 
circadian rhythms of electrical activity in situ which are higher during the light phase 
and also persist under constant light conditions.
Experiments that provide the most convincing evidence to date that the SCN has a 
self-contained oscillator demonstrated that the SCN generates rhythmic oscillations
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in neural activity even when cells are isolated in vitro (Green and Gillette, 1982; 
Groos and Henricks, 1982). Electrical stimulation of these SCN cells produces phase 
shifts in the rhythmic oscillations (Rusak and Groos, 1982).
Entrainment of the SCN to the environment is mediated by light input, however, 
melatonin may also play a role in entrainment of the SCN as melatonin receptors are 
found on the SCN (Vanecek et al., 1987) and melatonin administered at the time of 
activity onset in rats entrains free-running locomotor activity rhythms (Redman et al., 
1983).
1.2.3 Neural Connections Between the Eye and the SCN
Light information is conveyed to the SCN from the retina directly via a 
monosynaptic pathway, the RHT (Hendrickson, 1972; Moore and Lenn, 1972), that 
arises from a distinct set of retinal ganglion cells (Pickard, 1980). The retinal 
ganglion cells also project to the intergeniculate leaflet (IGL) of the thalamus 
(Pickard, 1985) that provides a secondary indirect visual input to the SCN via the 
geniculohypothalamic tract (GHT) (Swanson et al., 1974). These pathways enable 
entrainment of the SCN to changes in the environmental light dark cycle.
Destruction of all visual pathways leaving the optic chiasm results in the loss of 
vision and visual reflexes but not of circadian entrainment. The RHT appears to be 
sufficient to maintain entrainment (Klein and Moore, 1979). Bilateral transection of 
the RHT leads to a loss in entrainment and rhythms free run with a periodicity close 
to 24 hours (Johnson et al., 1988). This provides evidence that light transmitted via 
the eyes and through the RHT is the most important zeitgeber for entraining SCN 
rhythmicity. Evidence suggests that the IGL-GHT system serves to integrate photic 
and non-photic inputs into the SCN (Moore and Card, 1994).
The neurotransmitters involved in the transfer of light information along these 
pathways are excitatory amino acids such as glutamate. Glutamate is present in 
presynaptic terminals of the SCN (Van den Pol, 1991) and N-methyl-D-aspartate
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NMDA glutamate receptors have also been identified in the SCN (Meeker et al., 
1994). It is proposed that light induces clock resetting by glutamate, NMDA receptor 
activation, and stimulation of nitric oxide synthase and then by the movement of 
nitric oxide (Ding et al., 1997). Studies in hamsters show that injections of glutamate 
into the SCN phase shift the wheel running activity (Meyer et al., 1988) and 
antagonists of the NMDA receptors block the light-induced phase shifting response 
(Colwell et al., 1990). These studies support glutamate as being a prime candidate for 
the transmission of light information to the SCN.
The IGL is characterised by a population of neuropeptide Y (NPY) containing 
neurones that project to the SCN and all IGL neurones also contain y-aminobutyric 
acid (GABA) (Moore and Speh, 1993).
1.2.4 The Pineal Gland
The pineal gland is a pine shaped structure that is unpaired and found associated with 
the third ventricle in the brain. It plays a secretory role in mammals, secreting the 
hormone melatonin at night. In non-mammalian species the pineal gland is also 
photoreceptive. The main function of the pineal is to transduce day/night information 
to the rest of the body through its hormone melatonin which is secreted during the 
dark phase, secretion being inhibited during the day. The pineal receives a rich blood 
supply and this ensures the melatonin signal rapidly reaches the whole body.
1.2.5 Neural Projections Between the SCN and Pineal
Light information from the retina via the RHT entrains the SCN that in turn regulates 
the production of pineal melatonin. A neural pathway from the SCN via the 
paraventricular nuclei (PVN) of the hypothalamus and spinal cord (Berk and 
Finklestein, 1981) transmits information to the preganglionic sympathetic neurones 
of the upper thoracic intermediolateral cell columns which project to the superior 
cervical ganglia (SCG) (Klein et al., 1991). Postganglionic adrenergic fibres 
innervate the pineal gland and regulate melatonin production (Bowers and Zigmoun, 
1980). These postganglionic sympathetic nerves release noradrenaline (NA), which
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stimulates melatonin synthesis via adrenergic receptors (primarily pi) on the pineal 
gland.
1.2.6 Production and Control of Melatonin Synthesis
The rhythm of melatonin secretion varies between individuals but generally the onset 
of secretion occurs around 21.00 h in entrained conditions. Melatonin levels peak at 
approximately 2.00-3.00 h and fall back down to daytime levels between 8.00-9.00 h 
(Arendt, 1995). The melatonin rhythm persists in the absence of all time cues 
(Arendt, 1991) and is highly reproducible (i.e. the shape, period and amplitude) 
within subjects (Broadway et al., 1987). Although the rhythm is reproducible within 
an individual there is a large inter-individual variation in the amplitude and timing of 
melatonin secretion.
The pineal gland releases melatonin directly into the blood stream and the melatonin 
profile in the blood is considered a good reflection of melatonin synthesis (Wilkinson 
et al., 1977; Illnerovâ et al., 1978). Melatonin is also highly lipophlic so it is rapidly 
distributed through all tissues.
NA stimulates melatonin production and it is released in high concentrations during 
the night and low concentrations during the day (Brownstein and Axelrod, 1974). 
NA acts on the and P adrenergic receptors, p-receptor stimulation results in an 
increase in cAMP concentrations (Strada, 1972), an increase in NAT activity (Klein 
and Berg, 1970), and a resulting increase in melatonin synthesis (Axelrod and Kopin, 
1969). Activation of the receptors potentiates p adrenergic mediated increases in 
cAMP (Sugden et al., 1985; Vanecek et al., 1985) and NAT (Klein et al., 1983).
The first step in melatonin synthesis is the uptake of tryptophan from the circulation 
to the pineal gland (Figure 1.2). Tryptophan is then transformed to 5- 
hydroxytryptophan by tryptophan-5-hydroxylase. 5 -hydroxytryptophan is
decarboxylated to 5-hydroxtryptamine by aromatic amino-acid decarboxylase 
(Axelrod, 1974). N-acetylation of 5-hydroxtryptamine by N-acetyltransferase (NAT) 
completes the next step. It is this enzyme, which is rate limiting in melatonin
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synthesis (Klein and Weller, 1970). 0-methylation of N-acetylserotonin by 
hydroxyindoley-O-methyltransferase (HIOMT) is the final stage and results in N- 
acetyl-5-methoxytryptamine (melatonin) (Axelrod and Weissbach, 1960) (Figure 
1.3).
Melatonin is metabolised in the liver. 6-hydroxylation is cytochrome P450 mediated 
and results in 6-hydroxymelatonin, which is then conjugated with sulphate or 
glucuronide. In humans the major metabolite is 6-sulphatoxymelatonin (aMT6s). 
This metabolite provides a measurable output firom the pineal. The aMT6s rhythm is 
a good index of plasma melatonin secretion in terms of timing and amplitude and 
thus provides a non-invasive method of assessing pineal function (Bojkowski et al., 
1987b).
1.3. THE EFFECT OF LIGHT ON THE CIRCADIAN SYSTEM IN HUMANS
Environmental light entrains circadian rhythms to the 24-h day. Ocular light 
exposure affects the circadian axis in at least two ways: it alters the phase of 
circadian rhythms (Arendt & Broadway, 1986; Czeisler et al., 1986) and acutely 
suppresses the nocturnal production of pineal melatonin (Lewy et al., 1980) in a 
dose-dependent manner (Bojkowski et al., 1987a; Brainard et al., 1988; McIntyre et 
al., 1989a; Boivin et al., 1996; Zeitzer et al., 2000).
1.3.1 Acute Effects of Light
Light has acute effects on circadian regulation that include suppression of pineal 
melatonin production (Lewy et al. 1980; Bojkowski et al. 1987a; McIntyre et al. 
1989a; Brainard et al. 1997; Zeitzer et al. 2000), elevation of core body temperature 
(Badia et al. 1991; Dijk et al., 1991) and enhanced alertness (Badia et al. 1991; 
Cajochen et al. 2000).
As it is well established that ocular light regulates the production of pineal melatonin 
(via the SCN), the melatonin suppression test can be used to test various components
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of the retina-RHT-SCN- pineal pathway and the plasma melatonin rhythm is a good 
marker of the human circadian pacemaker (Arendt, 1995).
Figure 1.2 Melatonin synthesis
■ PINEALOCYTE 
Tryptophan
i
5-Hydroxytryptophan
i
5-Hydroxytrptamine
N-acetyltransferase (NAT)
N-Acetylserotonin
!
I Hydroxy-O-methyltranferase(HIOMT)
N-Acetyl-5-methoxytryptamine
Figure 1.3 The structure of N-Acetyl-S-methoxytryptamine (melatonin)
CH2- CH2-NH-C- CH.3
H
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There are numerous studies investigating the effects of ocular light on night-time 
melatonin production in animals and humans. The major difference between the 
animal and human work is that humans require higher irradiances of light to suppress 
melatonin than most animals. The following section will review mainly the human 
experiments.
1.3.1.1 Light-induced suppression of melatonin in humans
A number of factors are important when evaluating light-induced melatonin 
suppression studies, these include light intensity, timing, duration, wavelength as 
well as the procedure of light exposure (i.e. looking directly at the light or 
occasionally glancing at the light) and the area of retinal exposure to light (e.g. 
central/peripheral exposure and constricted/dilated pupils). These factors need to be 
taken into consideration when examining the various studies and differences in these 
factors may explain the variation in results between studies.
In the 1980’s after the discovery that bright light (2,500 lux) could suppress 
melatonin in humans (Lewy et al., 1980) there were many studies investigating the 
effects of factors such as dose, wavelength and timing of exposure. These early 
studies are summarised in Table 1.1. However, as these studies were not similar in 
terms of the time of light exposure, the dose of light and the procedure of exposure, it 
is very difficult to compare them directly. For this reason differences in results were 
observed.
Overall the degree of melatonin suppression increases with increasing intensity and 
200-500 lux (room lighting) is capable of significantly suppressing melatonin. 
However the only way to compare results firom a number of laboratories is to 
compare the absolute dose of light in terms of the number of photons delivered. Even 
when comparing photon density of the light other factors such as the protocol (e.g. 
the method and timing of light exposure) and the method of calculation of 
suppression (e.g. comparison of melatonin values before and after light exposure as 
opposed to comparing to baseline control levels) can still lead to discrepancies 
between results.
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Other factors that also need to be evaluated are the nature of the subjects studied 
(e.g. gender and age differences).
When using the light-induced suppression of melatonin as a model to investigate the 
retina-RHT-SCN-pineal pathway it is important to ensure that the timing, duration 
and method of light exposure are standardised. Factors known to influence the shape 
and timing of the melatonin rhythm should also be controlled so as to measure 
accurately the true effect of the light, as opposed to effects of other confounding 
variables.
1.3.1.1.1 The effects of light intensity
Lewy and colleagues (1980) were the first to report that light suppressed melatonin at 
night using bright white light of 2500 lux. Attempts were made before this to 
suppress melatonin with light in humans using 100-800 lux but all failed to show 
suppression. It was therefore believed that only bright light of 2500 lux could 
suppress melatonin in humans as in the same study 500 lux did not significantly 
suppress melatonin.
Later studies demonstrated melatonin suppression using lower intensities of light 
(300 lux) when compared to dark controls (Bojkowski et al., 1987a). These 
differences may be explained by the differences in the protocol between the two 
studies (Table 1.1). The timing of the light exposure, how the light was given and the 
duration of the light treatment were different between the two studies.
The dose response relationship to white light in humans was confirmed by McIntyre 
et al. (1989a). This study investigated the level of suppression caused at different 
intensities of light (3000, 1000, 900, 350 and 200 lux). The corresponding values of 
suppression measured were 71%, 67%, 44%, 38%, and 16%, respectively. Brainard 
and colleagues conducted further dose-response studies where subjects were exposed 
to five irradiances of monochromatic light (Imax 509 nm) for 60 mins between 2.00 
and 3.00 h. This study showed that light of much lower irradiances was capable of 
suppressing melatonin. However, it should be noted that this study used subjects with
33
dilated pupils. They showed that the threshold for melatonin suppression with 
monochromatic Imax 509 nm lights was between 5-17 lux, which is much less than 
was initially thought.
1.3.1.1.2 The effects of timing of light exposure
The timing of light with respect to clock time and circadian phase can influence the 
degree of melatonin suppression. McIntyre and colleagues (1989b) showed that light 
given during the dark period between 4.00 and 5.00 h significantly suppressed 
melatonin synthesis by 70%. This was more than the suppression (60%) observed for 
light administered between 0.00 and 1.00 h. This observation has been confirmed by 
other studies (Owen and Arendt, 1992). These small differences in melatonin 
suppression may be explained by the fact that melatonin production is generally 
decreasing between 4.00-5.00 h. Therefore the increase in suppression seen at this 
time may also be as a result of the natural decrease in melatonin production. Studies 
in rats have shown that NAT activity does not recover to the same extent after light 
treatment in the latter half of the night as compared to treatment in the early half of 
the night (Ilnerova et al., 1988). It is important that light is always given at the same 
circadian time, preferably on the rising curve of melatonin, to prevent an 
overestimation of suppression. Melatonin values on light exposure night should also 
be compared to a baseline night, preferably the melatonin profile the night before, in 
order to determine the actual changes occurring in the rhythm at the time of light 
exposure.
1.3.1.1.3 The effects of wavelength of light
The first study examining the effect of different wavelengths of light on melatonin 
suppression in humans was conducted by Brainard et al. (1985). Six wavelengths of 
monochromatic light (Imax 448, 476, 509, 542, 574, and 604 nm) were tested. Equal 
quanta of light caused percentage melatonin suppression of 12%, 26%, 64%, 20%, 
16% and 8% at 448, 476, 509, 542, 574, 604 nm of light, respectively. This single 
dose of light was given at 2.00-3.00 h. As there was no baseline night it was not
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known at which circadian phase the light treatment was given and there may have 
been differences in the subjects’ melatonin phase between 2.00-3.00 h.
Although this study showed that wavelengths of 509 nm produced maximum 
suppression of melatonin, because it was a single dose study it does not allow us to 
conclude which photopigment is responsible for mediating light-induced suppression 
of melatonin in humans. Dose response relationships between light irradiance and the 
suppression of melatonin need to be performed at each wavelength so that irradiance 
response curves (IRCs) can be established and an action spectrum constructed from 
these. One dose response curve at Imax 509nm was performed. The threshold for the 
response was between 0.3 and 1.6 pW/cm^ (2.76 x lG^^-1.47 x 10^^photons/cm^) at 
509 nm in maximally dilated pupils (Brainard et al., 1988).
Similar studies in Syrian hamsters found broad band blue (435 -500 nm) fluorescent 
light to be the most effective at suppressing pineal melatonin followed by green light 
(510-550 nm), yellow (558-636 nm), UV (339-371 nm) and red light (653-668 nm) 
was the least effective (Brainard et al., 1984). The authors suggested that the retinal 
photopigments responsible for mediating the pineal glands response to light might be 
either rhodopsin or another blue sensitive chromophore (Brainard et al., 1984). This 
study was in contrast to the human study in which green light (509 nm) was shown to 
be the more effective than the shorter wavelength light (448 nm and 476 nm).
Studies investigating the effect of wavelength on the light-induced suppression of 
melatonin in rats also showed green light (Imax 520 nm) to be more effective than red 
light (Xmax 660 nm) when given at midnight (Honma et al., 1992). However, there 
was no difference in suppression between the two wavelengths when light was given 
at 4.00 h.
Further studies in humans showed green and blue light (light of a higher colour 
temperature, 6500 K) of 1000 lux to inhibit the fall in core body temperature and the 
rise in nocturnal melatonin more strongly then 1000 lux of red light (light of a lower 
colour temperature 3000K) (Morita et al., 1995). However, morning (4.00 -9.00 h) 
irradiation with 1000 lux of red, green and blue light did not show the same effects as
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those observed with the nocturnal stimuli (21.00-2.00 h) (Morita et al., 1997). Green 
and blue light of 2500 lux at 4.00-5.00 h showed the same effects as nocturnal blue 
and green light of 1000 lux at 21.00-2.00 h.
In order to determine accurately the effect of a particular wavelength of light on 
melatonin suppression it is important to use narrow band monochromatic light so as 
to precisely determine the most effective wavelength. Preliminary studies reported at 
a conference during the PhD work have shown shorter wavelength light in the blue 
and green region (X a^x 480 nm) of the spectrum to be more effective than longer 
wavelengths in the red region (Imax 555 nm) of the spectrum (Brainard et al., 1999).
1.3.1.1.4 The effect of pupil size
Pupil dilation leads to the diameter of the pupil approximately doubling in size 
compared to freely constricting pupils. A study by Gaddy and colleagues (Gaddy et 
al., 1993) investigated the effects of pupil dilation on melatonin suppression. The 
effect of 100 lux white light was tested in subjects with pupil dilation and those 
without. Light was given for 90 minutes between 2.00-3.30 h and plasma melatonin 
was compared before and after light exposure to calculate melatonin suppression. 
Pupils were significantly larger 7.3 mm (compared to 3.3 mm without dilatation) 
with pupil dilator administration. Pupil dilation significantly increased low level 
white light-induced melatonin suppression (45% suppression) over that elicited with 
freely constricting pupils (25% suppression).
The use of pupil dilators is also important in order to standardise the amount of light 
over a maximum area in the eye. Higher doses of light cause pupil constriction and 
this response will reduce the amount of light entering the eye and so in effect, 
although the actual light dose has been increased by a set amount, the light received 
by the retina may not have increased proportionately. Pupil dilation also avoids inter 
individual differences in pupillary reflexes.
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1.3.1.1.5 The effect of age
Nathan and colleagues (1999a) investigated the effect of age on the light-induced 
suppression of melatonin by investigating the effect of 200 lux of light in three age 
groups. Light administered for 1 h from 0.00-1.00 h was tested in subjects aged 18- 
25 y, 26-35 years and over 36 years. There were no significant differences between 
the percentage melatonin suppression between the different age groups. This study 
also compared 18-35 y olds with those over 36 y and although endogenous melatonin 
concentrations may start decreasing at this age, the changes in melatonin suppression 
due to changes in lens density may only happen at a later age. This study also 
examined the relationship between pre-light melatonin values and the % melatonin 
suppression in order to assess if  low concentrations of melatonin before light 
treatment caused a reduced light-induced suppression of melatonin. The study 
showed no correlation between pre-light melatonin values and % melatonin 
suppression.
1.3.1.1.6 Menstrual cycle and gender effects on light-induced suppression of 
melatonin
The effect of gender on the light-induced suppression of melatonin is a controversial 
issue. Initially studies by Monteleone and colleagues (1995) tested the effect of 2,000 
lux of light given for 2 h between 2.00-4.00 h to 6 men and 6 women matched for 
age, mean body weight and height. The light treatment was given in the follicular 
phase (day 6-9 from menses) of the menstrual cycle in women and a control dark 
conditions showed plasma melatonin values reach a maximum between 2.00-4.00 h 
in both men and women. This study found melatonin suppression to be 40% greater 
in women than men suggesting that there are gender differences in the light-induced 
suppression of melatonin and that women may be more sensitive to the light-induced 
suppression of melatonin compared to men when suppression is calculated by 
comparison to before light values and also to a dark controlled baseline.
Nathan and co-workers (2000) compared a dose-response curve to the light-induced 
suppression of melatonin in 5 men and 5 women between 19-28 y. Five light
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intensities (0, 200, 500, 1,000, 3,000 lux) were given for 1 h on one night between 
0.00-1.00 h for five consecutive weeks. As expected they found the mean melatonin 
suppression to be dose-dependent (0%, 17%, 40%, 56% and 74%). However no 
significant gender differences were found at any of the five light intensities studied.
It is difficult to compare these studies as the study by Monteleone et al. (1995) tested 
bright light (2,000 lux) at a particular phase of the menstrual cycle in women and 
compared this to men whereas the Nathan et al. (1999b) study compared the effect of 
various doses of light throughout the menstrual cycle as the study was run for five 
consecutive weeks. The difficulty in comparing melatonin suppression between men 
and women is that in women the stage of the menstrual cycle may affect the 
melatonin profile and the light-induced suppression of melatonin. Nathan et al. 
(1997) in an earlier study had examined this. The effect of 200 lux on the light- 
induced suppression of melatonin was investigated in females in the three stages of 
their menstrual cycles. Light of 200 lux was administered to each subject for 1 h 
between 0.00-1.00 h on three occasions, menstrual phase (day 1-5), follicular phase 
(day 6-13) and luteal phase (day 15-28). No significant differences in percentage 
melatonin suppression were observed across the different stages of the menstrual 
cycle.
1.3.1.1.7 Season-dependent effects on light-induced suppression of melatonin.
One of the factors that may contribute to variability in melatonin suppression is 
seasonal effects. The effect of season on melatonin suppression was first studied by 
Thompson et al. (1990) in which no seasonal variation in light-induced melatonin 
suppression was reported.
A study by Owen and Arendt (1992) used the large variations in the natural light in 
the Antarctica to evaluate the timing and seasonal effects of light. In Antarctica the 
sun does not rise for 3 months in the winter and the sun does not set for 3 months in 
the summer. There is consequently a drastic change in light levels with maximum 
light during the winter not exceeding 500 lux and light levels in the summer are
100,000 lux. Two intensities of light were tested, 290-310 lux and 2,100-2,300 lux at
38
2.00 h and 6.00 h in both summer and winter. Both bright and dim light significantly 
suppressed plasma melatonin at both times during the winter. In both cases melatonin 
suppression at was greater at 6.00 h than at 2.00 h. In summer only bright light 
suppressed plasma melatonin significantly and this occurred at 2.00 h only.
These two studies show conflicting results. As although both studied the effect of 
season the actual changes in light levels were very different. Also in the Antarctica 
study subjects had long-term adaptation to the unusual light conditions prior to the 
study.
1.3.1.2 Effects of light on core body temperature
Core body temperature like melatonin exhibits an endogenous circadian rhythm and 
has been used as a marker of circadian phase. Endogenous/exogenous melatonin may 
have an acute effect on CBT via melatonin receptors in the hypothalamus (Cagnacci 
et al., 1992). At night, as melatonin begins to rise, there is a concurrent fall in body 
temperature. As plasma melatonin peaks body temperature reaches its trough about 
1-2 h later between 5.00-6.00 h.
At the same time as suppressing melatonin, light has been shown to raise core body 
temperature. Dijk et al. (1991) demonstrated that after 3 hours of bright light 
exposure (2500 lux) core body temperature was significantly higher than the control 
condition of dim light (6 lux). This light-induced elevation in body temperature 
persisted into the sleep episode and an increase in sleep latency was observed but no 
changes in sleep architecture. Elevation of body temperature was not observed in 
subjects that had their eyes covered during the light exposure period. Alternating 
bright (5,000-10,000 lux) and dim light (50 lux) showed increases and decreases in 
body temperature respectively, whereas continuous bright light exposure showed a 
small increase in temperature compared to continuous dim light that showed a sharp 
decrease in body temperature (Badia et al, 1991). However, no changes were 
observed in daytime body temperature values following light exposure. The increase 
in core body temperature with bright light exposure is seen only during the period of
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melatonin secretion and is thought to be due to the suppression of melatonin (Myers 
and Badia, 1993).
1.3.1.3 Effects of Light on Alertness and Performance
Performance decreases through the night and this decrement can be improved by the 
administration of light. Badia and co-workers showed that performance tasks under 
bright light conditions (5,000 lux) were better than under dim light conditions (50 
lux). However, there was a time of night decrement in both groups. Ninety minutes 
of bright light (5,000-10,000 lux) alternated with 90 minutes of dim light (50 lux) for 
9 hours during the night improved performance. A Study by Campbell and Dawson
(1990) compared lower light intensities (10-20, 100 and 1000 lux) administered 
during a stimulated 8 h night shift. Subjects exposed to 1000 lux maintained a 
significantly higher level of alertness than those receiving the lower light intensities.
A study investigating the effects of different doses of light on melatonin suppression, 
temperature and alertness at 4 intensities (50, 500, 1000 and 5000 lux) showed no 
differences in alertness when light was administered prior to melatonin onset (Myers 
and Badia, 1993). However, temperature and self-reported alertness was higher with 
500,1000 and 5,000 lux compared to 50 lux. No significant differences between 500,
1,000 and 5,000 lux were observed. Although these data are not suggestive of a dose 
response curve for alertness, the authors suggested that the threshold for the light- 
induced increase in alertness was 500 lux (Myers and Badia, 1993).
Deacon and Arendt (1996) developed an experimental model mimicking 
phase shifts that could occur in time-zone or shift work transitions. Subjects were 
exposed to 9 h pulses of bright light 1,200 lux for 3 days starting at 18.00 h on the 
first day, 21.00 h on day 2 and 24.00 h on day 3 each period was followed by 8 h 
darkness. During the gradual delay shift, a delay in the rhythms of urinary 6- 
sulphatoxymelatonin (aMT6s), temperature and alertness was seen. However, there 
were no detrimental effects on behavioural variables. Sleep patterns, temperature 
amplitude, aMT6s acrophase, alertness, and performance took at least 5 days to 
return to baseline patterns after the shift.
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More recently the dose response relationship for light intensity and ocular and 
electroencephalographic correlates of human alertness have been examined by 
Cajochen and colleagues (2000). Subjects were exposed to white light ranging from
3-9100 lux for 6.5 hours in the early subjective night. Alertness was assessed by a 
reduction in slow eye movements, a reduction in EEC activity and a reduction in self 
reported sleepiness. The alerting response to white light was positively correlated 
with melatonin suppression. Light of 100 lux produced half the maximum alerting 
responses.
The alerting effects of different durations of light exposure have also been 
investigated (Hoppen et al., 2001a). The effects of bright white light (10,000 lux) 
between 1.00-5.00 h for 1, 2, and 4 h were compared to a placebo no light condition. 
Performance and alertness measures were significantly improved during light 
exposure when compared to placebo but at least 2 h of light (2.00-4.00 h) was 
necessary to improve performance consistently.
Increases in alertness using bright light are particularly important for those people 
working night shifts as sleep related accidents are common during these shifts 
(Âkerstedt, 1988). Dawson and Campbell (1991) investigated the effects of a single
4-hour pulse of bright light (6000 lux) on the first night of night shift (0.00-4.00 h). 
Results from this study indicated that this single exposure to bright light was 
effective at reducing sleep and alertness problems associated with the transition to 
night shift work.
1.3.2 Phase Shifting Effects of Light
Light is capable of phase shifting and entraining circadian rhythms. Early studies of 
phase shifting involved entrainment regimes of one week or more of a light/dark 
cycle and measurement of rhythms before and after this light/dark cycle intervention. 
Bright light given in this manner has been shown to be effective at resetting the 
biological clock (Czeisler et al., 1986). One of these early studies showed that CBT 
and sleep propensity could be shifted by bright light exposure in the morning (Dijk et
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al., 1987). Further studies on the melatonin profile showed it could be shifted after 6 
weeks of periodic bright light exposure to men living in Antarctica (Broadway et al., 
1987). This ability of light to entrain circadian rhythms relies on the ability of light to 
produce regular small phase shifts of the circadian clock and its rhythms. Suitably 
timed light has been shown to produce phase shifts of melatonin, core body 
temperature and cortisol rhythms (Shanahan and Czeisler, 1991).
The relationship between the timing of the light pulse and the resulting phase shift is 
known as a phase response curve. This was demonstrated in humans by Minors et al.
(1991). The effect of a single pulse of light given at different times on core body 
temperature was assessed. It was shown that light given in the early hours of the 
morning after the temperature minimum (4.00-5.00 h) produced phase advances 
whereas light given in the evening before the temperature minimum produced phase 
delays. This study used three conditions: 1) entrained subjects were exposed to 3 h 
pulses of 5000 lux light, 2) free-running subjects were exposed to light of 9000 lux 
light and 3) free running subjects were exposed to 3 cycles of 9000 lux of light. The 
largest phase shifts were observed with the free running subjects exposed for three 
cycles. Similar phase response curves have been demonstrated by Van Cauter et al. 
(1994) who used melatonin and thyrotropin as circadian rhythm markers and Honma 
and Honma (1998) who used the free running sleep wake cycle as a circadian 
marker. Much larger phase shifts were observed by Czeisler and colleagues (1989) 
who generated a phase response curve to light using subjects kept in temporal 
isolation under constant routine conditions which abolish any masking effects by 
sleep, activity, postural changes, social contact, food and light/dark cycle. Subjects 
maintained a regular sleep/wake cycle and were exposed to 5 hours of bright light 
(7,000-12,000 lux) for 3 consecutive days. Phase shifts in the temperature rhythm of 
up to 12 hours were measured with the greatest shifts occurring around the time of 
the temperature minimum with the subjects in darkness and asleep during the day.
In constant routine conditions, the magnitude and direction of phase shifts of plasma 
melatonin, cortisol, thyrotropin and core body temperature rhythms are similar 
(Czeisler et al., 1989; Shanahan and Czeisler, 1991; van Cauter et al., 1994). These 
response curves allow the prediction of the effects of light treatment during different
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times of the day and night. However, in the normal environment the circadian system 
is influenced by the daily alterations in light/dark cycles and phase response curves 
generated using free running or temporal isolation states may not apply in the normal 
environment.
Many studies have shown the effect of multiple pulses of light for 3-6 hours on phase 
shifting the melatonin rhythm over a shorter time interval of 3-4 days (Dijk et al., 
1989; Shananhan and Czeisler, 1991; Illnerova et al., 1993; Deacon and Arendt, 
1994). The only disadvantage of these multiple pulsing studies is that if  the first light 
pulse phase shifts the measured rhythm the next pulse on day 2 will affect the rhythm 
at a shifted circadian phase. This may be the reason for the large phase shifts 
observed in multiple pulse studies. Evidence that a single pulse (3-6 h) of bright light 
can phase shift the melatonin rhythm has been provided by a number of studies 
(Kennaway et al., 1987; Buresovâ et al., 1991; Van Cauter et al., 1994; Hashimoto et 
al., 1996).
1.3.2.1 Effect of light intensity
Early studies investigating the ability of light to phase shift the melatonin rhythm 
used only a bright light stimulus. However, more recently a dose response curve for 
the phase shifting effects of light has been published (Boivin et al., 1996). The 
m i n i m u m  amount of light capable of causing phase shifts in the body temperature 
rhythms was reported to he 180 lux (administered for 5 hours for 3 consecutive days 
centred 1.5 hours after the temperature minimum). As light intensity increased the 
amount of phase shifting also increased. Room light of intensity 150-500 lux has also 
been shown to be effective at phase shifting rhythms in humans (Waterhouse et al., 
1998). More recently a study investigating the sensitivity of the phase shifting 
response using the endogenous melatonin rhythm as a marker predicted maximal 
phase shifts to occur at 550 lux and a half-maximal response at 120 lux using a 6.5 h 
light stimulus administered during the early biological night (Zeitzer et al., 2000)
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1.3.2.2 Effect of wavelength
The spectral characteristics of the photoreceptor(s) mediating the phase shifting 
effect of light on circadian rhythms have not been fully studied in humans. A study 
conducted by Takahashi et al., (1984) in the hamster found that monochromatic light 
in the region of 476 nm and 515 nm was more effective at causing phase shifts of 
free-running locomotor activity than light of 574 nm. At each wavelength the amount 
of phase shift increased with light intensity. It was concluded that the spectral 
sensitivity of the photoreceptors causing a phase shift has a maximum near the 500 
rim range, similar to the rhodopsin-based photopigment. Since the hamster retina is 
composed predominantly of rod photoreceptors and as the spectral sensitivity of the 
phase shift response was similar to that of rhodopsin it was concluded that the rod 
photoreceptors might be responsible. If this is the case the authors concluded that 
there must be a mechanism for reducing the sensitivity of the circadian system to 
photic input because the threshold for phase shifting is much higher than the 
threshold for rod vision.
A recent study in humans by Zeitzer et al., (1997) suggested that the cone pigments 
may mediate circadian effects of light. Broad-hand red light in the 600 nm region 
below the sensitivity of rod vision (scotopic) but sufficient for cone vision (photopic) 
induced phase shifts that were comparable to those seen with ordinary white room 
light (180 lux). However, although phase shifts were induced by light of longer 
wavelengths (600 nm) no comparison was made with a scotopic light stimulus. This 
study does not suggest which of the cone photoreceptors may be involved. To 
decipher which photoreceptors mediate circadian phase shifting accurately, an action 
spectrum for phase shifting needs to be constructed using a number of 
monochromatic light sources at a range of irradiances.
1.3.3 Comparison of Light Required for Melatonin Suppression Versus Phase 
Shifting
As described earlier light has two effects on the melatonin rhythm. It can acutely 
suppress night-time melatonin production and phase shift the endogenous rhythm. It
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was initially thought that the light required to suppress melatonin production in 
humans (>500 lux) was not able to phase shift the melatonin rhythm (Hashimoto et 
al., 1996). However more recent studies show light of 180 lux is capable of phase 
shifting rhythms in humans (Boivin et al., 1996).
A direct dose-response comparison of light required to suppress and phase shift the 
melatonin rhythm was performed by Nelson and Takahashi (1991a) in the golden 
hamster. Monochromatic light of Xrmx 503 nm for 300 sec (previously shown to be 
the most effective at phase shifting the hamster clock) at different irradiances was 
studied. Using the four parameter logistic equation the half saturation constant for 
melatonin suppression was 1.3 x 10^  ^ photons/cm2/sec compared with 3.1 x 10^' 
photons/cm2/sec for phase shifting. The slopes of the two best-fit curves were also 
significantly different (0.6 for phase shifting and 1.1 for melatonin suppression). 
These two responses to light were thus shown to be significantly different, melatonin 
suppression being 25 times more sensitive than the phase shifting response. Whether 
this is because the two responses are mediated by two distinct photoreceptors or one 
photoreceptor that conveys the light differently (i.e. more photoreceptor integration 
for the pineal response making it more sensitive than the phase shifting response) 
still needs to be characterised in both animals and humans.
However, more recent studies in humans illustrate similar illuminance-response 
curves for circadian phase shifting and melatonin suppression with saturation of the 
phase shifting response predicted at 550 lux and saturation of the melatonin 
suppression response at 200 lux (Zeitzer et al., 2000). The authors suggested that a 
common photoreceptor pathway may mediate both responses. At present there is no 
firm evidence to contradict the assumption that the photoreceptor system is the same 
for circadian phase shifting and acute melatonin suppression responses to light. On 
the contrary, anatomical studies (Klein et al., 1979; Moore et al., 1995; Larsen et al., 
1998) support the existence of a common neural circuit (type III retinal ganglion 
cells-RHT-SCN) for circadian resetting and melatonin suppression.
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1.4. CIRCADIAN PHOTORECEPTION
In both animals and humans more light is required to suppress night-time melatonin 
production and to phase shift circadian rhythms than is required for vision so it can 
be assumed that the circadian and visual pathways have different thresholds.
In order to evaluate which retinal photoreceptors may be mediating circadian 
photoreception an action spectrum for a measurable light-induced response 
(melatonin suppression or phase shifting) needs to be constructed. The resultant 
spectral sensitivity curve will allow determination of the photoreceptor(s) mediating 
the response. Another method of identifying the photoreceptors is to eliminate 
known photoreceptors (e.g. using transgenic mice models) and measure any changes 
in the light-induced effect compared to controls (Lucas et al., 1999a; Freedman et al., 
1999; Lucas et al., 1999c). However, this model only works if there is no redundancy 
of function. Recent reports suggesting redundancy (Selby et al., 2000) have brought 
this model system into question.
1.4.1 The Structure of the Retina
The retina is composed of ten layers (Berne and Levy, 1993). Layer one is the 
pigment epithelium layer that is just inside the choroid. The pigment epithelium 
absorbs stray light through projections in the photoreceptive layer to prevent light 
scatter between photoreceptors. These projections also maintain contact between 
layers one and two. This layer also plays a role in the removal of outer segments of 
rods (which are continuously shed) by phagocytosis. The pigment cells also convert 
all-trans retinal to 11-cis-retinal and transport this back to the photoreceptors.
Layer 2 consists of the inner and outer segments of the photoreceptors. Layer 3 is 
known as the outer limiting membrane and consists of retinal glial cells known as 
Mueller cells. These cells maintain the geometry of the retina. The outer ends of 
these cells form tight junctions with the inner segments of the photoreceptors. The 
nuclei of the photoreceptors form the outer nuclear layer, which is layer 4. Layer 5 is 
the outer plexiform layer, which is the synaptic zone between photoreceptors and
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retinal intemeurones, including bipolar and horizontal cells. The inner nuclear layer 
makes up layer 6 and this contains cell bodies and nuclei of bipolar, horizontal, 
amacrine and interplexiform cells. The inner plexiform layer is layer 7 of the retina 
and this is also another synaptic zone. Layer 8 is the ganglion cell layer. The 
ganglion cells transmit the output information to the brain. The optic fibre layer is 
layer 9 and is formed by the axons of the ganglion cells that leave the eye via the 
optic nerve. The innermost layer of the retina, layer 10 is the inner limiting 
membrane and this is formed by projections of the Mueller cells.
1.4.2 The Photoreceptors
There are four types of photoreceptors used in human vision. The rods provide night­
time or scotopic vision as they are effective at low light levels. The three classes of 
cones provide daytime or photopic vision, as they are effective at moderate to high 
light levels. The three cone photoreceptors have different spectral sensitivities and 
provide the basis of trichromatic colour vision. Each photoreceptor comprises a cell 
body and an inner (site of photopigment synthesis) and outer segment.
1.4.2.1 The rod photoreceptors
Rods are structurally different to cones as rods have a longer outer segment that 
contains stacks of freely floating membrane disks rich in rhodopsin. The outer 
segments of cones are not as long as those of the rods the disk membranes are 
infoldings of the membrane and these contain the cone photopigments.
1.4.2.2 The cone photoreceptors
There are three types of cones that differ in their opsins and have distinct spectral 
sensitivities. These cones are characterised by the wavelengths of light they absorb 
and include the blue cones (short wavelength cones, S-cones), green cones (middle 
wavelength cones, M-cones) and red cones (long wavelength cones, L-cones). The 
differences in absorption account for colour vision.
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The absorbance spectra of the three cones overlap considerably but each have a 
wavelength of maximum absorbance (Imax) in different parts of the visible spectrum 
(Figure 1.4). S-cones absorb at 419 nm, M-cones at 531 nm and L-cones at 558 nm 
(Dartnall et al., 1983). However, estimates in vivo show that the A^ ax are shifted to 
longer wavelengths 440, 545 and 565 nm respectively for S-, M- and L-cones by the 
transmission properties of the yellowish crystalline lens and the macular pigment of 
the eye (Stockman et al., 1999) (Figure 1.4). The lens transmission data and the 
macular transmission data are shown in Figure 1.5.
There are approximately 50,000 cones in the central fovea (Wandell, 1995). This 
explains why we cannot see very dim sources when looking straight at them. There is 
also a blind spot in the retina at the optic disk where the ganglion cell axons exit the 
retina.
The cone mosaic of the rod-free foveal region is shown in Figure 1.6. From this it is 
evident that red cones (62%) are the most abundant followed by the green cones 
(31%) and blue cones (7%). The spacing between the blue cones and red and green 
cones is also larger (Curcio et al., 1991).
The S-cones are rare in the retina. The S-cones account for approximately 7% of the 
cone population (Curcio et al., 1991). The photopigment in the S-cones is also 
significantly different from the L and M cones. The S-cone absorbs much shorter 
wavelengths than the L- and M- cones which absorb photons in similar areas of the 
spectrum. It is also suspected that there are no S-cones in the central fovea and that 
they are distributed further out (Curcio et al., 1991). The L and M cones are found in 
the fovea in a ratio of 2:1 (Cicerone and Neger, 1989).
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1.4.2.3 Differences between rod and cone photoreceptors
There are about 100 million rods in the retina and about 5 million cones in the retina 
(Curcio et ah, 1990). The cones are found in the fovea and there are no rods in this 
area. The peripheral retina is rod dominated.
Rods contain much more photopigment than cones and this accounts for their greater 
sensitivity to light. For example one photon of light can elicit a rod response and 
therefore rods have a relatively low threshold of light detection and so operate best 
under low light levels (scotopic vision Figure 1.7). However, rods only contain a 
single photopigment and can therefore not detect different wavelengths. Cones are 
not as sensitive to light as rods and work best under daylight conditions. Rods do not 
provide well defined images as they share a single neurone connection to the brain 
nor do they contribute to colour vision. Cones in contrast provide a high visual acuity 
and are responsible for colour vision.
Scotopic (Xmax = 505 nm) and photopic (Imax = 555 nm) luminous efficiency curves 
(Fig. 1.7) developed from human psychophysical experiments reveal the sensitivity 
of the rods (scotopic curve) and the cumulative sensitivity of the three cones (long, 
medium and short wavelength sensitive) (photopic curve), which are used for vision.
1.4.2.4 Colour blindness
There are genetic defects that result in the loss of one or more cone mechanisms. 
Loss of one cone results in dichromats and if it is the long wavelength cone this is 
known as Protanopia. M-cone loss is known as deuteranopia and loss of the S-cone is 
known as tritanopia. People who have lost two or more of the cones are known as 
monochromats.
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1.4.3 Evidence for Ocular Circadian Photoreceptors
The retina-RHT-SCN-pineal pathway mediates light-induced melatonin suppression. 
Melatonin suppression cannot be induced in blindfolded or bilaterally enucleated 
subjects (Czeisler et al. 1995) or by extraocular light exposure (Lockley et a l 1998). 
In addition, only non-24 h (free running) circadian rhythms are observed in 
bilaterally enucleated people (Lockley et a l 1997; Skene et a l  1999), suggesting 
that, in the absence of eyes, the light-dark cycle is unable to synchronise the human 
circadian clock to the 24-h day.
1.4.3.1 Extraocular light
For many years the eyes were considered the transducer of light information for the 
regulation of the circadian system as bilateral enucleation in animals and man results 
in free running circadian rhythms. However, this dogma was recently challenged by 
a study investigating the effect of extraocular light of 13,000 lux administered to the 
popliteal region (behind the knee). In healthy volunteers light to this region was 
shown to cause phase shift of the core body temperature rhythm and salivary 
melatonin rhythm (Campbell and Murphy, 1998). The light was administered using 
bili-blankets, which emit a cool green light, for 3 h from 0.00-3.OOh. The timing of 
the light pulse and the magnitude of phase shifts measured were the same as those for 
a classic phase response curve to ocular light.
However, experiments investigating the effect of extraocular light on the suppression 
of melatonin show that popliteal light exposure does not suppress nocturnal 
melatonin compared to ocular exposure. Two studies administering light to the back 
of the knee for 3 h, one using white light (Lockley et al., 1998) and the other using 
bili-blankets (Hébert et al., 1999), showed that no suppression of melatonin occurred.
Studies investigating the phase shifting and melatonin suppression effects of light in 
hamsters also showed that extraocular light does not phase shift or suppress 
melatonin secretion (Yamazaki et al., 1999; Meijer et al., 1999).
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The effect of extraocular light on circadian phase shifting and entrainment remains 
unclear and requires further investigation in humans. To date the inability of 
researchers to confirm the findings of Campbell and Murphy casts doubt on a role for 
extraocular light exposure.
1.4.3.2 Effects of light on melatonin suppression in the visually impaired
A study by Czeisler et al. (1995) evaluated whether the same entrainment 
mechanisms were in place in the blind as in sighted individuals. The study 
investigated whether the eyes convey sufficient photic information to suppress 
melatonin secretion even though the subjects had complete loss of visual function. 
Melatonin suppression (69%) was only observed in three of the eleven totally blind 
subjects given 6,000-13,700 lux and was comparable with the sighted control group 
(66% melatonin suppression). The three blind individuals in which melatonin 
suppression was observed had intact eyes and were retested with their eyes covered 
during exposure. No suppression of melatonin was observed. This finding indicated 
that it was the eyes that were mediating the effect of light. Compared to the other 
eight blind individuals, who did not show light-induced suppression of plasma 
melatonin, these three individuals had no difficulties sleeping and maintained 
apparent entrainment to the 24 h day. Whereas the other eight subjects (5 with intact 
eyes and 3 with no eyes) had a history of insomnia and four of them had a 
temperature rhythm that was not entrained to the 24 h day. This work suggests that 
the non-image forming system that mediates melatonin suppression may remain 
intact in some blind people. More recent studies by Lockley et al. (2000) examining 
the effects of light on melatonin suppression in the blind found no light-induced 
suppression of melatonin in any of the blind subjects studied.
The absence of photic input into the circadian system results in circadian rhythm 
abnormalities (Smith et al., 1981; Sack et al., 1992). The secretion of melatonin has 
been shown to free-run in some blind subjects and also may be abnormally entrained 
to the 24 h day (Lewy and Newsome, 1983; Lockley et al., 1997). Blind subjects 
with light perception have normally entrained rhythms whereas those with no 
conscious light perception tend to have abnormal circadian rhythms. O f these, those
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subjects that are bilaterally enucleated have free running circadian rhythms (Lockley 
et al., 1997; Skene et al., 1999)
1.4.3.3 Localisation of receptors
In order to localise the receptors responsible for circadian responses to light such as 
the acute suppression of melatonin, studies have investigated the effects of light 
given to different parts of the retina. The area of the retina most effective at 
producing the light-induced suppression of melatonin is an important factor for 
determining light treatments for patients with seasonal affective disorder as well as 
for determining the nature of the photoreceptors that may be involved.
The central retina is the area of the fovea that contains the cone photoreceptors 
(Section 1.4.1.2.4). The rods are found in the periphery (Wandell, 1995). Bearing this 
in mind it is important to know if light administered to the peripheral retina is more 
effective at suppressing melatonin than centrally positioned light. Alder and co­
workers (1992) examined the effect of 1000 lux of white light given for 2 h between 
1.00-3.00 h on two occasions. Exposing the central visual field 5 fi*om the centre of 
gaze was one of the conditions. The second condition was exposing the peripheral 
visual field 60° lateral to the direction of gaze. No significant differences in 
melatonin suppression for the two conditions were observed. The authors concluded 
that the light administered to the peripheral retina might be as effective as centrally 
positioned light.
More recently two groups have investigated the light-induced suppression of 
melatonin following exposure of the lateral and nasal retina (Visser et al., 1999) as 
well as illumination of the upper and lower visual fields (Lasko et al., 1999). Visser 
and colleagues investigated the effects of 500 lux of light given for 2 h (1.30-3.30 h) 
to the lower lateral retina, upper lateral retina, lower nasal retina and the upper nasal 
retina. The respective percentage melatonin suppression was 33%, 22%, 63% and 
59%. There was a significant difference between exposure to the lateral and nasal 
parts of the retina. However, no significant differences were observed between the 
upper and lower parts of either the nasal or lateral parts of the retina. In contrast.
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Lasko et al. (1999) found differences between the suppression of melatonin using 
500 lux for 2 h (1.30-3.30 h) to the lower and upper visual field. They found 
suppression to be greater when light was administered to the upper visual field 
(lower retina) as opposed to the lower visual field. These studies suggest that the 
most sensitive areas of the retina are the nasal retina and lower retina (upper visual 
field).
A study by Brainard et al. (1997) investigated the effect of light given to one eye 
compared with light given to two eyes. Greater melatonin suppression was observed 
when the same intensity of light was administered to both eyes. Constant versus 
intermittent light exposure was also examined by Brainard and co-workers (1998). 
Equal photon density pulses of continuous light exposure appeared to be more 
effective than intermittent light exposure.
1.4.3.4 Visual versus circadian responses to light.
For many years it was thought that the eyes were required for vision alone. However, 
in mammals removal of the eyes blocks all circadian responses to light. The eyes are 
thus necessary for circadian entrainment as well as vision. The pathway that this light 
information travels out of the eye is different to vision. The retinohypothalamic tract 
carries this light information to the SON. These are two functionally distinct 
pathways, one an image forming and the other a non-image forming pathway. 
Lesioning and viral tract tracing studies show that both neural pathways are 
completely independent of each other (Klein et al., 1991). Totally blind humans as 
well as blind animals such as the blind mole rat have no vision but may have 
entrained circadian rhythms (Lockley et al., 1997; David-Gray et al., 1998).
Although it is known that light via ocular photoreceptors and the RHT is used to 
entrain the circadian clock it is not yet known if  the receptors used for vision are the 
same as those used for circadian entrainment. Animal knockout experiments have 
attempted to address this issue (see Section 1.4.3.1.1).
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As well as the neural pathways being distinct, the actual responses to light are also 
different. For example, the circadian system has a much higher intensity threshold 
response to light compared to vision. Visual responses cover 12 log units of 
irradiance whereas circadian responses cover about 3 log units of irradiance (Foster 
and Provencio, 1999).
1.4.4 Candidate Circadian Photoreceptors
Although we know that light entrains circadian rhythms via the retina-RHT-SCN 
pathway, it is still not known which photoreceptors are responsible for circadian 
entrainment by light. There is the possibility that unique retinal photoreceptors 
“circadian photoreceptors” exist which are separate from the visual system and are 
responsible for mediating the effects, of light on the circadian clock. On the other 
hand the photoreceptors responsible for vision i.e. rods and cones (Section 1.4.1 and 
1.4.2) may be responsible for mediating the circadian effects of light. Although it is 
not known which of these photoreceptors mediate circadian entrainment in humans 
much work has been done in animals to investigate which photoreceptors may be 
involved.
1.4.4.1 Involvement of rod and cone photoreceptors
The involvement of the classical photoreceptors used for vision (rods and cones) in 
non-image forming responses has been an area of intensive study in the field of 
circadian biology. Initial studies in animals and humans showed circadian responses 
have a similar spectral sensitivity to the rod photoreceptors (Takahashi et al., 1984) 
and M-cones (Brainard et al., 1985; Morita et al., 1995; David-Gray et al., 1998). 
However, studies in rodless/coneless transgenic mice show that these animals still 
preserve their ability to phase shift (Freedman et al., 1999) and acutely suppress 
melatonin rhythms to light (Lucas et al., 1999c).
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1.4.4.1.1 Animals studies
Initial studies on the spectral sensitivity of phase shifting in golden hamsters showed 
peak spectral sensitivity around 500 nm (Takahashi et al,, 1984). The shape of the 
action spectrum very closely resembled that of the rod photoreceptors. However, this 
rod-mediated response for circadian photoreception was different to the rod-mediated 
visual response in that the threshold for phase shifting free running locomotor 
rhythms was high. The intensity-duration reciprocity relationship was maintained for 
stimuli of long durations of up to 45 minutes (Takahashi et al., 1984).
Other experiments in favour of either a rod or cone mediated mechanism are studies 
on the blind mole rat (spalax ehrinherghi), a subterranean mammal with regressed 
subcutaneous eyes incapable of image formation (Cooper et al., 1993). Even with 
total loss of image forming vision these mammals still have circadian responses to 
light and the retina has been shown to have functional rod and cone photopigments 
(David-Gray et al., 1998). The spalax shows an irradiance-dependent response to 
light for circadian entrainment with the M-cones mediating these effects (David- 
Gray et al., 1999).
More recent evidence from electrophysiological studies in rats suggests that the SCN 
receives inputs from both rod and cone photoreceptors (Aggelopoulos and Meissl,
2000). Input under dark adaptation was primarily from rods (92%) and the action 
spectrum had a maximal sensitivity at 505 nm. Whereas under light adaptation 77% 
of neurones responded from cone input. The action spectrum confirmed the spectral 
sensitivity of this response to match that of the M-cones with the main peak at 510 
nm and a significant secondary peak in the near UV region. These findings therefore 
show that rods and cones stimulate neurones in the rat SCN but these actions are 
state dependent.
Experiments using knockout animals to investigate the role of rod photoreceptors in 
circadian responses involved studies on retinally degenerate (rd/rd) mice that 
gradually lose all photoreceptors. These experiments show that rd/rd mice have a 
similar circadian response to light as that of mice with normal healthy retinae (Foster
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and Provencio, 1991). Rodless mice were given 15 minutes of monochromatic light 
(1 max 515 nm) at CT 16 (4 hours after activity onset) at various intensities to phase 
shift locomotor activity. Despite the loss of visual responses these mice showed 
phase shifting responses to light similar to those seen in control mice suggesting that 
the rod photoreceptors are not solely responsible for circadian photoreception in 
these animals.
Spectral sensitivity studies on these rd/rd mice using different wavelengths of light 
(459, 480, 499, 516, 539, 578 and 600 nm) indicated that M-cones (Imax 511 nm) 
may regulate circadian rhythmicity. In addition, UV light elicited phase shifts in 
rd/rd and wild type (+/+) mice were not significantly different suggesting the 
involvement of short wavelength cones (UV-cones lmax= 359 nm) (Provencio et al., 
1995).
Further studies investigating the effect of light on melatonin suppression in rd/rd 
mice as well as in mice with no photoreceptor outer segments {rds) (outer segments 
of rods and cones contain visual pigments and the inner segments contain metabolic 
machinery) showed no significant difference between light-induced melatonin 
suppression between the wild type and the two mice mutants (Lucas et al., 1999a). 
The authors concluded that circadian photoreception may be mediated by a very 
small number of rod or cone cells without outer segments or alternatively a novel 
class of photoreceptors within the retina.
More recent studies by this group have used rodless/coneless {rd/rd/cl) mice that 
have no functional rod or cone photoreceptors. Studies have shown that there was no 
significant difference in the suppression of melatonin by a 15 minute pulse of Imax 
509 nm light in mutants compared to wild type (Lucas et al., 1999c). The phase 
shifting effect of light has also been examined in mice without rods or cones (rdta/cl) 
(rdta undergo specific ablation of all rods early in development). A 15 min pulse of 
Xmax 509 nm light produced phase shifts that were not significantly different to those 
observed in wild type mice. As the {rdta/cl) mutants had no rods or green cones and 
very few UV cones it was concluded that none of these functional photoreceptors 
that are used for vision are involved in circadian regulation (Freedman et al., 1999).
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From these data there appears to be no requirement of rod or cone photoreceptors in 
the transduction of photic information, implying that novel photoreceptors may be 
involved in circadian photoreception.
In the Freedman et al. (1999) study it was reported that at high light irradiances 
phase shifts were significantly enhanced in rdta/cl mice compared to wild type 
animals. This finding, that irradiance detection may be enhanced in mutants, is 
supported by a recent study in which rd mice were given a 1 h pulse of light at night 
which decreased locomotor activity. Rodless mice showed a greater decrease in 
activity at 2 lux of light compared to wild type animals. In addition the rd mice 
exposed to dim light showed no changes in activity compared to wild type mice in 
which activity increases with dim light (Mrosovsky et al., 2000). This finding 
suggests that irradiance detection may be enhanced in mutant mice. One reason for 
this may be that in normal mice the pupillary reflex alters the amount of light 
entering the retina at high light intensities whereas rd/rd mice do not have this reflex. 
This phenomenon was tested by atropine treatment (pupil dilator) of normal mice. 
However, no differences were observed between the treated and untreated wild type 
mice (Foster and Provencio, 1991). Another explanation is that irradiance detection 
could be enhanced by the absence of image forming vision (Mrosovsky et al., 2000).
Although these animal studies have suggested rod and cone photoreceptors are not 
required for circadian photoreception identification of the photoreceptors mediating 
circadian responses to light has not occurred. The first study to positively 
characterise a non-rod, non-cone ocular photoreceptor in mice shows that a 
rhodopsin based photopigment of maximum sensitivity at 479 nm mediates the 
pupillary light reflex in rodless/coneless mice (Lucas et al., 2001). Rodless/coneless 
mice have been shown to have a robust pupillary reflex to light but of reduced 
sensitivity compared to wild type mice. Rodless/coneless mice and the wild types 
were tested at 10 monochromatic wavelengths of light between 421 and 625 nm 
using between 4 and 10 irradiances and an action spectrum constructed. The results 
show that the green and UV-cones mediate pupillary responses to light in wild type 
mice. A rhodopsin-based photopigment with a Àmax 479 best fitted the 
rodless/coneless data suggesting the involvement of a novel photoreceptor mediating
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the pupillary reflex in Rodless/coneless mice. As innervation of the olivary pretectal 
nucleus (OPN), which is involved in pupilloconstriction, involves the same retinal 
ganglion cells that innervate the SCN (Foster and Provencio, 1991), the current 
results suggest that the mouse circadian system may also use this novel 
photoreceptor.
1.4.4.1.2 Human studies
Defining the role of rod or cone photoreceptors in human circadian vision has not 
been investigated to the same extent as in animals. The only studies similar to the 
knockout studies in mice (Section 1.4.3.1.1) are those involving assessment of the 
effects of light in colour blind subjects lacking green or red cones.
A study by Ruberg et al. (1996) investigated the effects of light on melatonin 
suppression in red-green deficient individuals. Two separate experiments were 
conducted. One investigated the effects of white light (200 lux for 90 minutes) 
between 2.00-3.30 h. The second experiment investigated the effects of broadband 
green light (Xmax 509 nm) for 30 minutes between 0.30-1.00 h. Both studies showed 
that the suppression of melatonin was not significantly different in colour-blind 
individuals compared to controls. The authors therefore concluded that trichromatic 
vision was not necessary for the light- induced suppression of melatonin. Further 
work is required to investigate the role of the S-cone photoreceptor in the regulation 
of circadian rhythms by studying subjects with tritanopia.
More recently two human studies have compared the visual response with the light- 
induced suppression of melatonin (Brainard et al., 2001a; Rea et al., 2001). Photopic 
(1 max 555nm) and scotopic (X max 505nm) light was administered. Brainard and 
colleagues (2001a) investigated monochromatic light at the maximum sensitivities of 
photopic (X max 555nm) and scotopic {X max 505nm) illuminance. A dose response 
curve at X max 505nm (scotopic sensitivity) was constructed and compared to a single 
dose of 555 nm light (photopic sensitivity) at an equal photon dose. Comparing equal 
photon doses at 505 nm and 555 nm revealed that the 505 nm was significantly more 
effective at inducing melatonin suppression than the 555 nm light. The authors
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concluded from this that melatonin suppression could therefore not be mediated by 
the three cone photopic system. Although this study shows that the three cone system 
is unlikely to mediate melatonin suppression it cannot rule out that the effect of light 
on melatonin suppression may be mediated by a single cone or a combination of rods 
and cones. The only way to truly elucidate the identification of the photoreceptors 
mediating melatonin suppression is to construct an action spectrum. This will allow 
determination of the spectral sensitivity of the response thereby allowing 
characterisation of the underlying photoreceptors.
A further study by Rea et al. (2001) suggested that melatonin suppression may be 
mediated by the scotopic visual system. The approach of this group was different to 
the Brainard study in that monochromatic light was not used. Instead four lighting 
conditions using two light sources (one scotopic and one photopic based) of different 
spectral power distributions were tested in five subjects. The results show that when 
melatonin suppression is plotted as a function of photopic illuminance, it does not 
predict melatonin suppression well (fits of R^ = 0.35). On the other hand plotting 
melatonin suppression against scotopic illuminace improved the fits (R^ = 0.91). This 
finding suggested that the photopic luminous efficiency function may not be 
primarily responsible for melatonin suppression in humans. These data suggest a 
scotopic rod based system may be responsible for melatonin regulation. However, 
the authors did not rule out a novel photoreceptor or a complex combination of 
receptors mediating melatonin suppression that may have similar sensitivities to 
scotopic vision.
In summary at present there is no consensus as to whether the rods and cones are 
primarily involved.
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1.4.4.2 Novel photoreceptors
1.4.4.2.1 Opsin based photoreceptors
Animal studies showing that neither rods nor cones are needed to mediate light- 
induced suppression of melatonin have led to the suggestion of novel photoreceptors 
mediating circadian responses. A novel photoreceptor VA opsin was discovered in 
salmon (Soni et al., 1997). VA opsin has been shown to form a functional 
photopigment and therefore suggests that photoreception is not just restricted to rods 
and cones in salmon. VA opsin absorbs maximally at 451 nm and the presence of 
VA opsin in the eye (in amacrine and horizontal cells) as well as the pineal gland 
suggests it may mediate the effects of light on circadian rhythms.
Since this report other novel photoreceptors have been described that may be 
involved in circadian regulation (review von Schantz et al., 2000). These include 
pinopsin (Okano et al., 1994), which is found in the chicken pineal gland and is 
sensitive to blue light (Xmax = 470 nm), encephalopsin (Blackshaw et al., 1999) which 
is found in various areas of the brain but not in the eye and so its role in circadian 
photoreception remains unlikely and peropsin (Sun et al., 1997) which is found in the 
retinal pigment epithelium of humans and its function remains unknown. Retinal- 
binding G protein-coupled receptor (RGR) (Hao and Fung et al., 1999) absorbs blue 
light (Xmax = 470 nm) and is found in the retinal pigment epithelium and Müller cells 
and therefore signalling to the ganglion cells maybe difficult. It also uses the 
chromophore all-^ra«5-retinal rather than ll-cw-retinal. Melanopsin is located in 
dermal melanophores o f Xenopus laevis (Provencio et al., 1998) and more recently 
has been localised in the inner retina of humans (Provencio et al., 2000). Melanopsin 
is found in the horizontal and amacrine cells indicating it may be of functional 
significance. These cells may also be directly photosensitive. The inner retinal 
localisation suggests it is not used in image formation but may mediate non-image 
forming effects of light such as circadian entrainment and acute melatonin 
suppression. The anatomical distribution of these melanopsin containing cells is also 
similar to those ganglion cells known to project from the retina to the SCN
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(Provencio et al., 2000). However, neither the spectral absorbance nor the function of 
melanopsin is presently known.
1.4.4.2.2 Non-opsin based photoreceptors
Cyptochromes are vitamin B2-based blue light photoreceptors, which have also been, 
identified in humans (Hsu et al., 1996) In mice the discovery of cryptochromes 
(CRYl and CRY2) in a subset of retinal ganglion cells and inner nuclear layers has 
led to the suggestion that these photopigments may be involved in circadian 
photoreception (Miyamoto and Sancar, 1998). Mice lacking cry2 have a lower 
sensitivity to light induction of mammalian period genes (mPerl) in the SCN 
(Thresher et al., 1998). These mutants also have a period 1 h longer than normal 
mice and have high amplitude phase shifts at CT 17. This study suggested that CRY 
2 may modulate circadian responses to light as well as have a role in circadian 
photoreception (Thresher et al., 1998). A number of studies have also shown that the 
cry genes are required for normal expression of circadian rhythms. For example 
knockout mice lacking cryptochrome are arrhythmic or ultradian in continuous 
darkness suggesting that the cryptochromes are an essential component of the 
circadian clock (Van der Horst et al., 1999; Kume et al., 1999; Griffen et al., 1999).
More recently knockout experiments have shown that cryptochromes may play a role 
in circadian photoreception. Studies show that dcry mutations in the fruit fly 
'Drosophila block arrhythmicity observed under constant light conditions (Emery et 
al., 2000). Studies have investigated three groups of knockout mice lacking either 
classical photoreceptors or cryptochromes or both classical photoreceptors and 
cryptochromes (triple mutants that do synchronise locomotor activity and 
behavioural responses to light (masking responses) (Selby et al., 2000). Mice lacking 
either cryptochromes or the classical photoreceptors exhibited rhythmic locomotor 
responses to 10 and 100 lux daily, whereas the triple mutant mice were arrhythmic 
under both light/dark cycles and complete darkness. The light induction of c-fos in 
the SCN was also markedly reduced in the triple mutant mice. This finding suggests 
that the classical photoreceptors and cryptochromes have functionally redundant 
roles in circadian photoreception in addition to their roles in the central clock.
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1.4.5 Action Spectra Studies
An action spectrum is simply defined as the measurement of a biological effect as a 
fimction of wavelength. Action spectroscopy plays a central role in the initial 
characterisation of biological responses (Coohill, 1992). In order to determine the 
spectral sensitivity of a light-dependent response (e.g. melatonin suppression) several 
monochromatic wavelengths at different intensities have to be studied and an 
irradiance response curves constructed. At each wavelength the irradiances required 
to produce a set response (usually the half maximal response) are then plotted to give 
an action spectrum. Known photoreceptor absorption curves can then be fitted to the 
action spectrum in order to determine the characteristics of the photoreceptors which 
mediate the response being observed.
Early action spectrum studies investigated the effect of light on the suppression of 
two enzymes involved in the synthesis of melatonin, namely HIOMT and NAT. 
Studies by Cardinali et al. (1972) showed that the action spectrum for photic control 
of the rat pineal was similar to the absorption spectrum of rhodopsin. A similar study 
investigating NAT suppression by light in rats also showed peak sensitivity at 495 
nm, which is around the sensitivity of the rat rod photoreceptors (Bronstein et al., 
1987).
A recent study evaluated the spectral sensitivity of melatonin suppression in Xenopus 
eyecups (Cahill et al., 1998). Irradiance response curves at wavelengths between 
400-650 nm were constructed. An action spectrum curve revealed that the green 
absorbing rods (l^ax 522 nm) are the principal photoreceptors involved in the light 
suppression of melatonin in this species. Action spectrum studies in hamsters 
investigating the spectral sensitivity of the phase shifting response indicate that the 
response has a maximum sensitivity near 500 nm (Takahashi et al., 1984).
Many action spectra studies have been conducted in a number of species to 
determine the spectral sensitivity of circadian responses. These are summarised in 
Table 1.2 (adapted from Johnson, 1995).
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1.4.6 Implications of Identifying Circadian Photoreceptors and their Spectral 
Sensitivity
Light has been used to treat circadian rhythm disorders such as sleep disorders, 
seasonal affective disorder, adaptation to shift work, jetlag and also for improving 
alertness and performance and reducing sleepiness and accidents during night work.
The ability of light to entrain circadian rhythms by phase shifting has therapeutic 
benefits in correcting circadian sleep disorders, jet lag and shift work. Studies using 
patients with delayed sleep phase syndrome (inability to fall asleep and waking at 
conventional clock times) have shown core body temperature and sleep latency to be 
advanced following 2 h of bright light exposure in the morning (between 6.00-9.00 
h) and light restriction firom 16.00 h by wearing dark glasses (Rosenthal et al., 1990). 
In a similar fashion light treatment has been used to adapt to shift work. Exposure of 
bright light (5,000 lux) for 6 h during the first two nights of night shift results in 
phase advances of body temperature (Eastman et al., 1994). However, bright light 
together with the use of dark glasses on the travel home from work resulted in phase 
delays. The explanation for this is that the journey home in daylight in the morning 
prevented phase delays and advanced the clock whereas eliminating this morning 
light and continuing with the evening bright light delays the temperature rhythm and 
allows better alignment to a 12 hour shift of sleep. Similar studies by Deacon and 
Arendt (1996) showed phase shifts using 1200 lux of light in the evening for three 
cycles. This lighting regime was used to stimulate shift work/jet lag and resulted in 
similar phase delays of the melatonin rhythm and alertness rhythms. Czeisler and 
colleagues (1990) demonstrated that bright light at night (7,000-12,000 lux) and 
complete darkness during the day shifted the temperature nadir to mid afternoon 
(approximately 15.00 h) after four consecutive days of treatment. Similar shifts in the 
24 h pattern of cortisol, urine excretion rate, alertness and performance were also 
recorded in the treatment group, whereas the non-light treatment group did not adapt 
with their temperature nadir occurring during the night (approximately 3.30 h). 
Bright light has thus been shown to successfully phase shift circadian rhythms to 
adapt to shift work, jet lag and to realign rhythms in delayed sleep phase syndrome.
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Seasonal affective disorder is a type of depression that affects sufferers in the autumn 
and winter months with remission of symptoms in spring and summer (Rosenthal et 
al., 1984). The symptoms of SAD include hypersomnia, sadness, increased appetite, 
loss of energy and weight gain. Light treatment through the eyes rather than the skin 
has been shown to produce a therapeutic response (Wehr et al., 1986). Treatment 
with bright light results in a 70-80% reduction in symptoms in those suffering from 
SAD whereas phototherapy has no effect in non-seasonal depression (Yerevanian et 
al., 1986). A dose of 2500 lux of broad-spectrum white light has been shown to be 
effective in treating SAD patients (Rosenthal et al., 1988). Improvements in 
symptoms are seen whatever time light is administered (James et al., 1985; Wirz- 
Justice 1993) however, morning bright light is more beneficial than evening 
treatment (Lewy et al., 1987; Termen et al., 2001).
More recently the effect of wavelength of light has also been assessed in SAD 
patients. This study showed that broad spectrum white light was more effective than 
broad-band blue (430-465 nm) or red (615-665 nm) light at one dose (equal photon 
number) in treating patients with SAD (Brainard et al., 1990). However, more 
research is required as wavelengths between 465 and 615 nm were not examined in 
this study and it is between these wavelengths that the majority of photoreceptors i.e. 
rods, green cones and red cones peak. Construction of an action spectrum using 
narrower monochromatic wavelengths at more irradiances would lead to improving 
therapy and reducing light levels for SAD treatment.
The majority of studies investigating the effect of light on individuals with circadian 
rhythm sleep disorder, SAD, adaptation to shiftwork and jet lag have used broad 
spectrum bright white light. As it is well established that light has therapeutic effects 
further investigations into the most effective spectral quality of light or the 
identification of the photoreceptors mediating circadian responses may prove 
beneficial. This knowledge would improve the design and use of lighting for the 
treatment of certain types of sleep disorders, seasonal affective disorder, adaptation 
to shift work and jetlag. It may also be useful in improving alertness and 
performance and reducing sleepiness and accidents during night work with broad 
applications in, for example, factories, hospitals and old age homes.
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1.5 NON PHOTIC FACTORS AFFECTING MELATONIN SECRETION
1.5.1 The Effect of Posture
Changes in posture have been shown to alter plasma and salivary melatonin 
concentrations (Deacon et al., 1994). Seven subjects were tested in the following 
conditions, standing-supine-standing (30 mins in each condition from 0.00-01.30 h), 
supine standing supine (30 mins in each condition from 0.00-01.30 h), supine (from
0.00-01.30 h), standing (from 0.00-01.30 h). Plasma and salivary melatonin 
concentrations increased when moving from a supine to standing position and 
decreased when moving from a standing to supine position. It was suggested that 
these changes were be attributed to gravity changes on standing and sitting. There is 
a decrease in plasma volume on standing thereby increasing plasma melatonin 
concentrations and there is an increase in plasma volume on lying down thereby 
decreasing the melatonin concentrations. As postural changes can influence the 
amount of melatonin it is important to control for posture in all experiments 
measuring plasma or salivary melatonin.
1.5.2 Menstrual Cycle Effects
Early studies by Wetterberg et al. (1976) showed that there were differences in 
melatonin concentrations at different stages of the menstrual cycle. Melatonin levels 
were elevated at the time of menstrual bleeding and at a nadir at the time of 
ovulation. Later studies also showed differences in melatonin levels with higher 
melatonin concentrations during the follicular phase (Fernandez et al., 1990). 
Another study showed higher melatonin levels during the luteal phase (Webley and 
Leidenberger, 1986).
More recent studies by Parry and colleagues (1997) investigated the effect of 
menstrual cycle in subjects with premenstrual dysphoric disorder and normal control 
subjects on the melatonin rhythm and after light therapy. Subjects were studied 
during mid-follicular, late follicular, midluteal and late luteal phases. In normal
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controls there were no significant differences in the melatonin rhythm at all four 
stages. This finding was consistent with a study by Berga and Yen, (1990). However, 
in premenstrual dysphoric subjects’ melatonin concentrations were different in the 
luteal phase compared to the follicular phase. Melatonin onset time was significantly 
later, melatonin duration was shorter and the area under the curve and mean 
melatonin levels were reduced in the follicular phase.
1.5.2 Exercise
The effects of acute exercise on melatonin production are inconsistent. Early studies 
by Vaughan et al. (1979) showed no changes in melatonin levels after exercise, 
whereas more strenuous exercise has been shown to elevate melatonin levels (Carr et 
al., 1981). Night-time exercise has also been shown to decrease plasma melatonin 
levels (Monteleone et al., 1990). These conflicting results may be due to differences 
in the timing and strength of exercise with late evening exercise blunting melatonin 
levels (Monteleone et al., 1990) whereas further elevation of melatonin was observed 
with high intensity but not low intensity exercise at night. (Buxton et al., 1997). 
However, exercise during the offset of melatonin secretion or during the daytime had 
no effects of melatonin levels (Theron et al., 1984; Elias et al., 1993).
Exercise has also been shown to phase delay the melatonin rhythm when exercise is 
centred at 1.00 hrs with the magnitude of delays being determined by the duration of 
exercise (Buxton et al., 1997). Exercise has also been shown to phase delay the 
temperature rhythm in humans (Eastman et al., 1995).
It is important to control for factors affecting the melatonin rhythm such as light 
when measuring the effect of exercise on the melatonin rhythm. Exercising in light in 
the late evening and during the night may cause phase delays as a result of the light 
rather than the exercise.
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1.5.3 Caffeine
There is evidence that caffeine can acutely reduce melatonin levels and increases 
body temperature at the time of melatonin onset (Wright et ah, 1997). The 
mechanism by which caffeine does this may be by delaying the rise in pineal NAT 
activity, the rate limiting enzyme for melatonin production (Sabry, 1997).
Apart from these acute effects caffeine has also been shown to shift the melatonin 
rhythm in chicken pineal cells (Zatz and Heath, 1995), shift the temperature rhythm 
in rats (Pelissier et ah, 1999), and cause phase delays in SCN firing when 
administered in the early subjective night in rats (Ding et ah, 1998) and hamsters 
(Diaz-Muhoz et ah, 1999).
Caffeine may also affect the metabolism of melatonin. 6-hydroxylation of melatonin 
is mediated by CYP1A2 (a cytochrome P450 isoform) in humans (Facciola et ah,
2001) and rats (Skene et ah, 2001) and caffeine is a substrate and inducer of 
CYP1A2 (Ayalogu et ah, 1995). Therefore there may be a possible interaction 
between caffeine and melatonin at the cytochrome P450 level.
1.5.4 Alcohol Ingestion
There are reports that alcohol can suppress melatonin concentrations when 
administered at melatonin onset time (Ekman et ah, 1993: Rojdmark et ah, 1993). 
More recent studies in women show that the nocturnal urinary concentration of the 6- 
sulphatoxymelatonin decreases in a dose dependent manner with no effect after one 
drink, a 9% reduction after two drinks and a 17 % reduction after four drinks 
(Stevens et ah, 2000).
1.5.5 Drugs
A number of drugs can affect the melatonin rhythm and it is important to avoid these 
drugs in studies assessing the melatonin rhythm in response to light stimuli. Drugs
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can act by affecting the pineal gland or at the level of liver metabolism (Skene et ah, 
2001).
Non steroid anti-inflammatory drugs (NSAID) have been shown to affect the 
melatonin rhythm. Ibuprofen (400mg) reduces plasma melatonin 2 h after 
administration at 24.00 h (Surrall et al., 1987). The study showed that maximum 
plasma ibuprofen levels coincided with minimum plasma melatonin in 3 out of 4 
subjects and administration of ibuprofen at 18.00 h delayed the onset of melatonin. 
The same study examined the effect of indomethacin (75g), which completely 
prevented the rise of nocturnal plasma melatonin. Other studies have shown sleep 
and body temperature also to be affected by NSAIDs and it has been speculated that 
these effects are related to prostaglandin synthesis inhibition and/or the suppression 
of melatonin (Murphy et al., 1996).
A number of antidepressant drugs can affect the melatonin rhythm. Those that affect 
noradrenergic and serotonergic function have been shown to affect melatonin 
production. These include depsiramine, which can advance the onset and increase the 
duration of melatonin production in humans (Franey et al., 1986; Skene et al., 1994). 
Monoamine oxidase inhibitors such as clorglyline and tranylcypromine have been 
shown to elevate plasma melatonin (Murphy et al., 1986). Serotonin reuptake 
inhibitors such as fluvoxamine have been shown to elevate melatonin levels (Skene 
et al., 1994). The mechanism for this has been recently been determined by Skene et 
al. (2001). As melatonin is metabolised by CYP1A2 and fluvoxamine is a CYP1A2 
inhibitor fluvoxamine prevents melatonin metabolism keeping melatonin levels 
raised.
Beta adrenergic blockers such as atenolol and propranolol decrease nocturnal 
melatonin levels (Cowen et al., 1983; Arendt et al., 1985; Deacon et al., 1998, 
Stoschitzky et al., 1999), as melatonin synthesis occurs due to adrenergic stimulation 
of p (and possibly a) receptors. Therefore p blockers prevent this stimulation and the 
synthesis of melatonin.
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1.5.6 Advancing Age
There is debate as to whether melatonin levels decrease with age. Most studies in 
humans have shown decrease in the amplitude of melatonin with ageing (Iguchi et 
al., 1982) and a shorter night-time profile (Nair et al., 1986). The excretion of the 
melatonin metabolite aMT6s, has also been shown to decrease with age (Sack et al., 
1986) with significant changes occurring after 60 years (Bojkowski and Arendt, 
1990). An ongoing database of melatonin concentrations across a wide age range 
(18-80 years) has been compared by Arendt and English (unpublished results) and a 
decline in melatonin concentrations with age has been observed. However, in 
contrast a recent study by Zeitzer et al. (1999) has shown that plasma melatonin 
levels were not significantly different in healthy older men and women (65-81 years) 
compared to younger men (18-30 years). In this study the duration of the nocturnal 
peak of plasma melatonin was also not significantly different between the older and 
young group being 9.3 and 9.1 hours, respectively. Contrary to this Nathan and 
colleagues (1999a) reported age-related decreases in melatonin concentrations in 
healthy subjects on no medication.
The reasons for this decrease in melatonin production with age are unknown, 
although suggestions include morphological changes in the pineal (Schmid et al., 
1995) and calcification of the pineal with age (Welsh, 1985). However, calcification 
of the pineal has not been shown to affect melatonin production in young and middle 
aged adults (Bojkowski and Arendt, 1990). Age-related changes in lens density may 
also decrease the strength of the light/dark cycle, which may also contribute to a loss 
in the strength of the melatonin signal. For example, it has been demonstrated that 
the thresholds for the phase shifting effects of light on locomotor activity and photic 
induction of Fos in hamster SCN are shifted to higher intensities in older hamsters. 
The older hamsters were 20 times less sensitive to the resetting effects of low 
intensity light on locomotor activity and the induction of Fos positive cells was 
reduced by 43% (Zhang et al., 1998).
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1.6 RESEARCH PROPOSAL AND AIMS OF THESIS
The eye is a complex component involved in the input pathway of circadian 
entrainment. Further investigations of its role with respect to light-induced melatonin 
suppression and circadian rhythm entrainment are needed to determine the 
photoreceptors involved, their location and spectral characteristics. In the long term 
this knowledge can be exploited to optimise light treatment for people with disorders 
of the circadian system and to adapt to abrupt phase shifts (e.g. shift work and jet 
lag).
To investigate these photoreceptors and their spectral characteristics, a light-induced 
response, melatonin suppression was employed. The ability of light to suppress 
nocturnal melatonin production can be used indirectly to assess:
1. the integrity of the retina- RHT- SCN-pineal pathway
2. the neurotransmitters involved in the pathway and the effect of drugs
3. the photoreceptors in the eye mediating these effects of light
The effect of light on melatonin production has been intensively studied since the 
discovery that light could suppress melatonin (Section 1.3.1.1.). More recent studies 
showing that low intensity light can induce melatonin suppression illustrate that the 
protocol used is very important. It is the differences in protocol design such as the 
timing and duration of light, the light source, when it is given (clock time and 
circadian time) and the subject’s gaze behaviour that can affect the amount of 
melatonin suppression. Therefore the first aim of this research was to design a 
protocol that would accurately and reliability measure plasma melatonin 
concentrations following light exposure.
This validated protocol was used to address the two main questions that need further 
investigation in order to determine the spectral characteristics of the photoreceptors 
that are involved in meditating light-induced melatonin suppression in humans. 
These are:
• Irradiance-response studies at various monochromatic wavelength in sighted 
subjects
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• Construction of an action spectrum to determine the spectral characteristics of the 
photoreceptor(s) involved.
Irradiance-response studies at various wavelengths will provide an indication of the 
most effective wavelength of light for suppression of melatonin. They also allow the 
construction of an action spectrum by plotting the ED50 of each irradiance response 
curve constructed for each wavelength relative to the most sensitive wavelength. The 
action spectrum provides the spectral sensitivity of the melatonin suppression 
response. Fitting photopigment curves to the action spectrum leads to identification 
of the underlying photopigment involved.
Determination of an action spectrum for melatonin suppression will result in future 
work to assess if this action spectrum is similar to an action spectrum for phase 
shifting and alertness and performance. Light suppression studies using this action 
spectrum data in colour blind, blind and ageing subjects will allow determination of 
changes in the action spectrum in those with visual deficiencies.
The construction of an action spectrum and identification of the photopigments 
involved will allow the spectral composition of light to be optimised to manipulate 
(or avoid manipulating) the human circadian axis. It may also have broad 
applications in situations where light therapy is used to synchronise the circadian 
clock and have a major impact in the design and use of lighting for the treatment of 
certain types of sleep disorders, seasonal affective disorder, adaptation to shift work, 
jetlag, improving alertness and performance and reducing sleepiness and accidents 
during night work with broad applications in, for example, factories, hospitals, old 
age homes.
76
CHAPTER 2 
METHODOLOGY
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2.1 THE STUDY DESIGN
The effect of wavelength of light on melatonin suppression was investigated in study 
legs, which consisted of three consecutive nights in the Clinical Investigation Unit 
(School of Biological and Life Sciences). The first night was a baseline night 
followed by two light exposure nights. In total twenty study legs were conducted and 
each subject completed between one and sixteen legs. Three or four study legs were 
conducted consecutively and this constituted a study session.
Table 2.1 The study design
Study night 19.00 -  7.00 h (in clinical investigation unit)
Study leg 3 consecutive study nights 
Night 1 -  baseline 
Night 2 -  light treatment 1 
Night 3 -  light treatment 2
Study session 3-4 consecutive study legs every week or every other week
2.2 SUBJECTS
2.2.1 Subject Selection Criteria
Subjects selected for these trials were apparently healthy adults. They were drug free 
except for minor analgesics or the oral contraceptive pill. The exclusion criteria were 
as follows:
1. Subjects who had undertaken a transmeridian flight or night shift work within
a month of the start of the trial.
2. Subjects with a familial or personal history of psychiatric disorders, or
epilepsy.
3. Subjects with glaucoma or an allergy to Tropicamide.
4. Colour blind subjects.
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5. Subjects with a low production of 6-sulphatoxymelatonin (aMT6s) (< 5pg 
aMT6s/24h) and/or an abnormally timed peak of 6-sulphatoymelatonin 
(outside 01.00-06.00 h).
6. Subjects who had donated 400 ml of blood within four months preceding the 
study.
2.2.2 Subjects Selected
Twenty-two subjects (4 Females; 18 Males) ranging in age from 18-45 years (mean ± 
SD = 27 ± 7 years) participated in this study. All subjects gave written informed 
consent (Appendix 1). The University of Surrey Advisory Committee on Ethics 
(USACE) granted approval for the study (ACE/97/53/SB S).
2.3 PRE-STUDY MEASUREMENTS
2.3.1 Pre-Study Questionnaires
Subjects completed a pre-study questionnaire on general health (Appendix 2) and 
were tested for:
1. Colour vision deficiencies using The Ishihara Colour Blindness Plate Test 
(Appendix 3).
2. Sleep disorders assessed using The Pittsburgh Sleep Quality Index (Buysse et 
al., 1989) (Appendix 4). Scores of above 5 were indicative of a sleep 
disorder.
2.3.2 Pre-Study 6-SuIphatoxymeIatonin Screening
Subjects were screened for the presence of a normal melatonin rhythm by assay for 
urinary aMT6s (Aldhous and Arendt, 1988). Samples were collected sequentially 
every 4 h (8 h overnight) for 48 h. Cosinor analysis was used to calculate the aMT6s 
acrophase time for each subject. The subjects’ mean acrophase time (± SD) was 4.6 h 
(± 0.9 h) and the mean (± SD) 24 h aMT6s production was 17.5 ± 7.0 pg /24 h
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(normal aMT6s values for this age range mean (± SD) 16.2 ± 10.3 pg /24 h English 
and Arendt, unpublished results).
The aMT6s acrophase data were used to set the light treatment time for each subject. 
The light treatment was timed to occur on the rising phase of each subject’s 
endogenous melatonin rhythm (circadian time CT 16-18 h = 23.30-2.30 h).
2.3.3 Pre-Study Subject Details
The Subject details obtained from these pre-study measurements are summarised in 
Table 2.2.
2.4 PRE-STUDY CONDITIONS
Three days prior to the study
1. Subjects were required to keep a regular sleep wake cycle and were asked to 
retire to bed at 23.00 h and arise at 7.00 h.
2. Subjects completed sleep and nap diaries on waking (Appendix 5). From these 
diaries the sleep onset and offset were calculated to ensure subjects were 
maintaining a regular sleep/wake cycle 3 days prior to the studies.
3. Subjects wore Actillumes (Ambulatory Monitoring Inc., New York, NY, 
USA), on their wrists that measure light exposure and activity.
24h prior to the study andfor the duration o f the study leg 
Subjects were also asked to avoid:
1. Bright lights
2. Refrain from heavy exercise
3. Alcohol consumption
4. Caffeine consumption
Table 2.2: Pre-study details of subjects
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Subject Sex Age aMT6s 
acrophase 
time (h)
pg/24h PSQI Eye
colour
Medication
SI M 25 3.2 18.5 2 brown none
S2 F 25 3.3 5.0 0 hazel none
S3 F 26 3.8 8.4 5 brown Trinordil 
(contraceptive pill)
S4 M 21 4.8 12.7 3 blue Isotretinoin 
(acne treatment)
S5 F 22 5.3 21.9 5 brown Mercilon 
(contraceptive pill)
S6 F 24 5.7 15.7 2 brown Cilest 
(contraceptive pill)
S7 M 19 4.8 14.7 2 brown none
S8 M 31 2.9 16.5 3 brown none
S9 M 25 4.1 14.7 2 blue none
SIO M 31 5.6 27.4 3 hazel none
S ll M 19 4.7 7.6 2 hazel none
S12 M 35 5.9 25.2 0 brown none
S13 M 29 5.6 8.7 3 brown none
S14 M 26 4.4 22.4 4 hazel none
S15 M 39 4.1 12.5 2 brown none
S16 M 24 5.7 27.8 2 brown none
S17 M 25 4.9 20.9 3 green none
S18 M 20 3.7 20.7 2 blue none
S19 M 34 3.7 19.2 2 brown none
S20 M 26 5.7 30.3 3 hazel none
S21 M 45 4.2 12.8 3 brown none
S22 M 28 4.2 21.92 2 brown none
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2.5 EXPERIMENTAL PROTOCOL
2.5.1 Study Night
The subjects were admitted to the Clinical Investigation Unit at 19.00 h. A qualified 
nurse/general practitioner placed an indwelling cannula in the subject’s forearm. 
From 21.00 to 23.00 h the subjects were kept in dim light (< 10 lux). Ninety minutes 
before the light treatment a single drop of pupil dilator Mimins Tropicamide 0.5% 
(Chauvin pharmaceuticals, Romford, UK) was placed in each eye.
Immediately after insertion of the pupil dilator subjects were asked to wear eye 
masks and lie in a semi-recumbent position. At 23.00 h the room lights were turned 
off and all subjects lay in a semi-recumbent position in complete darkness wearing 
eye masks. Subjects were given 30 mins of light treatment at a set time 
predetermined from their aMT6s acrophase data between 23.30 and 2.30 h. The 
summary of a typical study night is shown in Figure 2.1. Subjects were allowed to 
sleep between 23.00-7.00 h except from 15 mins before light exposure, during light 
exposure and 15 mins after light exposure (total of 1 h around the light exposure).
2.5.2 Modifications to Study Nights
1. In study legs 1-4 the time when the pupil dilator was given was not 
standardised to -90 mins before lights but was administered at 23.00 h to all 
subjects (= -60 to -120 mins before light exposure).
2. In study legs 1-4 additional blood samples were taken at 150 mins after lights 
on and at 7.00 h for all subjects.
2.5.3 Blood Sampling
Blood samples were taken at -90 mins just before administration of the pupil dilator 
and then at 15 minute intervals, 15 minutes before light exposure to one hour after 
lights off and then a final sample 30 mins later. The closed circles in Figure 2.1 
represent the blood sampling points.
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E y e  m a s k s  o n
Figure 2.1 : Summary of a typical study night
Subjects enter the clinical investigation unit at 19.00 h and a cannula is placed in their 
forearm. Lights are dimmed at 21.00 h. Ninety minutes before the light exposure subjects 
are asked to lie in a semi-recumbent position and a pupil dilator is administered, after 
which subjects wear eye masks. Blood samples (•) are taken at - 90 mins and then at 15 
min intervals until 90 mins after the onset of light exposure (subjects then lie supine) and a 
final sample is taken 30 mins later. Light exposure (30 mins) occurs 90 mins after the pupil 
dilator is administered. There is no light treatment on night 1- baseline night.
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Blood samples were collected into lithium heparin tubes and centrifuged for 10 
minutes at 3000 rpm. Plasma was separated and stored at -20°C until assayed.
2.5.4 Light Treatment
Each different light treatment was given for 30 mins at various times between 23.30 
and 2.30 h to between 3-7 subjects. Appendix 6 details each light treatment. All 
subjects received more than one wavelength of light during a study session and 
therefore each dose response curve consists of a different group of subjects. Subjects 
were asked to place their heads in the sphere (shown in Figure 2.2, Section 2.6.1) and 
position themselves correctly by placing their chin on the chin rest and head against a 
headband. The chin rest was adjusted so that the individual’s eyes were positioned at 
the level of the centre line. They were asked to keep their eyes open and fix their 
gaze at a point marked in the back centre of the sphere.
2.6 LIGHT EQUIPMENT
2.6.1 Light Source
For the light treatment subjects placed their heads in a 45 cm diameter sphere 
(Apollo Lighting, Leeds, UK), which was set up as shown in Figure 2.2. The sphere 
had an opening cut in order to accommodate the subject’s head. The inside of the 
sphere was coated with 8 coats of white reflective paint (Kodak White Reflective 
Coating, Integra Biosciences Ltd., Letchworth, Hertfordshire, UK) to give a 96% 
reflective surface (Macam Photometries Ltd., Livingstone, Scotland, UK). An 
adjustable chin rest was built in house and painted with the reflective coating. This, 
together with a headband, was fitted to the sphere.
This light sphere aims to provide uniform illumination of the entire retina in a pupil- 
dilated individual. The sphere was illuminated via a fibre optic cable, which was 
attached to the top of the dome at a 20° angle. This cable was connected to the light 
source, which was provided by a metal halide arc lamp (Enlightened Technologies 
Associates Inc., Fairfax, VA, USA).
I n p u t  p o r t
C e n t r e
p o i n t
H e a d b a n d
- 4
E y e  l e v e l
W h i t e  
r e f l e c t a n c e  
c o a t i n g  
A d j u s t a b l e  c h i n  r e s t
Fig 2.2 Light spheres
Diagrammatic representation of the spheres used to administer light. The fibre optic 
cables delivering the light from the light boxes fit into the input port at the top of the 
sphere.The sphere is coated in white reflectance coating to ensure the subjects receive 
uniform illumination from every angle in the sphere. Subjects place their heads in the 
sphere with their head against the headband and chin on the chin rest which can be 
adjusted to ensure subjects’ eyes are level with the centre point of the sphere. Subjects 
focus on the centre point at the back of the sphere.
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Four different light boxes were used in the experiments. Light boxes A and B have a 
21 Watt (W) miniature metal halide arc lamp developed by Welch-Allyn. Light boxes 
C and D have a 50W miniature metal halide arc lamp also developed by Welch- 
Allyn. Each light box contains a heat mirror between the light source and the fibre 
optic cable, to ensure ultraviolet (UV) and infrared (IR) radiation is filtered. In later 
experiments (study legs 17-20), which required higher light irradiances, two fibre 
optic cables from two light boxes were fed into one sphere by adapting the input 
port.
All light sources showed no UV emission when tested with a UV radiometer (UVP 
Inc., San Gabriel, CA, USA). Light sources were also tested for electromagnetic field 
(EMF) generation (EMDEX II Magnometers, Enertech Consultants, Campbell, CA, 
USA). All light treatment conditions showed no EMF greater than a background 
level of O.lpT.
2.6.2 Monochromatic Light
Monochromatic filters at six different wavelengths of maximum transmission (Imax) 
430, 460, 480, 500, 530 and 560 nm (half maximal bandwidth 1% = 10 nm) 
(Coherent Ealing, Watford, Herts.,UK) were placed in the input port of the sphere. 
The intensity of the monochromatic light was adjusted using combinations of Kodak 
Wratten neutral density filters (Richard Frankfurt, Croydon, Surrey, UK) which were 
also placed in the input port of the sphere between the light probe and the sphere.
The set up of the light source altered the spectral quality of the monochromatic light 
slightly and measurements with a spectrophotometer (Spectrascan 650 portable. 
Photoresearch, Chadsworth, CA, USA) confirmed the actual wavelengths at eye 
level. The Xmaxs of these are shown in Table 2.3.
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Table 2.3 Monochromatic filter transmissions
Ealing Transmission Actual Transmission
Wavelength (nm) 1^/2 Wavelength (nm) 1^/2
430 10 424 8-13
460 10 456 7-13
480 10 472 7-13
500 10 496 6-10
530 10 520 5-11
560 10 548 6-11
A range of irradiances (0.70-65 pW/cm^) for each wavelength were assessed (Table 
2.4).
Table 2.4 Summary of light wavelengths and irradiances tested.
Wavelength (nm) Irradiance (pW/cm'*)
424 1.9 (6), 2.8 (6), 4.5 (6), 9.0 (6), 11(5)
456 2.0 (5), 4.0 (5), 8.0 (5), 29 (4)
472 1.8 (6), 2.8 (7), 4.1 (6), 9.0 (6), 14 (6), 22 (6), 31 (5)
496 3.0 (4), 6.5 (7), 13 (6), 18 (6), 26 (5), 31 (5)
520 0.7 (3), 1.8 (6), 3.3 (3), 4.1 (5), 7.0 (7), 16 (6), 27 (5), 41 (6), 65 (5)
548 7.2 (5), 14 (5), 26 (3), 52 (3), 65 (5)
White 2.2 (3), 3.9 (6), 6.6 (4), 7.2 (5), 91 (8)
The numbers in brackets indicates the number of subjects studied at each irradiance.
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2.7 LIGHT MEASUREMENTS AND CALCULATIONS
2.7.1 Measurement of Light
The light irradiance (pW/cm^) was measured at subjects’ eye level using a portable 
radiometer (Macam Photometries Ltd., Livingstone, Scotland, UK). It was noted that 
even if the detector was turned at right angles the irradiance did not change. 
Irradiance measured in pW/cm^ was then converted to a photon number by the 
calculations described in Section 2.7.2.
The spectral characteristics of the monochromatic light were also measured at the 
subjects’ eye level to determine the percentage transmission of light at each 
wavelength through the filter (Section 2.6.2). This was done so that if  the sphere or 
fibre optic cable set up changed the spectral characteristics of the filters then this 
could be accounted for in the photon calculations.
2.7.2 Calculation of Photons Density
In order to calculate the number of photons in a given irradiance of monochromatic 
light, the measured irradiance and the energy/photon for each nanometer of light is 
used.
photons/cm^/s = irradiance (pW/cm^) / energy of 1 photon at wavelength
The energy of 1 photon of, for example 500 nm light, can be calculated by the 
following equation;
E = hV
h = Plank’s constant (6.625 x  watts/s^)
V = frequency of wave d X  (speed o f light (C) = 3.00 xlO^^ nm/s)
Therefore if 3 pW/cm^ of 500 nm of light is measured the number of photons is 
calculated as follows:
Firstly the energy in 1 photon of this light is calculated 
E = hV (V = C/X)
E = (6.625 X 10'^ "^  watts/s^) x (3.00 xl0^^nm/s)/500 run)
E = 3.975 X 10'^  ^pW/photon/s 
Thus at an irradiance of 3pW/cm^
Number of photons/cm^/s = (3 pW/cm^ )/(3.975 x 10'^  ^pW/photon/s)
= 7.5 x l 0^  ^photons/cm^ /s
In order to calculate the total number of photons given for 30 mins of light exposure, 
the total number of seconds are calculated = 30 x 60 = 1800 seconds 
Total number of photons = (7.5 xlO^^photons/cm^/s) x (1800)
= 1.35 X 10^  ^photons /cm^
2.7.3 Calculation of Total Photons in the Monochromatic Light
Coherent-Ealing the manufacturers of the filters provided the % transmittance for 
each monochromatic filter (shown in Figure 2.3). The total photons were calculated 
by adding the photons/cm^/s transmitted at each 10 nm wavelength. For example, if  a 
500 nm filter only transmits 50 % at 500 nm and 1% at 490 nm and 1% at 510 nm in 
order to calculate the photons of the measured light which consists of 96% 500 nm 
and 2% each of 490 nm and 510 nm, photons/cm^/s were calculated as described in 
Section 2.7.2 and multiplied by the actual percentage transmittance. The 
photons/cm^/s at each 10 nm wavelength were then summed to give the total number 
of photons/cm^/s for the measured irradiance.
In order to check that the light delivery system (lamp, fibre optic cable, spheres) was 
not in some way altering the monochromatic light a spectrophotometer (Spectrascan 
650 portable. Photoresearch, Chadsworth, CA, USA) was used to measure the 
spectral composition of each filter at eye level. The graphs of the % transmittance of 
each filter in each light delivery set up (i.e. box and sphere) are shown in Figure 2.4. 
The percentage transmittances from these measurements were then used to calculate 
the total number of photons.
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Although the spectral transmittance data provided by Ealing and the measured 
spectral transmittance graphs look slightly different, the calculated number of 
photons/cm^/sec were not significantly different when comparing both methods of 
photon calculations for each light treatment (see Table summarising this data in 
Appendix 7). However, for all calculations the real measured photons were used.
2.8 RADIOIMMUNOASSAY (RIA) OF MELATONIN AND aMT6s
2.8.1 Basic Principles
A sample containing an unknown amount of antigen (melatonin/aMT6s) is incubated 
with a fixed amount of antiserum specific to the antigen and a fixed amount of 
radiolabelled antigen (^H-melatonin/^^^I-aMT6s). The labelled and unlabelled 
antigen competes for the fixed number of antibody binding sites. The amount of 
antibody associated with the labelled antigen depends upon the amount of unlabelled 
antigen there is in the sample. Once equilibrium is reached the free and antibody 
bound fractions of the antigen are separated using charcoal, which absorbs the free 
antigens. The radioactivity is measured in the free (aMT6s) or bound (melatonin) 
fractions and is compared to that obtained using a set of melatonin/aMT6s standards 
of known concentration. This gives the concentration of melatonin/aMT6s in the 
sample.
2.8.2 RIA of Melatonin in Human Plasma
Plasma melatonin levels were determined by direct RIA using the method described 
by Fraser et al. (1983). All plasma samples for each subject for each leg were 
measured in the same assay. Samples were assayed in night sequence (i.e. 23.00 h 
N l, N2, N3 and then the next time point for all three nights) to minimize any effect 
of assay drift on the measurements.
2.8.2.1 Materials
Antiserum (product no. G/S/704-8483) - Stockgrand Ltd.
92
Melatonin free plasma - Stockgrand Ltd.
melatonin (product number TRK-798) -  Amersham Ltd, Buckinghamshire, UK 
2,5-diphenyloxazole (PPO) -  Fision, UK 
l,4-bis-[2-(5-phenyloxazolyl)]benzene (POPOP) -  Fision, UK 
All other chemicals including melatonin were obtained from Sigma Chemical Co. 
Ltd. (Poole, Dorset, UK)
2.S.2.2 Reagents
Buffer: Tricine (Sigma product no. Y0377)was made up at 0.1 M with 0.9% NaCl 
and 0.1% gelatine in fresh double-glassed distilled water (DGDW). In order to 
dissolve the gelatine the buffer was heated up to 50°C for 30 mins.
Antiserum: The sheep anti-melatonin antiserum was supplied freeze dried and 
reconstituted with 2 ml of DGDW to provide an intermediate dilution of 1:10. This 
was stored in 50 pi aliquots at -20°C. The working solution was made by diluting the 
50 pi aliquot with 20 ml of tricine buffer, which provides enough antiserum for 100 
assay tubes with a initial dilution of 1:4000.
Radiolabel: An intermediate dilution from stock melatonin was made by diluting 
50 pi up to 2 ml in absolute ethanol and stored at -20°C. A working dilution was 
made up in Tricine buffer by diluting an aliquot to give approximately 4000 counts 
per minute (cpm) in 100 pi.
Dextran coated charcoal: Sigma activated charcoal (2%) was suspended in tricine 
buffer for 5 mins. After centrifugation at lOOOrpm at 4° C, the supernatant and any 
fines around the side of the vessel were discarded. The charcoal was resuspended in 
the original volume of tricine buffer and stirred with 0.02% Dextran T70 for at least 
1 h at 4° C. This is then stored at 4° C.
Scintillation fluid: 12.5 g of PPO and 0.75g of POPOP was mixed with 2.5 litres of 
toluene for Ih.
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Melatonin standards: A stock melatonin solution was prepared by dissolving 10 mg 
melatonin in 0.5 ml of absolute ethanol. This was made up to 10 ml with DGDW to 
give a concentration of 1 mg/ml and stored at 4° C.
The working dilution was made up freshly for each assay from the stock solution as 
follows:
100 pi of 1 mg/ml stock to 100 ml DGDW to give Ipg/ml
500 pi of Ipg/ml solution to 50 ml in DGDW to give 10 ng/ml
125 pi of 10 ng/ml solution to 2.5 ml in melatonin-free plasma to give 0.5
ng/ml
Standards were prepared by further dilutions in melatonin free plasma as follows:
Melatonin standard 0.5ng/ml
M
Melatonin free plasma
w
Melatonin conc. 
pg/ml
500 0
5 495 5.0
10 490 10.0
25 475 25.0
50 450 50.0
100 400 100
200 300 200
500 - 500
2.S.2.3 Procedure
All standards, samples, quality controls, non-specific binding (NSB) and total tubes 
were set up in duplicate. Zero melatonin concentration tubes were set up in 
quadruplicate.
Melatonin standards, plasma samples and quality controls in 500 pi were incubated 
with 200 pi of antiserum for 30 mins at room temperature. 100 pi ^H-melatonin was
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added to each tube and vortexed. The assay was incubated at 4° C for 18 h. The 
antibody bound fraction was separated from the free fraction by mixing with 500 pi 
of dextran-coated charcoal (which is continuously stirred for 30 mins prior to 
addition) then incubated for 15 mins at 4° C. The total tubes contained only lOOpl 
and 1200 pi of tricine buffer. The NSB tubes contained 100 pi ^H-melatonin, 500 pi 
of dextran-coated charcoal and 700 pi of Tricine buffer.
Assay tubes (all except total tubes) were then centrifuged at 3000 rpm for 15 mins at 
4° C. All of the supernatant was then transferred to scintillation vials and 4 ml of 
scintillation fluid was added. The scintillation tubes were shaken for 1 h in order to 
extract the ^H-melatonin into the organic phase for radioactivity detection. 
Radioactivity in the vials was measured using a p-counter (Wallace, Milton Keynes, 
UK) and the sample concentrations were calculated using a RIAcalc program.
The RIAcalc program determines the percentage of the total counts bound or free, 
and then plots them as a function of the known concentrations of the melatonin 
standards. A curve based on the smoothing spline calculation method is fitted 
through the standard points and the concentrations of the unknown samples are 
determined from this curve.
2.8.3 RIA of aMT6s in Human Urine
aMT6s was determined by the method described by Aldhous and Arendt (1988).
2.8.3.1 Materials
The antiserum (product no. AB/S/04), ^^^I-aMT6s, charcoal stripped urine, and the 
aMT6s standards were all obtained from Stockgrand Ltd. All other chemicals were 
obtained from Sigma Chemical Co. Ltd. (Poole, Dorset, UK).
2.8.3.2 Reagents
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Buffer: As described in 2.S.2.2
Antiserum: The sheep antiserum was supplied freeze dried and was reconstituted 
with 1 ml DGDW and 9 ml of tricine buffer to provide an intermediate dilution of 
1:100. 50 pi aliquots were stored at -20°C. 50 pi aliquots were diluted up to 20 ml 
with tricine buffer and provided enough antiserum for 100 assay tubes at an inital 
dilution 1:20,000.
Radiolabel: ^^^I-aMT6s was diluted with tricine buffer to give approximately 
lOjOOOcpm per 100 pi.
Charcoal stripped urine: This was provided in freeze-dried vials (100 pi) and was 
reconstituted with 25 ml of assay buffer to give a dilution of 1:250.
Dextran-coated charcoal: As described in Section 2.S.2.2
aMT6s standards: 500 pg aMT6s is supplied at 100 pg/ml diluted 1:250 in charcoal 
stripped urine and this is stored at 4° C. Standards are further diluted for the standard 
curve as follows:
aMT6s standard 200 pg/ml
w
aMT6s free urine (1:250)
w
aMT6s conc. 
ng/ml
0 500 0
5 495 0.5
10 490 1.0
20 480 2.0
40 460 4.0
70 430 7.0
100 400 10.0
200 300 20.0
500 0 50.0
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2.S.3.3 Procedure
All standards, samples, quality controls, NSB and total tubes were set up in 
duplicate. Zero aMT6s concentration tubes were set up in quadruplicate. Urine 
samples were diluted 1:250 with buffer using an automatic dilutor (Hamilton G.B. 
Ltd., Lancashire, UK). 500 pi aliquots of urine samples, quality controls and 
standards were incubated with 200 pi of antiserum at room temperature for 30 mins. 
100 pi of ^^^I-aMt6s was then added, mixed and incubated at 4° C for 18 h. The 
antibody bound aMT6s was separated from the free fraction using 100 pi of dextran 
coated charcoal (which is continuously stirred for 30 mins prior to addition) and 
incubating at 4°C for 15 mins. The total tubes contained only 100 pi ^^^I-aMT6s. The 
NSB tubes contained 100 pi ^^^I-aMt6s, 100 pi of dextran-coated charcoal and 700 
pi of buffer.
The assay tubes were centrifuged at 3500 rpm for 15 mins at 4° C. The supernatant 
was then immediately discarded and the radioactivity of the free fraction in the 
charcoal pellet was counted in a gamma counter (Wallace, Milton Keynes, UK) and 
the sample concentrations calculated using a RIAcalc program.
2.9 DATA ANALYSIS
2.9.1 Comparison between Light Treatment Night and Baseline Night
For each light treatment for each individual, each time point was expressed as a 
percentage of the corresponding baseline time point value. At each irradiance studied 
the individual data were averaged for each time point and the results are shown in the 
Section 4.2.1. Paired Student’s t test checked for significant differences between the 
baseline night and the light treatment night at each time point.
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2.9.2 Melatonin Suppression
Percentage light-induced suppression of plasma melatonin was calculated by 
comparing the average of the point at 30 and 45 mins (time points of maximum 
suppression in all subjects) after lights on, on the light treatment night (N2) to the 
same values for the baseline night (Nl) for each individual as follows:
% melatonin suppression = (Nl (m ean  3 0 + 4 5 m in s ) - N 2 ( m e a n  3 0 + 4 5 m in s )  ) X 100
N 1  (m ean  3 0 + 4 5 m in s )
Data from all the subjects receiving the same light treatment were averaged. The 
individual data were also log transformed and then averaged. Retransforming the 
values produced the geometric mean.
2.9.3 Irradiance Response Curve Fitting
For each wavelength irradiance response curves were plotted (photons/cm^/s against 
% melatonin suppression). Best fit curves were generated (SAS 6.12) using the four- 
parameter logistic equation described below.
y = a - c + c 
( !+ ( % ) “)
y = % melatonin suppression
a = response when Irradiance (I) = 0
c = response when irradiance (I) is maximum
X = total number of photons
b = half saturation response
d = slope of line
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2.9.4 Construction of an Action Spectrum
An action spectrum was constructed using the 50% maximal suppression from the 
irradiance response curves. The 50% maximal sensitivity values were expressed 
relative to the most sensitive wavelength and then log transformed. These values (log 
relative sensitivity) were then plotted against wavelength to achieve an action 
spectrum for melatonin suppression.
2.9.5 Fitting Nomograms to an Action Spectrum
DartnalTs nomograms for the known photoreceptors (rods (A^ iax 496 nm), S-cone 
(Xmax 419 nm), M-cone (Imax 531 nm), L-cone (Imax 558 nm) Dartnall et al., 1983) 
were fitted to the action spectrum. This was achieved by first approximating the 
nomogram with a third order polynomial equation. The parameters of the third order 
polynomial equations were then fitted to the action spectrum and a goodness of fit 
value obtained (Graphpad 3.0). This procedure was also employed for fitting novel 
rhodopsin based photopigments to the action spectrum. Third order polynomial 
curves, generated from rhodopsin templates with Imax ranging between 420-480 nm, 
were also fitted to the action spectrum by the same method.
In order to investigate whether two photopigments contribute to the observed action 
spectrum, various combinations of photopigments were fitted to the data. This was 
achieved by adding various ratios of the opsin-based photopigments. The generated 
curves were fitted to a third order polynomial and fits of > 0.99 were achieved. 
The goodness of fit between the polynomial curves and the action spectrum was 
calculated.
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CHAPTER 3 
PROTOCOL DEVELOPMENT
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3.0 PROTOCOL DEVELOPMENT
Many factors were considered when designing this protocol. Firstly it was important 
to recruit subjects who had no colour vision deficiencies, regular sleep/wake cycle, 
measurable melatonin, were healthy and on no medication and did not do shift work 
or have travel across time zones for 2 weeks prior to the study. As melatonin is the 
marker to be measured it is important that the subjects had a robust melatonin rhythm 
and avoided factors that may alter it. Therefore in the design of the protocol it was 
important to do pre-study measurements of melatonin (aMT6s) and then apply 
conditions that would minimise any changes to the rhythm, i.e. regular light/dark and 
sleep/wake cycle (verified by Actillumes and sleep diaries), avoidance of bright light, 
caffeine, exercise, and alcohol which have been shown to phase shift rhythms.
In terms of the protocol for the study night, factors immediately affecting the 
melatonin rhythm such as light and posture were controlled for i.e. light control was 
21.00-23.00 h < 10 lux; 23.00-07.00 h complete darkness with subjects wearing eye- 
masks and posture was 21.00-23.00 h sitting; 23.00-2.00 h semi-recumbent; 2.00-
7.00 h recumbent.
The method of light exposure is the most important factor for determining melatonin 
suppression from timing of exposure to direction of gaze all were controlled for. The 
timing of exposure was standardised for each subject to occur on the rising phase of 
melatonin production (this was determined from the pre study aMT6s data). As the 
light-induced suppression of plasma melatonin is a marker to determine the 
photoreceptors responsible for melatonin suppression in the eye it is also important 
to take into account factors such as pupil dilation to minimise differences in pupillary 
constriction between individuals but also to ensure the entire visual field was covered 
with the light. Therefore the pupils were dilated for the light exposure and the effect 
of pupil dilation and time period over which pupils remained dilated was assessed in 
preliminary studies. Light equipment was designed and constructed to model a 
sphere, which the subjects sat into to ensure that subjects received constant uniform 
illumination across the entire retina. Subjects were instructed to look at a central 
point in the back of the sphere to control for changes in gaze behaviour. Blood
101
samples were timed every 15 mins around the light exposure time to ensure 
sensitivity in measurement of suppression. The protocol also includes a baseline 
night which was used to compare light exposure nights. These occurred the night 
before the first light exposure and two nights before the second light exposure 
therefore controlling for changes in the melatonin rhythm between study legs.
During the first four study legs of the research various procedures of the protocol 
were examined, for example the effect of the pupil dilator on plasma melatonin 
concentrations and the duration of its action (Section 3.1). The repeatability of the 
subjects’ baseline melatonin profile was also assessed (Section 3.2). The 
repeatability of light-induced melatonin suppression using broad-spectrum white 
light was also evaluated (Section 3.3) to check the reliability of the procedure.
3.1 PUPIL DILATION TEST
3.1.1 Introduction
A study by Gaddy and colleagues (1993) showed that pupil dilation increased the 
amount of melatonin suppression by increasing the amount of light reaching the 
retina. This experiment showed that pupil dilation nearly doubled the percentage 
melatonin suppression (60% suppression at 200 lux) compared to non-dilated pupils 
(30% suppression at 200 lux).
It is important that a pupil dilator is used in the present experiments to eliminate 
differences in pupillary reflexes to light and pupillary constriction as a confounding 
effect when using higher light intensities.
Although pupil dilators have been used before (Brainard et al., 1985; Gaddy et al., 
1993), the effect on plasma melatonin concentrations has not been reported. This 
experiment aimed to assess the effects of the pupil dilator Tropicamide (Minims, 
Chauvin Pharmaceuticals, UK) on the night-time melatonin rhythm.
102
Tropicamide is an anticholinergic drug which blocks the response of the sphincter 
muscles of the iris and the ciliary muscles to cholinergic stimulation thereby dilating 
the pupil. It was chosen as it is a short acting dilator that starts to have an effect at 30 
mins which lasts up to 6 hours (Chauvin Pharmaceuticals).
3.1.2 Methods
3.1.2.1 Effect of pupil dilator on melatonin rhythm
The effect of the pupil dilator was evaluated in leg 2 of the study. Subjects 1-5 were 
studied and the experimental procedure was the same as for the other study legs 
(Section 2.5). On night 1 no pupil dilator was administered and on night 2 a drop of 
Tropicamide was placed in each subject’s eyes at 23.00 h. No light treatment was 
given on either of the nights. Plasma melatonin was analysed by radioimmunoassay 
(Section 2.8.2).
3.1.2.2 Duration of action of pupil dilator
A further one night study was conducted to determine the duration of action of the 
pupil dilator and to check that at all times up to the time of lights off the pupils 
remained dilated. The study involved the same subjects (subjects 1-5) coming into 
the Clinical Investigation Unit at 22.30 h and having a drop of the pupil dilator 
inserted into each eye at 23.00 h. The subject’s eyes were checked for any pupillary 
reflex with an ophthalmic light (120 pW/cm^), held 15 cm from their eyes at 15 min 
intervals from 75-210 mins after administration of the pupil dilator.
3.1.3 Results
3.1.3.1 Effect of pupil dilator on the melatonin rhythm
The effect of the pupil dilator on plasma melatonin concentrations is shown in Figure 
3.1. The pupil dilator did not significantly affect the melatonin levels at any time 
point compared to baseline (no pupil dilator) using a paired Students’ t-test.
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Each time point on the night 2 (pupil dilator administration) was expressed as a 
percentage of night 1 (baseline) (Figure 3.2). All values shown in Figure 3.2 are 
around the 100% point showing that they are similar to the baseline night (100%).
To confirm this analysis the area under the melatonin curve has also been compared 
for pupil dilator and no pupil dilator (paired Students’ t-test). The total area under the 
curve from 23.00-7.00 h was compared for each individual. No significance 
difference (P = 0.78) in the area under the curves was found. The intensive period of 
blood sampling around the time of light exposure was also examined (-15 to 150 
mins). Analysis of this data also shows no significant difference (P = 0.71) in the 
area under the curve between pupil dilation and no pupil dilation.
3.1.3.2 Effect of pupil dilator on pupillary reflex
Following administration of the pupil dilator at 23.00 h, all the subjects’ pupils 
showed no reflex action between 75 - 210 mins after dilation. However, some 
constriction in pupil size was noted after 210 mins in all subjects. The extent of pupil 
dilation decreased slightly 2-3 h after the insertion of the dilator and the pupillary 
reflex began to return at around 3.5 hours.
3.1.4 Conclusions
The pupil dilator (Tropicamide) has no effect on plasma melatonin rhythm 
concentrations at any of the time point studied. There was no statistically significant 
difference between the subjects’ melatonin concentrations with or without pupil 
dilation.
As the pupillary reflex started to re-appear at 3.5 h and some constriction of the pupil 
was noticed 2-3 h after pupil dilator administration, the time of administration of the 
pupil dilator was standardized to 90 mins before lights on in all subjects from study 
leg 4 onwards.
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Figure 3.1 The effect of pupil dilation on plasma melatonin
Plasma melatonin concentrations mean (± SEM) in 5 subjects with ( ■ ) 
and without (O) pupil dilation. The pupil dilator was inserted at -90 mins
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Figure 3.2 Effect of pupil dilator as a percentage of baseline night
Melatonin values mean (± SEM) expressed as a percentage of the non pupil 
dilator (baseline) night.
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3.2 REPEATABILITY OF MELATONIN BASELINES
3.2.1 Introduction
A baseline night (no light treatment) was completed for each leg of the study. The 
baseline night was always the first study night (night 1) of a 3-night study leg. For 
each individual the baseline night was used as the control to compare the effect of the 
light treatments given on the two subsequent nights. In view of the possible effect of 
light exposure, exercise, caffeine and alcohol, inter-study consistency of the 
individuals’ baselines were compared.
There is some debate as to whether a night 1 baseline is essential. Some studies do 
not have a baseline night 24-hours before the light treatment night (Brainard et al), 
whereas our laboratory consistently performs these (Lockley et al., 1998).
Analysis of the baseline night data and the intra-subject consistency will enable the 
protocol and pre-study conditions to be checked.
AIM: Is a baseline night necessary? Is our control in the protocol sufficient not to 
affect the melatonin rhythm and circadian phase?
3.2.2 Methods
The melatonin curves from the baseline nights (Nl) were assessed for repeatability in 
all subjects. Study leg 2 had two baseline nights (Appendix 6), one with a pupil 
dilator and one without a pupil dilator being administered. As there was no 
significant effect of the pupil dilator on the melatonin rhythm (Section 3.1.3.1), both 
of these nights were included in the repeatability of baseline analysis.
For each subject, the reproducibility of their baseline was assessed by comparing the 
melatonin profile for all completed baseline nights within a study period (3 
baselines), which spanned three to six weeks. Subjects that completed two 
consecutive study periods (6 baselines) over 7 months (October 1998-May 1999) and
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6 months (August-Febmary 2000) were also analysed by repeated measures 
ANOVA. Finally a few subjects completed three consecutive study periods spanning 
11 months (October 1998-September 1999) and four consecutive study periods over 
16 months (October 1998-February 2000) which were also assessed by repeated 
measures ANOVA.
3.2.3 Results
Figure 3.3 Shows 9 baselines of a representative subject. The P-values from testing 
repeatability of baseline melatonin rhythms over different study periods and time 
courses are shown in Table 3.1.
Table 3.1: Repeatability of baselines using repeated measures ANOVA.
n No. of baseline 
nights
Time period 
(weeks)
Effect of night 
(P-value)
Effect of time 
(P-value)
Effect of night 
and time 
(P-value)
29 3 3-6 0.88 <0.05 0.28
4 6 28 0.93 <0.05 0.51
5 6 24 0.84 <0.05 0.65
3 9 44 0.57 <0.05 0.33
2 12 64 0.48 <0.05 0.84
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These results show that there is no significant effect of night i.e. they are repeatable. 
There is a significant difference in samples taken at different times through the night, 
which is what would be expected as melatonin rises during the night and falls in the 
morning. There is also no significant difference in night and time between the 
baselines showing that they are truly repeatable.
However, when examining the plots of the baselines during the course of the study it 
was observed that the female subjects (n = 3) showed greater variation in their 
baselines. It was noted that two of these three subjects took oral contraceptives. 
Subjects 3 and 5 had consistent baselines when taking the oral contraceptive pill (S3 
took Trinordil; S5 Mercilon, Table 2.2). The baseline melatonin profile when no oral 
contraceptives were taken was markedly different to those during oral contraceptive 
administration (Figure 3.4). Melatonin concentrations were higher in both subjects 
when they were not taking oral contraceptives compared to the days on the oral 
contraceptive. There was also a significant variation in the baselines for subject 2 
who was not taking oral contraceptives.
3.2.3 Conclusion
Within each subject the melatonin baseline nights were repeatable. For each 
individual the baselines were reproducible irrespective of the time interval over 
which they were assessed (3-64 weeks). This finding implies that the developed 
protocol and pre-study conditions (regular sleep-wake cycle, avoidance of bright 
lights, caffeine and exercise and alcohol. Section 2.4) are sufficient to control for 
factors known to affect the melatonin rhythm. Variation in the baselines of the 
female subjects may be due to the effects of the menstrual cycle on the melatonin 
rhythm. There is some evidence that melatonin levels change during the menstrual 
cycle and during oral contraceptive administration (Section 1.5.2). As a result of the 
inconsistency in the melatonin baselines for female subjects, only male subjects were 
used fi*om leg 5 onwards.
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Figure 3.4 Baseline melatonin concentrations of a female subject (S3).
Melatonin concentrations on the baseline nights from study legs 1 ( 0 ) ,  
2 ( ♦ ,  ■) and 3 (□). The subject took the oral contraceptive, Trinordil, 
on all study legs except study leg 3.
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3.3 REPEATABILITY OF LIGHT-INDUCED MELATONIN SUPPRESSION
3.3.1 Introduction
There is little research assessing the repeatability of light-induced suppression in the 
same individuals. The re-test reliability using 500 lux of light has previously been 
studied by Lewy and colleagues (1997). Light (500 lux) given every week for four 
consecutive weeks significantly suppressed (68%) plasma melatonin and the 
observed suppression did not change significantly over the four-week period. The 
repeatability of our melatonin suppression protocol was assessed. The effects of the 
same amount of light (91 p.W/cm^ white light) on two separate occasions were 
evaluated in the same individuals to be confident of the intra-individual 
reproducibility and re-test reliability of the light-induced suppression of melatonin.
3.3.2 Methods
Four subjects (SI, 2, 4, 7; 3M: IF aged 19-25 years) were given 91pW/cm^ of white 
light on two separate occasions separated by 10-12 weeks. For each study leg the 
percentage melatonin suppression was calculated using the 30 and 45 min time 
points (method 1) and compared using a paired Student’s t-test.
3.3.3 Results
The melatonin values as a percentage of baseline for the first and second exposure 
are shown in Figure 3.5. Using method 1 (Section 2.9.2) there was no significant 
difference (P = 0.14) in the % melatonin suppression between the first and second 
light exposures.
The % melatonin suppression using the area under the curve from 0-45 mins was 
also calculated using the following formula:
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Figure 3.5 Repeatability of light-induced melatonin suppression
Melatonin values expressed as a percentage of baseline (mean ± SEM, n = 4) 
for 1st (O ) and 2nd (■) exposure to 91 pW/cm^ white light.
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% suppression = (N l(auC  0-45mins)-N2(AUC 0-45mins) )
N 1 ( a UC 0-45mins)
This method also showed no significant difference (P = 0.55) in % melatonin 
suppression between first and second light exposure.
3.3.4 Conclusion
This experiment shows the intra-individual variability in melatonin suppression is 
not statistically significant.
3.4 CALCULATION OF MELATONIN SUPPRESSION
3.4.1 Introduction
Light-induced melatonin suppression can be calculated by various methods. 
Depending upon the method used the degree of melatonin suppression can vary. A 
popular method in the field is to compare melatonin concentrations before the light 
treatment with those after the light treatment (Brainard et al. 1997). The first four 
legs of the study were used to assess four different methods of calculating melatonin 
suppression in terms of sensitivity and consistency.
3.4.2 Methods
Nine subjects (S1-S9; 6M: 3F; 19-31 years) have been included in the analysis. Four 
different methods of calculating melatonin suppression have been used to analyse the 
plasma melatonin data.
Method 1\ %  s u p p r e s s i o n  (Nl(niean30+45mins)“N2(mean30+45mins) )  X  1 0 0
N 1 (mean30+45mins)
Baseline (Nl) values at 30 and 45 mins were compared with light treatment night 
(N2/N3) values (30 + 45 mins).
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Method 2: % suppression = (N 2 (m e a n -1 5 + 0 m in s ) -N 2 (m e a n 3 0 + 4 5 m in s )  ) xlOO
N2(mean-15+Omins)
Light treatment night (N2/N3) values before lights on (-15 mins + 0 mins) were 
compared with values after lights on (30 + 45 mins). No account is taken of the 
baseline night.
Method 3: % suppression = (AUC Nl(o-45mins)- AUC N2(o^5mins) ) x 100
AUC N 1 (0-45mins)
The Area under the curve (AUC) from 0-45 mins on the baseline night (Nl) was 
compared with the area under the curve (0-45 mins) on the light treatment night 
(N2/N3).
Method 4: % suppression = (N2(0mins)-N2(30mins) )
N 2 ( 0 m in s )
Light treatment night (N2/N3) values before lights on (0 mins) were compared with 
values after lights on (30 mins). No account is taken of the baseline night.
3.4.3 Results
The melatonin suppression calculated by all four methods is shown in Table 3.2
In the initial study legs all four methods were used to calculate the light-induced 
suppression of melatonin. After examining all these methods it was clear that the 
different methods could produce very different values of melatonin suppression for 
the same light treatment in the same subjects. One of the reasons for this is that low 
levels of light are being used in these experiments and these low irradiances produce 
little melatonin suppression. It is clear that when high intensity light (white 
91pW/cm^) is used all methods show a significant suppression of melatonin (Table 
3.2, 44-55% suppression). However, low intensity light produces little melatonin 
suppression and different methods give different results. Suppression with low light 
levels can sometimes only be seen if it is compared to the baseline night. In our 
protocol light exposure is timed to occur on the rising phase of the melatonin rhythm 
as a consequence of this comparing melatonin values after light treatment to those
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before light exposure (i.e. methods 2 and 4) suppression may not be observed as the 
values after light exposure may remain similar to those before lights on (Figure 3.6). 
However compared with the baseline night, suppression of melatonin is observed. As 
methods 2 and 4 only compare values before and after lights on, these methods are 
not sensitive enough to detect melatonin suppression by low intensities of light on 
the rising curve of the endogenous melatonin rhythm.
Careful consideration of the methods has led us to the conclusion that method 1 is the 
method of choice followed by method 3 area under the curve. Both methods takes 
into consideration the baseline night (Nl) comparing the melatonin concentrations on 
the light exposure night to those on the baseline night. Method 1 uses the 30 and 45 
minute time points, which is where maximum melatonin suppression was observed 
in all subjects. Methods 2 and 4 do not take the baseline night into account.
3.4.4 Conclusion
When low intensity light is being tested on the rising curve of the endogenous 
melatonin rhythm, a baseline study night 24 hours prior to the light treatment night 
should be conducted. Using this baseline data and the values obtained on the light 
treatment night the percentage melatonin suppression can be calculated. As the 
baseline night (Nl) is being used in the calculation of melatonin suppression (method 
1) experimental conditions need to be carefully controlled before and during the 
study. Factors affecting the melatonin rhythm such as posture, exercise and light 
exposure must be controlled so that any observed changes from the baseline are only 
the effect of the light exposure and not confounded by other factors. In our protocol 
exercise, caffeine, alcohol, bright lights are avoided. Subjects also keep a regular 
sleep wake cycle for three nights prior to the study leg (Section 2.4). The observed 
consistency in the subject’s baselines (Section 3.2) implies that control of these 
factors in our protocol is sufficient.
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Figure 3.6 Melatonin concentrations following low irradiance light.
Melatonin concentrations on a baseline night (■) and following light treatment 
(7.0 jaW/cm^ - 520 nm light) (O). The bar indicates lights on. When comparing 
the values before and after lights on on the light treatment night no suppression 
of plasma melatonin is observed. However, if  the values on the light treatment 
night are compared to the baseline night there is a significant suppression of 
plasma melatonin.
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3.5 DISCUSSION
These initial experiments served to validate the protocol. No effect of the pupil 
dilator on the melatonin profile was observed (Section 3.1) however, due to the small 
sample size these findings should be considered as preliminary. As the pupil dilator 
was given to all subjects on all study nights any effect of pupil dilator on the 
melatonin rhythm would be controlled for. The timing of administration of the pupil 
dilator was also at a set time (90 minutes before light onset. Section 3.1). The 
baseline repeatability and repeatability of melatonin suppression (Sections 3.2, 3.3) 
confirmed the reliability of the protocol. Melatonin suppression was calculated using 
the baseline and light treatment night values (Section 3.4). All the subsequent study 
legs incorporated the findings from the protocol development studies.
The protocol minimised factors affecting the melatonin rhythm. A baseline night on 
each 3-night study session was conducted to which the light exposure night was 
compared. This baseline night is especially important so that each individuals 
melatonin phase is known when the light is administered. This allows accurate 
calculation of melatonin suppression when measuring the effects of low irradiance 
light. If light is given on the rising phase of the melatonin rhythm, the suppressive 
effects of low irradiances of light may not have been observed (Section 3.4). The 
baseline night has thus been essential in these studies, in which a range (from 
threshold to saturation response inducing) of irradiances of light have been tested. 
The baseline night also controls for short-term factors such as pupil dilation and 
posture, and long-term factors such as stages of menstrual cycle, changes in circadian 
phase and seasonal changes. All procedures on all three nights of a study session 
were the same, and included control of posture and environmental lighting as these 
can alter the melatonin rhythm. As well as controlling factors that can affect the 
melatonin rhythm on the study nights, factors that can influence melatonin such as 
caffeine, drugs, exercise and bright light were also avoided before the study nights. 
The protocol was also designed to minimise sleep deprivation and subjects were 
allowed to sleep for at least 6-7 hours, thus avoiding any effects of sleep deprivation. 
Light exposure of 30 minute duration was chosen to minimise the chances of phase 
shifting but to be of sufficient duration to ensure melatonin suppression. Possible
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phase shifts of the melatonin rhythm between study sessions were also minimised by 
controlling the subjects’ sleep/wake cycle and monitoring their light exposure for 3 
days before the baseline night. These showed that the subjects complied with the 
protocol. This strict protocol control was essential to be sure that any effects seen on 
the melatonin rhythm were only that of the light exposure that was being tested.
As well as measuring the effect of light accurately, the delivery of light to the subject 
was developed to provide precise irradiances of monochromatic light to the entire 
visual field of a pupil-dilated subject. Pupil dilation is important in order to avoid the 
effects of a subject pupil constriction to a light source. The pupil dilator used, 
Tropicamide 5% had no effect on the melatonin rhythm (Section 3.1). The timing of 
administration of the pupil dilator was also standardised to 90 minutes before light 
onset (Section 3.1). This protocol produced reproducible melatonin rhythmns on the 
baseline nights between different study sessions (Section 3.2). In addition the 
repeatability of light-induced melatonin suppression in the same individuals for 
white light (Section 3.3) shows the reliability of this protocol.
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Chapter 4 
The Effect of CP-122, 721 on 
Light-Induced Suppression of 
Melatonin in Humans
121
4.1 INTRODUCTION
Substance P (SP) is an 11-amino acid neuropeptide of the tachykinin family of 
peptides. Although the precise role of SP and its primary receptor, neurokinin-1 (NK- 
1), remains to be defined it occurs in CNS areas that are known to be involved in the 
regulation of affective behaviour and stress responses. Selective NK-1 antagonists 
may be beneficial in the treatment of affective disorders. Several NK-1 antagonists 
have shown activity in animal models of depression and anxiety. Recently, a SP 
antagonist (MK-869, Merck) has been reported to have antidepressant effects in 
patients with moderate to severe major depression (Kramer et al., 1998).
The pineal gland is innervated by post-ganglionic sympathetic fibres. Noradrenaline 
is released firom these terminals and acts primarily on p-receptors (and a-receptors to 
a lesser extent) to stimulate melatonin synthesis via a cyclic AMP-dependent 
mechanism (Sugden et al., 1985). Melatonin is synthesized from its precursor, 
serotonin. Thus drugs that are known to affect noradrenergic and serotonergic 
pathways (e.g. antidepressants) have also been shown to affect pineal melatonin 
production (Skene et al., 1994). Whether NK-1 receptor antagonists affect melatonin 
synthesis in humans is not known.
There is evidence of a role for SP in the circadian system. SP is found in the 
amacrine and ganglion cells of the retina (Li et al., 1999). In humans Moore and 
Speh (1994) have shown positive immunoreactive SP axons in the human 
retinohypothalmic tract (RHT) that innervates the SCN. Fibres containing SP have 
also been demonstrated in mammalian pinealopetal nerve fibres, probably originating 
in the trigeminal ganglion (Moller et al., 1996). In addition, SP has been localised in 
the SCN (Mikkelsen and Larsen, 1993; Otori et al., 1993) and SP receptor-containing 
neurons have also been localized in the rat and hamster SCN (Mick et al., 1995; 
Takatsuji et al., 1995), primarily in the dorsal and lateral parts.
In vitro studies show that treatment with SP can induce phase shifts. Ionophoretic 
injection of SP has been shown to activate hamster SCN cells in vitro and modulate
the response of SCN cells to the excitatory amino acid (EAA) agonists, glutamate
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and N-methyl-D-aspartate (NMDA) (Piggins et al., 1995). Also in the rat SCN in 
vitro SP produces phase shifts of the circadian firing rhythms of SCN neurons with a 
phase response curve similar to that for light pulses (Shibata et al., 1992).
Light is transmitted to the SCN via the retina and the RHT. It causes acute 
suppression of melatonin production and it entrains the circadian oscillator and thus 
its output rhythms (e.g. melatonin rhythm) to the 24-hour day. SP has been proposed 
as a candidate neurotransmitter involved in the transmission of light information 
from the retina to the SCN. SP has also been shown to be present in the retinal 
ganglion cells, which project via the RHT to the SCN (Li et al., 1999).
Microinjection of SP into the SCN region produced small phase delays of hamster 
activity rhythms at CT 12-16 (Piggins and Rusak, 1997). These results led the 
authors to conclude that SP alone does not mimic the effects of light but may interact 
with other transmitters to modulate rhythmicity. Light also induces immediate early 
gene c-fos expression in the SCN. Abe and co-workers (1996) assessed the 
involvement of SP by investigating the effect of a SP receptor antagonist, spantide, 
on this photic induction of Fos. Light-induced Fos-like protein immunoreactivity was 
inhibited by spantide in a concentration-dependent manner.
Other antagonist R116301 and L-7600.735 have recently been shown to reduce the 
light induced phase advance in locomotor activity in hamsters when given before the 
light pulse (light pulse at CT19) but not when given after being exposed to the light 
pulse. However the drug did not affect the magnitude of phase delays (light 
administered at CT14). Finally hamsters were kept in constant light and injected 
during the subjective day and night with R116301. Those injected during the 
subjective day showed significant phase advances in locomotor activity whilst those 
injected during the subjective night showed no effects. The authors suggest that SP 
modulates the photic response of the circadian system and acts upstream of the phase 
resetting mechanism. They also suggest that inhibition of the NKl receptors signals 
darkness to the circadian clock (Challet et al., 2001; Challet et al., 1998).
The above described animal work thus suggests an involvement of SP in the retinal
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SCN-pineal-melatonin axis. The role of SP in the human circadian axis however, is 
currently not known. This present study aims to assess the effect of CP-122, 721, a 
centrally and peripherally active NK-1 receptor antagonist, on both nocturnal plasma 
melatonin content and on light-induced suppression of night time plasma melatonin 
in healthy males.
4.2 METHODS
This 5-leg study evaluated the effects of a single dose of CP-122, 721 (Pfizer Inc) on 
night time plasma melatonin concentrations. In addition the effects of two doses of 
CP-122,721 (20 and 200mg) on the light-induced suppression of melatonin were 
assessed. Each study leg consisted of two consecutive nights in the CIU - N l 
baseline no light, N2 -  light treatment night. This study was a randomised, double 
blind (third party blind), placebo-controlled, crossover, study involving six subjects.
4.2.1 Subject Selection Criteria
4.2.1.1 Initial inclusion criteria:
1. Males between the ages of 18 and 45 years of age, inclusive.
2. Body weight between -10 to +30% of the ideal weight.
3. Outpatients.
4. Subjects must be willing and able to provide written informed 
consent.
5. Non-smokers.
4.2.1.2 Medical inclusion criteria:
1. No evidence of clinically significant disease based upon a
complete medical history, physical examination, 12-lead 
electrocardiogram (ECG), and clinical laboratory tests.
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2. The following laboratory parameters must be within the 
reference range: WBC, absolute neutrophil count, urinalysis, 
sodium, potassium, calcium, chloride, bicarbonate, inorganic 
phosphorus, total protein, glucose, uric acid, serum albumin, 
haemoglobin, haematocrit, platelets, creatinine, alkaline 
phosphatase and total bilirubin.
The values for the following tests are to be:
HBsAg and Anti-HBc - negative;
Urine drug screen - negative; and
Urine cotinine - indicating non-smoker-negative
Subjects with minor deviations in clinical laboratory values 
judged to be clinically insignificant may be allowed to 
participate in the study if  approved by the Pfizer clinician.
3. Presence of a detectable aMT6s rhythm in the 48-hour urine 
collections obtained at screening.
4. Subjects must be discontinued from all prescription drug therapy, 
over-the counter medications, and drugs of abuse for at least two 
weeks prior to screening, and for the duration of the study. Certain 
drugs with prolonged half-lives, and drugs that are known to alter 
melatonin rhythms (Section 5.2.1.3), must be discontinued six 
weeks prior to screening. Any concomitant medications used 
regularly by any potential subject, even if  discontinued at 
screening, must be discussed with the Pfizer clinician prior to 
randomisation. Subjects may not have used any investigational 
drug for at least four weeks prior to the screening evaluation and 
they must agree not to participate in any investigational drug study 
for the duration of this study and for four weeks following the 
completion of this study.
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5. Subjects must agree to refrain from alcohol consumption for 24 h 
prior to and during each study leg. Additionally, for 2 days prior 
to each visit subjects must agree to limit alcohol consumption to 
no more than one pint of beer (or equivalent alcohol content in 
other beverages) per day.
6. Normal screening ECG, including normal sinus rhythm with 
resting rate between 50 and 90 beats per minute. No evidence of 
clinically significant rhythm abnormalities, ventricular 
hypertrophy, heart block, infarction, or ischaemia.
4.2.1.3 Exclusion criteria
1. Subjects with evidence of, or a history of psychiatric, 
neurological (including epilepsy), renal, hematological, 
endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic 
disease, drug or alcohol dependence, or a history of multiple 
drug allergies.
2. Subjects with any condition possibly affecting drug 
absorption.
3. Subjects who have used any of the following drugs known to 
alter melatonin synthesis or circadian rhythms within six 
weeks of screening:
lithium
antihypertensive drugs (e.g. p-blockers, calcium channel
blockers)
a-blockers
vitamins B12 and B6
non-steroidal anti-inflammatory drugs
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any hypnotic 
benzodiazepines
antidepressants (including monoamine oxidase inhibitors 
(MAOIs) and selective serotonin reuptake inhibitors 
(SSRIs)
antipsychotic drugs 
barbiturates 
antiepileptic drugs
Subjects also agree to discontinue the above drugs for the 
duration of the study. Additionally, subjects who have ever 
used any investigational drug (including CP-122,721) known 
to affect SP or NK receptors are specifically excluded from 
the study.
4. Subjects who have donated over 400 ml blood within four 
months of the screening visit. Subjects must also agree not to 
donate blood while participating in the study and for at least 
four months after completion of the study.
5. Subjects whose supine blood pressure at screening is below 
90/60 or above 150/90.
6. History or evidence of tobacco or nicotine use within the three 
months preceding screening.
7. Night shift workers, and/or subjects who have travelled across 
more than two time zones within two weeks of screening. 
Subjects must also agree not to travel across more than two 
time zones for the duration of the study.
8. Subjects predicted to be poor metabolizers (PMs) of CP- 
122,721 based on their CYP450 2D6 genotype.
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9. Subjects determined to have a low production of urine aMT6s 
(<5 pg aMT6s/24 h) and/or an abnormally timed peak of 
aMT6s (acrophase time outside 1.00-6.00 h range) as 
determined during screening.
10. Subjects with glaucoma or history of allergy to Tropicamide.
11. Concomitant medications, unless approved in advance by the 
Pfizer Clinician.
4.2.2 Pre-Study Screening
Subjects underwent a screening evaluation twenty-eight days prior to inclusion into 
the study which included:
-  complete history
-  full physical examination
-  blood pressure, pulse rate (supine and standing), and oral 
temperature*
-  12-lead resting electrocardiogram (ECG)*
-  clinical laboratory screen*
-  routine urinalysis (dipstick and microscopic)*
-  urine sample for drug screen and cotinine (single sample)*
-  blood sample for CYP450 2D6 (5 ml)
-  blood sample for pharmacokinetic baseline (10 ml)
-  48-h urine for aMT6s
The items marked by an asterisk (*) were performed within 14 days o f  
randomisation.
The 48-h sequential collection of urine was used for the analysis of the urinary 6- 
aMT6s rhythms. The light treatment was then timed to occur on the rising phase of
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the endogenous melatonin rhythm i.e. within 2-5 h before the urinary aMT6s peak, as 
determined by cosinor analysis of the aMT6s data.
4.2.3 Randomisation
After completion of all screening tests, the results were reviewed and subjects 
entered into the study and drug treatments were randomised. Each subject received 
two separate randomisations -  the first assigned treatment sequence for Visits 1 and 
2 (placebo vs. CP-122, 721,200 mg), and the second assigned treatment sequence for 
Visits 3-5 (placebo vs. CP-122,721, 20 mg vs. CP-122,721, 200 mg). 
Randomisations generated for Visits 1-2 and Visits 3-5 were entirely independent of 
each other.
All randomised subjects received placebo and CP-122,721 in a randomised, 
crossover manner, as indicated in Table 5.1 below. The placebo capsules were 
identical in appearance to capsules containing CP-122,721. A computer generated 
randomisation schedule was used to assign subjects to treatments within each group. 
Blinded disclosure envelopes were supplied with instructions regarding the breaking 
of a subject's blind in case of an emergency.
4.2.4 Pre-Study Conditions
Three days prior to the study
Following screening, randomised subjects were required to maintain a regular 
sleep/wake cycle (24.00-7.00 h sleep/darkness) in their home environment for three 
days prior to each visit (Visits 1-5). Subjective measures of sleep parameters (sleep 
onset, offset, duration, latency, quality, number and duration of night awakenings) 
were captured using sleep diaries for the three days prior to Visits 1-5. Subjects wore 
Actillumes, devices capable of measuring the subjects’ activity and light exposure 
during the 3-day period prior to each session. Actillume recordings also provided an 
objective measure of the subjects’ sleep.
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24 h prior and during study legs
Subjects were required to abstain from excessive exercise and caffeine-containing 
drinks for the day prior to Night 1 of each visit (Visits 1-5), and during the each visit 
(Visits 1-5).
4.2.5 Study Design
During Night 1 of Visits 1-5, subjects received no drug or light treatment (baseline 
nights). During Night 2 of Visits 1-5, subjects were randomised to receive either 
placebo or CP-122,721. During Visits 1 and 2 (Nights 1 and 2), subjects remained in 
the darkened, light-tight Clinical Investigation Unit through the night and received 
no retinal illumination. During Visits 3, 4, and 5 Night 1 was a baseline and on Night 
2 all subjects received 30 min of white light (91 pW/cm^) via the sphere as 
described in Chapter 2.
TABLE 4.1 Study design
Visits 1 & 2 (no retinal illumination)
Visit 1 (Night 1 
Visit 1 (Night 2 
Visit 2 (Night 1 
Visit 2 (Night 2
- Baseline night
- Placebo vs. 200 mg CP-122,721 (randomised)
- Baseline night
- Placebo vs. 200 mg CP-122,721 (randomised)
Visits 3,4, and 5 30 min retinal illumination)
Visit 3 (Night 1 
Visit 3 (Night 2 
Visit 4 (Night 1 
Visit 4 (Night 2 
Visit 5 (Night 1
- Baseline night
- Placebo vs. CP-122,721 (20 mg vs. 200 mg) (randomised)
- Baseline night
- Placebo vs. CP-122,721 (20 mg vs. 200 mg) (randomised)
- Baseline night
Visit 5 (Night 2) - Placebo vs. CP-122,721 (20 mg vs. 200 mg) (randomised)
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4.2.6 Drug Administration
Subjects received four capsules containing either 1) CP-122,721 (4 x  5 mg capsules 
= 20 mg), 2) CP-122,721 (4 x 50 mg capsules = 200 mg), or 3) placebo (4 capsules) 
p.o. 3 h before the light treatment on Night 2 of Visits 1-5, as determined by the 
randomisation schedules (Section 5.2.5). The randomised portions of Visits 1-5 
(Night 2) comparing CP-122,721 vs. placebo were double-blind. Doses were 
administered at least 2 h after food intake, and subjects remained fasting post-dose 
until 7.00 h the next morning in order to standardise experimental conditions.
4.2.7 Study Night
Subjects were admitted to the CIU at 19.00 h on Night 1 of each Visit. Upon arrival 
to the CIU, the following evaluation were performed:
brief assessment of subjective health status and concomitant medications (on 
Night 2 only)
blood pressure, pulse rate (supine and standing), and temperature (on Night 2 
only)
The subjects wore a rectal temperature probe with an ambulatory recording device 
which provided core body temperature at 6 minutes intervals (Grant squirrel memory 
loggers). A cannula was inserted in the subjects forearm (19.00-20.00 h).
The subjects remained seated in dim light (< 1 0  lux) firom 3 h before the light 
exposure. They were allowed non-caffeine containing drinks and a snack as desired, 
no later than 5 h before the light exposure. Non-caloric, non-caffeinated drinks were 
allowed ad libitum throughout the study.
At 2300 h (or 90 minutes before the light exposure if  before 2300 h) subjects wore 
eye masks and lay in a semi-recumbent position in complete darkness (< 1 lux). On 
both nights, 90 minutes before the time of the scheduled light exposure, subjects 
received a single drop of pupil dilator (Tropicamide 0.5%, Mimins) in each eye.
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During Visits 1-5 (Nights 1 and 2), blood samples (5 ml) for plasma melatonin were 
taken at -90 mins (time of pupil dilator administration) and then around the time of 
the scheduled light treatment (-15, 0, 15, 30, 45, 60, 75, 90, and 120 minutes after 
lights on). In addition, during Night 2 only (Visits 1-5), an additional 10 ml blood 
sample was taken just before lights on (for CP-122, 721 pharmacokinetics). Samples 
were taken under dim red light conditions.
The posture of the subjects was controlled so that on Nights 1 and 2 during Visits 1-5 
the same postural changes occurred. From 2300 h to the start of the light treatment 
(time 0), subjects were semi-recumbent. At time 0, subjects were in a sitting position 
and placed their heads in a spherical dome, positioning themselves correctly by 
placing their chins on the chin rest and their heads against a headrest. They remained 
in this position for 30 minutes during which time they received light or no light. 
Light treatment consisted of 30 minutes of white light (120 lux, 91 pW/cm^). The 
light source provided uniform illumination across the entire retina. During this time 
subjects kept their eyes open and fixed their gaze at a point marked in the centre back 
of the sphere (Fig. 2.2). After 15 more minutes of sitting, they were then allowed to 
be semi-recumbent. One hour after the end of the light treatment, subjects were 
allowed to lie down recumbent until 07.00 h.
Subjects remained confined to the CIU for at least 6 h after drug administration. Prior 
to discharge from the CIU after Night 2 of Visits 1-5, the following safety 
evaluations were performed: 
brief physical exam
blood pressure, pulse rate (supine and standing), and oral temperature 
laboratory screen
4.3 RESULTS
4.3.1 Melatonin Suppression
Plasma melatonin was analysed by RIA and calculation of melatonin suppression 
performed using method 1 (Section 2.4.2). The mean melatonin suppression data is 
summarised in Table 4.2.
Table 4.2 Mean melatonin suppression data
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Treatment % melatonin suppression 
(mean ± SEM)
No light exposure Placebo -51+26
High dose 200 mg -38 ± 22
Light exposure Placebo 68 ± 13
Low dose 20 mg 50+16
High dose 200mg 39 + 6
4.3.1.1 The effect of 200 mg CP-122,721 versus placebo on plasma melatonin
In a double blind, randomised, crossover design subjects received placebo or 200 mg 
CP-122, 721 (visits 1 and 2). The subjects' plasma melatonin concentrations on night 
2 (treatment night) were expressed as a percentage of baseline (night 1, no treatment) 
(Figure 4.1a). Time is expressed in relation to lights on. Paired Student’s t-test was 
used to test for statistical significance between night 1 and night 2.
There was no significant effect of placebo on plasma melatonin levels (Fig. 4.1a) 
except at 60 mins after lights on. Comparing melatonin values on night 1 with night 
2, 200 mg CP-122, 721 caused a significant increase at -15, 15, 30 and 75 mins after 
lights on (Fig. 5.1b). Figure 5.2 is a combination of Figures 4.1a and b. Comparing 
the effects of placebo and CP-122,721 there was no significant difference between 
the two treatments on melatonin levels at any time point.
Thus in summary, although 200 mg CP-122, 721 appeared to increase melatonin 
levels at some time points compared to the baseline night (Figure 4.1b), when the 
drug was compared to placebo no significant differences were observed.
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4.3.1.2 The effect of placebo, 20 and 200 mg CP-122,721 on light-induced 
suppression of plasma melatonin
In a double blind, randomised, crossover design subjects received placebo, 20 mg or 
200 mg CP-122, 721 with retinal illumination (Visits 3, 4 and 5). The subject’s 
plasma melatonin concentrations on night 2 (treatment night) were expressed as a 
percentage of baseline (night 1, no treatment) (Figure 4.3). Time is expressed in 
relation to lights on. Paired Student’s t test was used to test for statistical significance 
between night 1 and night 2.
Following placebo administration, light exposure caused a significant suppression of 
plasma melatonin at 15, 30, 45, 60, 75 and 120 mins after lights on (Fig. 4.3a). 
Following 20 mg CP-122,721, light caused a significant suppression of plasma 
melatonin at 15, 30 and 45 mins (Fig. 4.3b). Following 200 mg CP-122,721, light 
failed to suppress melatonin at 15 and 30 mins after lights on. Significant 
suppression was observed at 45, 60 and 90 mins (Fig. 4.3c).
Comparing melatonin suppression using a paired student’s t-test of placebo with 20 
mg CP-122,721 there was a significant difference ( P = 0.027). There was also a 
significant difference in % melatonin suppression comparing placebo and 200 mg 
CP-122,721 (P = 0.025). However, there was no significant difference between the 
two doses of the drug (P = 0.44).
In summary the findings show that light exposure produced a significant suppression 
of plasma melatonin (as predicted). Although this suppression of melatonin was 
observed following both 20 and 200 mg CP-122,721, the suppression was 
significantly reduced compared with placebo (Figure 4.4).
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Figure 4.3 Effect of placebo, 20 mg CP-122,721 and 200 mg CP-122,721 on light-induced 
suppression of plasma melatonin
Melatonin values as a percentage of baseline (mean ± SEM) are plotted against time in relation to 
lights on. The open bar shows the timing of light exposure, 30 mins of white light, 91pW/cm^. 
Panel a shows the effect of placebo, panel b shows the effect of 20 mg CP- 122, 721 and panel c 
the effect of 200 mg CP- 122, 721.
* P < 0.05; ** < 0.01; *** < 0.005 compared to baseline.
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4.3.2 Core Body Temperature
4.3.2.1 The effect of 200 mg CP-122,721 versus placebo on CBT
The mean core body temperature data is shown in Figure 4.5. This temperature data 
is masked. There appeared to be an increase in core body temperature with 200 mg 
CP-122, 721 compared to the placebo leg. This increase in temperature occurred 2 h 
after drug administration at which times the CBT is higher than baseline and higher 
than the placebo leg. However this increase at 2 h after drug was not observed the 
second time the 200 mg dose of CP-122,721 was administered or with 20 mg dose 
(visits 3-5) and was not statistically significant.
The effect of placebo, 20,200 mg CP-122,721 and light on CBT
Following placebo administration and light exposure, the temperature increased 
immediately after the lights were turned on (Fig.4.6a). This rise in temperature 
mirrored the drop in melatonin concentration. Examining 0-60 mins after lights on a 
mean increase of 0.32 % for the placebo treatment is calculated using the following 
formula.
% CBT change = 100 X (Nl(AUCO+60mms)"N2(AUCO+6Omins) )
N 1(A U C  0+60mins)
However, following administration of 20 and 200 mg CP-122, 721 (Figure 4.5b and 
c) there was no significant increase in body temperature (mean % increase of - 0.10 
% and decrease of 0.23 %, respectively).
Comparing the mean change in CBT from 0-60 mins after the low dose with placebo 
there was no significant difference (P = 0.25). However, comparing the high dose 
and placebo there was borderline significant difference in CBT (P = 0.06).
The CBT results were comparable with the melatonin suppression data. With placebo 
a significant increase in CBT and a significant suppression of melatonin was 
observed.
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Figure 4.5 Effect of placebo and 200 mg CP-122,721 on core body temperature
Core body temperature values as a percentage of baseline (mean ± SEM) are plotted 
against time in relation to lights on. Although no light was administered during 
these two treatments the timing of samples were standardised to tight treatment 
times in the last 3 study legs. The open bar shows the timing of light exposure 
during which time no tight was administered but subjects were seated in the spheres 
with eye masks on. Panel a shows the effect of placebo (n = 6) and panel b shows 
the effect of 200 mg C P -122, 721 (n = 4). The drug was administered at -180 mins
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Figure 4.6 Effect of placebo, 20 mg CP-122,721 and 200 mg CP-122,721 on core 
body temperature
Core body temperature values as a percentage of baseline (mean ± SEM) are 
plotted against time in relation to lights on. The open bar shows the timing of 
light exposure, 30 mins of white light 91pW/cm^. Panel a shows effects of 
placebo (n = 6), panel b the effect of 20 mg CP- 122, 721 (n = 5) and panel c 
shows the effect of 200 mg C P -122, 721 (n = 5).
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4.4 DISCUSSION
Light exposure produced a significant suppression of plasma melatonin. 
Administration of CP-122,721 3 h prior to light exposure significantly reduced the 
light induced suppression of melatonin. Light-induced suppression of melatonin, 
however, was not entirely prevented by drug administration.
During the no light treatment visits (visits 1 and 2) an increase of plasma melatonin 
was observed on night 2 following placebo or 200 mg CP122, 721 compared to night 
1 (Figure 4.1). This increase is also illustrated in Table 4.2 showing % melatonin 
suppression using method l(mean ± SEM) to be -51% ± 26% and 38% ± 22% for 
placebo and CP-122, 721, respectively. These findings are extremely unusual and 
were not observed using low irradiances of light in the action spectrum studies 
(Table 5.2). Differences in experimental design and methodology may explain these 
discrepancies.
CP-122,721 does not seem to affect the melatonin rhythm. However, the increase in 
CBT observed after light exposure does seem to be influenced by CP-122,721, as 
following administration of 20 mg of CP-122,721 a much smaller increase in CBT is 
observed compared to Placebo and following administration of 200 mg CP-122,721 
no increase in CBT is observed during light exposure.
The results suggest that CP-122,721 has some effect of the retina-SCN-pineal 
melatonin axis in humans. The exact mechanism of action remains to be elucidated.
In addition, in view of the present data, it would be interesting to investigate the 
effects of CP-122,721 on the melatonin rhythm further i.e. does it act on the 
production of melatonin as well as the light-induced inhibition of it ? The effects of 
the drug on phase-shifting may be worthwhile investigating.
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Chapter 5 Results
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5.1 SLEEP DIARIES AND ACTILLUME RECORDS
Subjects were required to keep a regular sleep wake cycle for three nights prior to 
the beginning of each study session (Section 2.4). As well as ensure that they kept 
a regular sleep/wake cycle it was also important to check that they did not expose 
themselves to bright light at inappropriate times. Both conditions ensured that 
subjects had a regular light/dark cycle prior to the study in the CIU. Subjects wore 
actillumes to record the light levels and their wrist motor activity. The sleep 
diaries and actillume data were examined between each study leg to ensure 
subjects were obeying the protocol. The sleep diaries were checked against the 
actillume record to verify the accuracy of the subjective sleep diary data e.g. when 
the subject recorded they went to bed the actillumes illustrated this with lower 
light levels and a decrease in activity. The actillume records were also examined 
for any unusual bright light exposure over 10 lux during the night in case this 
caused any phase changes in the subjects’ melatonin rhythm.
Sleep diaries were used to calculate the mean sleep onset time (time when sleep 
was attempted plus sleep latency in mins), sleep offset (wake up time) and sleep 
duration for each leg of the study. The mean values for the study subjects for each 
study leg are shown in Table 5.1. An example of a typical sleep map is shown in 
Figure 5.1 and the corresponding actillume record of light and activity levels is 
shown in Figure 5.2. The recorded sleep periods corresponded well against the 
actillume light and activity plots for all the subjects. At least 4 of the 6 subjects 
were given actillumes to wear for each leg of the study. All subjects kept fairly 
regular sleep/wake cycles during the three nights before the study legs. The 
example of an actillume plot (figure 5.2) illustrates that the subject received less 
light between 21.00 h and bedtime on the study nights in the CIU (<10 lux) 
compared to the 3 nights before the study when they were in their home 
environment. This phenomenon was noted in most of the subjects. It was also 
observed that the light changes were more abrupt in the CIU as lights are switched 
on/off whereas when subjects were in their own environment more natural 
changes in lighting were recorded (Figure 5.2a).
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No evidence of bright light exposure were noted during the night in any of the 
subjects neither were there any disrupted sleep/wake cycles observed that may 
have caused phase changes before the beginning of a study leg.
Table 5.1 The mean (±SD) values for sleep onset, offset and duration for each 
study leg.
Mean ±SD
Leg Date n Sleep onset (h) Sleep offset (h) Sleep
duration (h)
1 02.05.98 6 23.50 (± 0.76) 7.18 (±0.62) 7.2 (± 0.9)
2 26.05.98 5 23.37 (±0.53) 7.52 (±1.05) 7.8 (± 1.0)
3 16.06.98 6 23.50 (± 0.82) 7.67 (± 0.99) 8.2 (±1.0)
4 24.08.98 6 23.85 (± 0.63) 7.53 (±1.05) 7.9 (± 1.4)
5 13.10.98 5 23.30 (± 0.48) 7.75 (± 0.99) 8.5 (± 0.8)
6 27.10.98 6 23.38 (± 0.52) 7.50 (± 0.90) 8.1 (±0.9)
7 10.11.98 6 23.07 (± 0.56) 7.31 (±0.98) 8.6 (± 0.8)
8 26.04.99 5 23.29 (± 0.79) 8.04 (± 1.47) 8.7 (±1.3)
9 02.05.99 6 23.47 (± 0.72) 7.50 (± 0.79) 8.0 (± 0.8)
10 09.05.99 6 23.31 (±0.60) 7.80 (±1.31) 8.5 (±1.2)
11 24.08.99 6 23.22 (± 0.53) 7.58 (± 0.62) 8.4 (± 0.6)
12 31.08.99 6 23.50 (±1.15) 7.97 (±1.18) 8.5 (± 0.9)
13 07.09.99 6 23.56 (± 0.90) 7.36 (± 0.97) 7.8 (± 0.7)
14 14.09.99 6 23.49 (± 0.78) 7.47 (± 0.63) 8.0 (± 0.5)
15 21.09.99 4 23.42 (± 1.00) 7.66 (± 1.27) 8.2 (± 1.2)
16 28.09.99 5 23.53 (± 0.69) 7.89 (±1.37) 8.4 (±1.2)
17 18.01.00 6 23.44 (± 1.02) 7.79 (± 0.99) 8.4 (± 1.2)
18 25.01.00 6 23.51 (±0.88) 7.85 (± 1.23) 8.3 (±1.1)
19 01.02.00 6 23.68 (± 0.90) 7.76 (±1.05) 8.1 (±1.3)
20 08.02.00 6 23.64 (± 0.80) 7.18 (±1.10) 8.2 (±1.1)
Time in decimal hours
145
O
CM (j0
f
cS
1
s X b q
§■
ce4-1O
u
.1
ce
H
(U O  
! :  
I lçc _ ce c
s<g
3 s
II% w 
o o
i!
l i
s  g
S3T3
. i
S*
&0)
o mCN
u0>
¥
C /3
I
Iil
I
| i î
I l e
146
.yd
o o o o  o o o oo t n o i n  o t n o m i s l °  „ISI° _IS|s : |S |s I
I
ÜÜf
ce
g
ê
ICL
(U
I
ce
4- t
o
B
ce
d
S
f
(N
in
.1Pu
D
G
c
g
w"
I
VO
*â
•3 Z
g
SI
I
o
BoJC
m
Q
a
ce-o
>•ao
ce
j6
% )
g
W)
ce
147
5.2 PLASMA MELATONIN
Blood samples were taken around the time of light exposure during the course of 
each study night (Section 2.5.3). Plasma was separated, stored at -20°C and 
assayed for melatonin by radioimmunoassay (Section 2.8.2).
All individual’s melatonin values (pg/ml) were plotted against clock time. Figure
5.3 shows a typical example of a subject’s melatonin profile over a study leg, a 
baseline night followed by two light exposure nights. Following light exposure 
there was a marked suppression of plasma melatonin compared to both pre-light 
melatonin concentrations and baseline night.
To ensure that the observed suppression of plasma melatonin on night 2 was due 
to the light alone and not just a result of the procedure two consecutive nights of 
no light exposure were examined (the pupil dilator and non-pupil dilator nights 
were examined as there was no light exposure for these two consecutive nights). 
These show no suppression of plasma melatonin on night two without any light 
exposure. Thus any measured suppression of melatonin is due to the light only.
5.2.1 Effect of 30-Minute Light Exposure on Plasma Melatonin
In order to evaluate the effects of a 30-minute light exposure on the plasma 
melatonin rhythm, melatonin values on the light exposure night were expressed as 
a percentage of the baseline (no light exposure) night. The mean data for each 
irradiance at each wavelength are shown in Figures 5.4 -  5.10 for 424, 456, 472, 
496, 520 and 548 nm and white light respectively. Significant differences between 
the baseline and light treatment values were calculated at each time point (paired 
student’s t-test).
Before lights on, melatonin concentrations on the light treatment night were 
similar to those on the baseline night. The three plasma samples before lights on 
were thus around the 100 % mark. This finding also indicates that there has been 
no change of phase between the study nights. This is especially important for
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night 3 values as the light exposure on night 2 could have phase shifted the 
melatonin rhythm on night 3. For the light irradiances that have been used we see 
no evidence of a phase shift. If phase shifts were to occur they would be phase 
delays. As melatonin suppression is calculated using the baseline night, 
calculation of melatonin suppression following a phase delay would be an 
overestimation.
At all irradiances and wavelengths except 0.70 -  4.1 pW/cm^ for 520 nm and 7.2 
pW/cm^ for 548 nm light suppression of plasma melatonin occurred after 15 
minutes of light exposure. The amount of melatonin suppression increased after 
30 mins of light exposure. At 30 minutes the lights were switched off and 15 
minutes after this melatonin levels began to rise (this was noted for low light 
irradiances) or stayed around the same level. Thirty minutes after lights off 
melatonin level gradually increased back to baseline levels. The time course of 
this recovery depended upon the irradiance of light. In most cases 45 mins after 
lights off the melatonin values were similar to the baseline values. There were 
some exceptions to this mostly at the high irradiances at each wavelength.
The melatonin changes over time were dependent on irradiance and for each 
wavelength the same trend (increased melatonin suppression) was observed with 
increasing irradiance (Figures 5.4 -  5.10). Figure 5.11 illustrates this for all 
irradiances at 424 nm. However, there are some differences between wavelengths. 
At short wavelengths (424 and 456 nm) of low irradiance (1.9 and 2.0 pW/cm^) 
suppression of melatonin occurred at 15 minutes after lights on, whereas at longer 
wavelengths (520 and 548 nm) higher irradiances (7.0 and 13.6 pW/cm^) were 
needed to suppress melatonin within 15 minutes.
It is not entirely correct to compare irradiances of different wavelengths as 
different wavelengths have photons of different energies and therefore 
comparisons of photon density are more appropriate (Section 5.3). Figure 5.12 
shows melatonin as a percentage of baseline for 4 wavelengths (424, 456, 520 and 
548 nm) at an equal photon density of approximately 2.0 x 10^  ^photons/cm^/sec 
(± 10%). This comparison shows short wavelength light ( 424 and 456 nm) to be
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more effective at suppressing melatonin than longer wavelengths (520 and 548 
nm).
5.2.2 Light-Induced Melatonin Suppression
Melatonin suppression was calculated by method 1 (described in Section 3.4.2) in 
which the mean of the melatonin values at 30 and 45 minutes after light exposure 
on the light exposure night are compared to the same two points on the baseline 
night. These two points were used, because this was the time of maximum 
melatonin suppression (Figures 5.4 - 5.10). Table 5.2 shows the mean percentage 
melatonin suppression for all subjects studied at each irradiance for all 
wavelengths. The geometric mean is also included in the table.
The minimum irradiances of light required to produce a significant suppression of 
plasma melatonin were 1.9, 2.0, 1.8, 3.0, 4.1 and 7.2 pW/cm^ for 424, 456, 472, 
496, 520, and 548 nm, respectively.
Melatonin suppression increased with increasing irradiance at each wavelength 
(for example see Figure 5.11). There were also clear differences in melatonin 
suppression depending on the wavelength of light (Figure 5.12) which are further 
examined in Section 5.3. However the effect of wavelength can also be examined 
by comparison to studies using white light. White light of irradiances of 2.15, 
3.86, 6.60 and 7.2 pW/cm^ contain approximately the same number of photons as 
2.8 pW/cm^ of 472 nm, 4.1 pW/cm^ of 520 nm, 7.0 pW/cm^ of 520 nm and 7.2 
pW/cm^ of 548 nm light, respectively. However, the percentage of melatonin 
suppression is -6,17, 20 and 27% for white light as opposed to 15, 30, 24 and 6%, 
respectively for the monochromatic sources. This finding suggests that the system 
is not merely a photon counter but is sensitive to wavelength.
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Table 5.2 Percentage melatonin suppression for wavelengths at each irradiance
n wavelength irradiance
pW/cm^
Lux photons/cm^/sec % melatonin suppression 
mean ± SEM
% melatonin suppression 
geometric mean + SEM
6 424 1.90 2.5 4.14E+12 10 ±3 9 + 1
6 424 2.80 4.1 6.23E+12 21 ±5 20+1
6 424 4.50 6.4 9.62E+12 35 ± 4 35 ±1
6 424 9.00 12.9 1.92E+13 51 ± 2 48 + 1
5 424 11.00 15.5 2.36E+13 55 ± 4 55 + 1
5 456 2.00 3.3 4.61E+12 15 + 3 11 + 1
5 456 4.00 6.5 9.22E+12 33 ±3 31 ±1
5 456 8.00 13.0 1.84E+13 5 1 + 7 50+1
4 456 29.00 51.2 6.65E+13 65 + 2 65 + 1
6 472 1.80 2.9 4.25E+12 13 + 5 7 ± 1
7 472 2.80 4.40 6.70E+12 15 + 3 13 + 1
6 472 4.10 6.4 9.81E+12 20 ± 5 14 + 1
6 472 9.00 14.1 2.15E+13 52 + 6 50+1
6 472 14.20 2Z3 3.36E+13 65 + 6 63 + 1
6 472 22.00 40.1 5.23E+13 67 + 3 67+1
5 472 31.00 50.7 7.37E+13 67 + 1 67 + 1
4 496 3.00 5.1 7.50E+12 16 + 4 15 + 1
7 496 6.50 11.1 1.61E+13 3 1 + 4 29 ±1
6 496 13.00 20.1 3.25E+13 46 + 5 44 ±1
6 496 18.00 27.5 4.47E+13 52 + 4 52+1
5 496 26.00 42.9 6.45E+13 59 + 2 5 9+1
5 496 30.00 50.2 7.46E+13 60 ± 2 60+1
3 520 0.70 1.1 2.10E+12 3 + 2 2 ± 1
6 520 1.80 2.9 4.73E+12 6 + 6 5 + 1
3 520 3.25 5.2 8.53E+12 9 + 8 6 + 2
5 520 4.10 6.5 1.08E+13 30+4 28 + 1
7 520 7.00 11.0 1.85E+13 24 + 5 2 0+ 1
6 520 15.70 24.5 4.14E+13 47 + 7 4 4+ 1
5 520 27.00 42.2 8.10E+13 57 + 6 56 + 1
6 520 41.00 65.2 1.07E+14 63 ± 6 62 + 1
5 520 65.00 108 1.70E+14 67 + 4 67 ±1
5 548 7.20 11 2.00E+13 6 + 2 5 ± 1
5 548 13.60 21.3 3.78E+13 19 + 6 13 + 1
3 548 26.00 41.9 7.18E+13 36 + 15 29 + 1
3 548 52.00 83.8 1.43E+14 46+11 43 + 1
5 548 65.00 102 1.79E+14 48 ± 6 47 ±1
3 White 2.15 3.30 6.06E+12 -6 + 10 0 ± 1
6 White 3.86 5.9 1.09E+13 17 ± 6 10+1
4 White 6.60 10.2 1.87E+13 20 ± 2 19+1
5 White 7.20 11.1 2.03E+13 27 + 6 25 + 1
8 White 91.00 120 2.57E+14 55 + 6 5 4+ 1
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To examine this issue further white light with the same number of photons as 3.25 
pW/cm^ of monochromatic 520 nm light tested whether only photons number was 
important in the light-induced suppression of melatonin suppression. However, this 
is not the case. The white light source produced 55% suppression whereas the 520 
nm light produced 9% suppression. Thus there are other wavelengths within the 
white light source that are more effective than 520 nm light at suppressing melatonin.
Comparing this white light source that produces 55% suppression of melatonin with 
the other wavelengths at approximately the same photon densities that are 
represented in the white source indicated that one wavelength alone does not produce 
the response measured. For example 424, 456, 472, 496, 520 and 548 nm at 
approximately the same number of photons as that present in the white light source 
produce % mean melatonin suppression values of 21, 33, 20, 16, 9 and 6 % 
respectively. This indicates that the response seen with white light cannot be 
attributed to a single monochromatic wavelength and maybe due to a range of 
wavelengths most probably between in the short wavelength region (424 - 472 nm).
5.3 DOSE-RESPONSE STUDIES
The dose-response relationship between light irradiance and melatonin 
suppression at each wavelength was investigated by studying 4-9 irradiances at 
each wavelength in 3-7 subjects per irradiance.
For each wavelength there was an increasing amount of melatonin suppression 
with increasing light irradiance. The dose response relationship for each 
wavelength is shown in Figure 5.13. The % melatonin suppression (arithmetic 
mean) was plotted against photon flux (photons/cm^/sec) for each wavelength. 
Figure 5.14 shows plots of % melatonin suppression (geometric mean) against 
photon flux for each wavelength.
There are no significant differences between the % melatonin suppression 
calculated using the arithmetic mean compared to the geometric mean. The
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geometric mean weighs outliers to the general population less than for the 
arithmetic mean. The SEM is thus lower for the geometric mean.
In order to quantitate the effects of wavelength, dose-response curves were fitted to 
the data sets so that direct comparison between wavelengths at fixed photon flux or 
fixed melatonin suppression could be made.
5.3.1 Curve Fitting
To fit dose-response curves to the data it is important to determine the lower and 
upper asymptotic levels for the measured response as well as the slope of the line.
The lower asymptotic value was set to zero and this was based upon the 
assumption that zero photons (no light) produced no suppression of melatonin. In 
order to determine the best-fit line through these data the four parameter logistic 
model (Section 2.9.3) was fitted to the entire data set regardless of wavelength to 
determine the higher asymptotic range as well as the slope of the line.
During initial curve fitting the higher asymptotic range was left free from 50-100 
and the slope of the line was also left free from 0.1-8.1. The best fit resulted in the 
higher asymptotic value fixing at 60% and the slope of the line at 1.44 (Figure 
5.15). However, on examining the raw data four of the six wavelengths 
suppressed melatonin more than 60%. It was thus concluded that the longest 
wavelength (548 nm) may have been skewing the data as at the highest irradiance 
studied melatonin suppression was 48% and not at saturation. Therefore the curve 
fitting was redone without the 548 nm data. From this recalculation the higher 
asymptotic value (c) was fixed at 70 % and the slope (d) at 1.5 (Figure 5.16).
These data were then used in the four parameter logistic model to fit each 
individual wavelength data set.
y =  0-70 +70
( i + ( V )
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Each generated curve fitted the mean data for each wavelength with an value > 
0.99. The same curve fitted all the wavelengths well suggesting that these data 
obey the principle of univariance.
At each wavelength there was a clear dose-response relationship of light 
irradiance and melatonin suppression (Figure 5.17). Figure 5.17 shows that the fit 
of the logistic equation to the data points for 520 nm is not as good as for the other 
wavelengths. This was due to one exceptional point which yields 30% suppression 
at 1.03 X 10^  ^photons/cm^/sec which was a greater suppression of melatonin than 
the higher irradiance of 1.85 x 10^  ^photons/cm2/sec which only resulted in a 24 
% suppression. There was a change in the subjects studied between these two 
irradiances and individual differences in subjects may have caused this 
discrepancy in the dose-response curve at this point which is near the threshold of 
suppression and therefore sensitive. This point was thus removed from the data 
set. This improved the fit of the dose-response curve to the 520 nm data set (R = 
1.00 as opposed to 0.99) (the revised fitted curve is presented in Figure 5.18).
Figure 5.18 shows all the dose-response curves plotted together in order to 
compare the spectral sensitivity of melatonin suppression. The 456 nm light was 
the most effective at suppressing melatonin. All the other curves were shifted to 
the right with 424 nm light being the next most effective followed by 472 nm > 
496 nm > 520 nm > 548 nm. Generally the shorter wavelengths were more 
effective than the longer wavelengths
.3.2 Half-Maximal Sensitivities
The half-maximal sensitivities ( E D 50)  calculated from these fluence response 
curves are illustrated in Figure 5.19 and are shown in Table 5.3.
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Table 5.3 Half-maximal sensitivities (ED50) for each wavelength.
Wavelength
(nm)
ED50 
(photons/cm^/sec)
424 1.03x10^
456 9.94x10^^
472 1.27x10^
496 2.00x10^^
520 2.71x10^^
548 8.28 X 10^ ^
The most effective wavelength was 456 nm followed closely by 424 nm. 548 nm 
is the least effective wavelength with more than eight times as many 
photons/cm^/sec being required to observe the same effect as for 456 nm light. 
Compared with the 456 nm light twice as many photons of 500 nm light, 2.7 times 
as many photons of 520 nm and 1.3 times as many photons of the 472 nm light are 
required to produce the same amount of melatonin suppression.
5.4 ACTION SPECTRUM
The calculated half-maximal sensitivities ED50 were then used to construct an 
action spectrum. All the half-maximal sensitivities were logged and plotted 
relative to the most sensitive wavelength, 456 nm.
The action spectrum in Figure 5.20 shows that the most sensitive wavelength was 
456 nm and that there was only a small difference in sensitivity between 456 and 
424 nm. The spectral sensitivity curve covered a range of wavelengths with a 
maximum around 424-456 nm, a shallow decline up to 520 nm followed by a 
steeper drop. There was a well-defined peak around 424-456 nm and a smaller 
peak in the 520 nm region.
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For comparison the action spectra calculated using method 1 (arithmetic and 
geometric mean) and using the area under the curve (arithmetic and geometric 
mean) have been plotted in Figure 5.21. As the overall shapes of the action spectra 
were not different, method 1 using the arithmetic mean was used for all 
subsequent analysis (Section 5.4.1 onwards).
5.4.1 Corrections to the Action Spectrum: The Effects of Prereceptoral Filtering
Prereceptoral filtering by the lens and macular pigment can affect the sensitivity of the 
photoreceptors (Section 1.4.2.2) and therefore the action spectrum for melatonin 
suppression was corrected for the effects of lens and lens and macular pigment using 
Stockman et al., (1999) lens and macular pigment transmission data (Figure 1.5).
The EDsos were corrected for effects of lens and macular pigment by multiplying with 
the lens and macular pigment transmission values and these are shown in Table 5.4.
Table 5.4 Half-maximal sensitivities (ED50) for each wavelength after correcting 
for lens filtering and lens and macular pigment filtering.
Wavelength
(nm)
Lens alone 
EDjo 
(photons/cm^/sec)
Lens and Macular pigment 
ED50 
(photons/cm^/sec)
424 3.01 X 10‘^ 1.78 X 1 0 "
456 6.16 X 1 0 '^ 2.75 X 1 0 "
472 8.54 X 1 0 '^ 4.36 X 1 0 "
496 1.46 X 1 0 “ 8.36 X 1 0 "
520 2 1 2 x 1 0 " 1.88 X 1 0 "
548 6.95 X 1 0 " 6.94 X 1 0 "
Accounting for the effects of lens and macular pigment changes the sensitivity of the 
action spectrum so that the 424 nm point is more sensitive than the 456 nm point 
(Figure 5.22).
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Figure 5.22 Action spectra for melatonin suppression uncorrected (■), corrected for 
lens and macular pigment filtering(O) and corrected for lens filtering (•) .
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Lens density shows inter-individual differences so, although the lens density data 
used were calculated from mean data (Stockman et ah, 1999), the correction is at best 
an approximation. Lens opacity also changes with age and the full data set of these 
changes is not published.
Given the method of light exposure in the present study and the restricted 
distribution of the macula pigment (primarily in the fovea), macula pigment 
filtering is not likely to make a contribution to the observed response.
5.4.2 Fitting the Melatonin Action Spectra
The melatonin action spectrum uncorrected, corrected for lens and corrected for 
lens and macular filtering (Figure 5.22) were fitted to the absorption spectra of the 
known rod and cone photoreceptors, novel rhodopsin nomograms and 
cryptochromes. The lens corrected data was fitted with a combination of 
photoreceptors in order to determine which photoreceptors may be producing the 
observed melatonin action spectrum.
5.4.2.1 Fitting the melatonin action spectrum with single known 
photoreceptors
In order to determine which photoreceptors, may be contributing to the observed 
response, Dartnall nomograms were fitted to the melatonin action spectra data. The 
published absorption spectra templates of the rod and cone visual pigments (Dartnall 
et al., 1983) and cryptochromes 1 and 2 (Hsu et al., 1996) were fitted to a third order 
polynomial (Prism 3.0, Graphpad Software, San Diego, CA, USA). Fits of = 0.99 
were achieved and the resultant polynomial curves were fitted to the melatonin 
suppression action spectrum and goodness of fit values (R^) obtained. Third order 
polynomial curves, generated from rhodopsin templates with Xmax ranging between 
420-480 nm, were also fitted to the action spectrum by the same method.
The melatonin action spectra uncorrected, corrected for lens filtering and corrected 
for lens and macular filtering could not be fitted with any single known
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photoreceptor (S-cones, M-cones and L-cones) <0.1 (Figure 5.23 shows the lens 
corrected data). The lack of fit (R  ^ < 0.1) provides strong evidence that no single 
known retinal photoreceptor (rod or cone) could account solely for this response. The 
cryptochromes 1 and 2 absorption spectra (from 400 nm onwards to account for lens 
transmission) was also fitted and the cryptochromes do not produce good fits (R  ^ < 
0.41) (Figure 5.24 shows the lens corrected data).
5.4.2.2 Fitting the melatonin action spectrum with single novel 
photoreceptors
The melatonin action spectrum shows a well-defined spectral sensitivity peak around 
420-470 that may derive from a novel non-rod, non-cone photopigment. In order to 
determine the best fit to the action spectra (corrected and uncorrected) a series of 
Dartnall nomograms generated for rhodopsin-based photopigments over the Imax 
range of 420 to 480 nm were fitted to the data. Opsin photopigments with Imax 
ranging from 465 to 471 nm fitted the uncorrected action spectrum well (R^ > 0.8). 
Of these, an opsin with a Xmax 468 nm best fits the data (lowest sum of squares, R^ = 
0.85) (Figure 5.25). Rhodopsin photopigments with Imax ranging from 457-462 nm 
fitted the lens corrected action spectrum well (R^ > 0.73). Of these, an opsin with a 
Xmax 459 nm best fits the data (lowest sum of squares, R^ = 0.74) (Figure 5.25). 
Finally opsin based photopigments Xmax 445-449 nm fitting the lens and macular 
corrected data well (R^>0.80). Of these, the best fit was to the opsin template with 
Xmax 447 nm (R^=0.84) (Figure 5.25).
5.4.2.3 Fitting the melatonin action spectrum with a combination of known and 
novel photoreceptors
Although the lens corrected data are best described by a single novel rhodopsin 
template with Xmax 459 nm, it cannot be excluded that other photopigments may 
make a minor contribution to the response. An opsin with a Xmax 459 nm fits the 
whole data set well, however closer examination indicates that the shorter
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Figure 5.25 Action spectra for melatonin suppression fitted with novel opsins,
a. uncorrected action spectrum (■)fitted with a novel opsin ^max 468 nm (R  ^= 0.85), 
action spectrum corrected for lens and macular pigment filtering(O) fitted with a novel 
opsin ^max447 nm (R  ^= 0.84) and action spectrum corrected for lens filtering (# ) fitted 
with a novel opsin nm (R^  = 0.74) .
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wavelengths are not fitted well. A combination of known and novel opsin-based 
which best fits the shape of the observed action spectrum was thus assessed. The 
short wavelength points 424 -  472 nm fit the S-cone (Figure 5.23 a). The absorption 
spectrum of the blue cone (90%) in combination with a contribution (10%) from the 
rod absorption spectrum, resulted in curves that most closely followed the shape of 
the action spectrum (Figure 5.26) (R^ = 0.98). Combining the S-cone (90%) with the 
M-cone (10%) also fits the action spectrum well (R^ = 0.92).
A combination of the blue cone with novel photoreceptors between 460 and 490 nm 
was also assessed. Table 5.5 summarises the best fit combinations of S-cone and 
novel photoreceptors.
Table 5.5 Best fît combinations of S-cone and novel opsins to lens corrected 
melatonin suppression action spectrum.
Novel opsin
^max
%
S-cone
%
Novel opsin
460 nm 65 35 0.75
470 nm 75 25 0.89
480 nm 85 15 0.94
490 nm 85 15 0.90
A combination of S-cone and novel opsin Imax 480 nm best fit the lens corrected 
action spectrum for melatonin suppression (Figure 4.27)
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5.5 SPECTRAL SENSITIVITY OF MELATONIN SUPPRESSION 
COMPARED TO VISUAL SENSITIVITY
The action spectrum for melatonin suppression cannot be attributed to any single 
known photoreceptors (Section 5.4.1.1) and the sensitivity curve for melatonin 
suppression falls between the sensitivity curves of the known photoreceptors. Figure 
5.28 clearly demonstrates that this observed response is different to the known visual 
responses.
The observed action spectrum for melatonin suppression is also very different to the 
known spectral sensitivity of the scotopic and pbotopic response curves (being 
shifted approximately 50 and 100 nm to the left of the scotopic and pbotopic 
response, respectively) (Fig. 5.29). The relative sensitivity of melatonin suppression 
appears to peak at lower wavelengths of light than scotopic or pbotopic vision. This 
is very different to the known scotopic or pbotopic visual responses.
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CHAPTER 6 
DISCUSSION
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6.1 Rationale
The rationale for this thesis was to investigate the spectral sensitivity of light-induced 
melatonin suppression in humans. Previous work in mice showed that neither rods 
nor cones are necessary for phase shifting rhythms or suppressing melatonin 
(Freedman et ah, 1999; Lucas et ah, 1999c). However, the eyes mediate these 
responses, as bilateral enucleation of rodless, coneless mice abolishes light-induced 
phase shifts and melatonin suppression. Similarly in humans melatonin suppression 
cannot be induced in blindfolded or bilaterally enucleated subjects (Czeisler et al., 
1995) but light-induced melatonin suppression has been observed in some blind 
subjects (Czeisler et al., 1995) and those with colour vision deficiencies (Ruberg et 
al., 1996). Thus melatonin regulation in humans may be controlled by photoreceptors 
that differ from those used for vision. In support of this, recent data suggests that the 
cone pbotopic system is not responsible for melatonin regulation (Brainard et al., 
2001a). As the photoreceptors regulating the light-induced suppression of melatonin 
are unknown the aim of this thesis was to characterise the spectral sensitivity of 
melatonin suppression by constructing an action spectrum.
Action spectroscopy plays a central role in the initial characterisation of a 
photobiological response. An action spectrum defines the relative effectiveness of 
different wavelengths for producing a given response and identifies the spectral 
characteristics of the photopigment/s responsible for the response. In this thesis 
action spectroscopy methodology has been used to characterise a non-image forming, 
circadian response, namely the light-induced suppression of melatonin in humans.
Melatonin is considered a reliable marker of the biological clock (Arendt, 1995) and 
light exposure at night has been shown to acutely suppress melatonin (Section 
1.3.1.1). We selected to use the light-induced suppression of melatonin as a model 
for establishing an action spectrum. This in turn would help to elucidate the spectral 
characteristics of the photoreceptors responsible for this light dependent response.
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The protocol used to construct the action spectrum for light-induced melatonin 
suppression was developed and validated (Chapter 3).
As well as identifying the spectral characteristics of the photoreceptors responsible 
for melatonin suppression, the possible role of the neurotransmitter Substance P in 
conveying the light information in the retinal-SCN-pineal-melatonin axis was 
investigated. The effect of CP-122,721, a substance P antagonist on the light-induced 
suppression of melatonin were studied (Chapter 5).
6.2 The Spectral Sensitivity of Melatonin Suppression in Humans
The data show clearly that melatonin suppression is irradiance dependent at each 
wavelength. These findings support and extend a previous study using Imax 509 nm 
monochromatic light (Brainard et al., 1988). This dose-dependent relationship has 
been described using the four parameter logistic equation (Nelson and Takahashi et 
al., 1999) which has been shown to be a good model to fit human melatonin 
suppression data (Zeitzer et al., 2000). In the present study the threshold for 
melatonin suppression (15-20% suppression) calculated from the IRCs was 
approximately 4x10^^ photons/cm^/sec for the short wavelength light (Imax 424-456 
nm) and approximately 3x10^^ photons/cm^/sec for the longest wavelength (A^ ax 
548 nm). This is comparable with IRC data from Brainard and colleagues (2001b) 
where the threshold values were approximately 2x10^^ photons/cm^/sec for A^ ax 440 
nm and approximately 2x10^^ photons/cmVsec for Imax 555 nm light (data obtained 
from graphs). Both studies thus show a one log unit difference between the short and 
longer wavelengths. The saturation response (65-70% suppression) required 
approximately 3x10^^ photons/cm^/sec for the short wavelength light (Imax 424-456 
nm) and approximately 1 log unit more for the longest wavelength (A^ax 548 nm). A 
previous study by Brainard and co-workers (2001a) reported the saturation response 
for 505 nm to be 6.84 x 10^  ^photons/cm^/sec. Similarly the saturation response for 
our wavelength closest to 505 nm, 496 nm is approximately 7.0 x 10^  ^
photons/cmVsec. Thus our melatonin suppression data are consistent with the few 
previous studies using monochromatic light.
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It is well established that the threshold of light required to suppress melatonin is 
greater than that required for vision in both animals and humans (Foster and 
Provencio, 1999). In the present studies all irradiances of light were seen by the 
subjects and therefore were above the threshold for vision. It is clear that circadian 
responses to light are different to visual responses (Section 1.4.3.4). The circadian 
system has been shown to respond differently to light, namely the circadian system 
has a higher threshold response and the reciprocal relationship between intensity and 
duration holds for extremely long duration (Nelson and Takahashi et al., 1991b). The 
visual response range covers a 12 log unit range of irradiance whereas the circadian 
system covers a 3 log unit response range within the higher irradiance range used for 
vision (Foster and Provencio, 1999). This higher threshold for circadian responses 
has suggested to some researchers that the cone photoreceptors were more likely to 
mediate the response than the rods, which have a lower threshold of activity.
The observed action spectrum for melatonin suppression is very different to the 
known spectral sensitivity of the scotopic and photopic luminosity curves (being 
shifted approximately 50 and 100 nm to the left of the scotopic and photopic 
response, respectively). The relative spectral sensitivity of melatonin suppression 
appears to peak at lower wavelengths of light than scotopic or photopic vision. A 
previous study comparing light-induced melatonin suppression to photopic (kmax 555 
nm) and scotopic (A^ ax 505 nm) visual responses using monochromatic light at A^ ax 
505 nm and 555 nm indicated that Xmax 505 nm light was more effective than A^ ax 
555 nm at suppressing melatonin (Brainard et al., 2001a). The authors concluded 
from this that melatonin regulation was not mediated by the photopic system. A 
further study (Rea et al., 2001) investigating light of two spectral distributions at two 
irradiances also showed that melatonin suppression was not predicted well when 
plotted as a function of photopic illuminance whereas plotting melatonin suppression 
against scotopic illuminace produced better fits. The authors thus concluded that 
melatonin suppression may be mediated by the rods or a rod-based mechanism (Rea 
et al., 2001). Although these studies suggest that the three-cone, photopic system is 
not responsible for melatonin suppression it does not rule out the hypothesis that 
single cones or a combination of two or all of the known photoreceptors mediate 
light-induced melatonin suppression. It also may not be correct to assume that the
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scotopic system regulates melatonin suppression because scotopic light (Imax 505 
nm) was better than photopic light (A^ ax 555 nm) at suppressing melatonin (Brainard 
et al., 2000a). Investigating the effects of shorter wavelengths (< 505 nm) on 
melatonin suppression and constructing an action spectrum are essential to 
characterise which photoreceptors mediate the response. Our action spectrum data 
show that the melatonin suppression response is unlike scotopic and photopic vision 
and is sensitive to shorter wavelengths (< 505 nm). These findings add to the body of 
evidence showing that the circadian system is different anatomically and 
physiologically to the visual system.
In the present study the spectral response curve was physiologically derived and 
would include the effect of prereceptoral filtering by the lens and macula pigment. 
Prereceptoral filtering is known to shift the spectral sensitivities of the human S-, M- 
and L-cones to longer wavelengths in vivo, A.max 440, 540 and 565 nm, respectively 
(Stockman et al., 1999). In order to determine the spectral characteristics of the 
underlying photopigment responsible for light-induced melatonin suppression, the 
filtering effect of the lens alone and lens and macular pigment was removed using 
macula and lens density data from Stockman et al., (1999). These corrections altered 
the shape of the action spectrum (Section 5.4.1) and shifted the maximum sensitivity 
to shorter wavelengths. Given the method of light exposure in the present study (full 
field) and the restricted distribution of the macular pigment (primarily in the fovea), 
macula pigment filtering was not considered likely to make a contribution to the 
observed response. However for completeness an action spectrum corrected for lens 
and macular pigment filtering was constructed and fitted with Dartnall nomograms 
(Section 5.4.2). Lens density shows inter-individual differences so, although the lens 
density data used were calculated from mean data (Stockman et al., 1999), the 
correction is at best an approximation.
Lens opacity also changes with age (Brainard et al., 1997). The present data was not 
corrected for age, as there is little data available. However, the subjects that we 
studied were within a narrow age range. Preliminary data from Brainard et al. (1997) 
show that the ageing lens yellows and cuts out the transmission of short wavelength 
light. This change in lens transmission may have important implications in the
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elderly as our data show that the most effective wavelengths at suppressing 
melatonin are those short wavelengths that are filtered out by the ageing lens. It will 
thus be important to study older people to evaluate the effects of the ageing lens and 
establish if changes in the melatonin suppression response are observed in these 
subjects. If the lens does not transmit short wavelength light in these elderly subjects 
the amount of light required to suppress melatonin may be increased or the most 
effective wavelength may be shifted to slightly longer to adapt to the changes in light 
transmission through the lens. It is important to determine what changes occur, as 
elderly people are known to suffer from disturbed sleep rhythms and a possible 
reason may be a lack of light stimulus. A recent study investigated the effect of 
bright light (10,000 lux) on phase shifting rhythms of CBT and plasma melatonin 
(Klerman et al., 2001) in older subjects. This study showed that bright light induced 
phase delays in the elderly that were not significantly different from those seen in 
younger subjects. However, the phase advancing effect of light was attenuated in the 
older subjects. The authors concluded that this responsiveness of the circadian 
pacemaker to light implies that appropriately timed light can be used to treat 
circadian rhythm disturbances in older subjects. Further studies investigating the 
effectiveness of short wavelength light to phase shift circadian rhythms are needed 
and would allow optimisation of the light used to treat circadian rhythm disturbances 
in this group of subjects.
6.3 Action Spectra for Melatonin Suppression in Humans
None of our action spectra (original, lens corrected and lens and macular corrected) 
fitted the published absorption spectra of the human rod and S-, M- and L-cone 
photopigments (R  ^< 0.1). The absorption spectra of the known photopigments were 
assessed by in vitro studies and the absorption spectrum in vivo may be different. 
Although a correction has been made for prereceptoral filtering (Stockman et al., 
1999) it is possible that other unknown factors may also alter the absorption spectra 
of these photopigments in vivo. However, the lack of fit with the rod and S-, M- and 
L-cone photopigments allows us to conclude that none of these known visual 
photoreceptors are solely responsible for light-induced melatonin suppression. This 
finding is consistent with the recent action spectrum published by Brainard and
193
colleagues (2001 b). These data thus support a primary role for a novel non-rod, non­
cone photopigment in light-induced melatonin suppression. The IRCs show 
univariance indicating that most likely a single photopigment drives the observed 
response. The data best fit a rhodopsin template shape suggesting the novel 
photopigment is opsin based. Best fitting a series of nomograms revealed peak 
sensitivity around 459 nm (457-462 nm, R^ > 0.73). Although this single novel opsin 
template best describes the present data, the possibility that other known or novel 
photopigments may make a minor contribution cannot be ruled out.
Recently during the preparation of this thesis an action spectrum for melatonin 
suppression was also published by Brainard et al. (2001b). Although there are many 
differences in the protocol design between the two studies broadly speaking their 
findings are similar to ours. Firstly none of the known visual photoreceptors fitted 
their action spectrum and a novel opsin based photopigment best described their 
action spectrum data. The action spectrum of Brainard and colleagues identifies 
wavelengths between 446 and 477 nm as being the most potent at suppressing 
melatonin and a novel opsin with Xmax 464 nm best fits the data. This is similar to our 
present finding showing an increased sensitivity between 424-472 nm (Imax 459 nm). 
However, there is a marked difference between the data sets at the very short 
wavelengths. We find an increased sensitivity at 424 nm whereas Brainard and 
colleagues show a marked decrease in sensitivity at the 420 nm data point. 
Unfortunately the 420 nm data point was derived from a single irradiance melatonin 
suppression test and fitted to a univariant IRC. The lack of a full IRC at this 
wavelength could account for this discrepancy. Our 424 nm data was constructed 
from 5 irradiances each tested on 5-6 people. Construction of a full IRC at 420 nm or 
lower is needed to confirm this point on the action spectrum.
Although a novel rhodopsin template fits our data well, it cannot be excluded that 
other photopigments may make a minor contribution to the response or that the 
observed spectrum may derive from a complex mix of underlying photosensitive 
pigments. Since our study subjects were sighted with normal colour vision the 
possibility of some contribution from the rod or cones cannot be excluded. Recent 
evidence of converging photopic and scotopic inputs to the SCN neurones in rats
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(Aggelopoulous and Meissl, 2000), suggests that the visual photoreceptors may also 
have a role in circadian regulation. The three short wavelength data points of the 
corrected action spectrum (A a^x 424, 456, 472 nm) lie on the S-cone absorption 
spectrum (Figure 5.28) however, the longer wavelength data points (Imax 496, 520, 
548 nm) do not and thus a poor fit with the S-cone template results (R^ < 0.1). The 
absence of a reduction in sensitivity at the shortest wavelength (424 nm) may 
indicate a contribution from another photopigment, perhaps the S-cone. A similar 
phenomenon was observed in the action spectrum for melatonin suppression in 
cwWmxqô. Xenopus eyecups (Cahill et al., 1998).
Although the IRCs obey the principle of univariance and suggest involvement of a 
single opsin the small dip in the action spectrum between the 496 nm and 520 nm 
data points may indicate a bimodal distribution, involving two photoreceptors. 
Brainard and colleagues (2001 b) have a similar dip in their data between the 480 nm 
and 505 nm data points. To investigate bimodality combinations of known 
photoreceptors have been fitted to our action spectrum data and any contribution 
from a novel photopigment ignored. This fitting (Section 5.4.2.S) indicates that the 
S-cones may make a major contribution to the lens corrected action spectrum 
together with a minor contribution from the rod photoreceptors. However, as rod 
photoreceptors become saturated at low irradiances of light it may be unlikely that 
they contribute to this response. A combination of S-cone and M-cones do not fit the 
action spectrum as well as the combination of S-cones and rods.
There is also the possibility that a novel photoreceptor together with a contribution 
from the S-cones could fit the action spectrum data. Further analysis (Section 
5.4.2.3) shows that the S-cones together with a minor contribution (15%) from a 
novel opsin photoreceptor with a A^ ax 480 nm fits the action spectrum data well (R^ = 
0.94). Involvement of a novel opsin (Xmax 480 nm) agrees with a recent study by 
Lucas and colleagues (2001). These researchers have identified the photoreceptor 
responsible for another non-image forming response, pupillary constriction in rodless 
coneless mice to be novel with a Imax 479 nm. Additional studies of wavelengths less 
than 424 nm and greater than 548 nm would help to resolve the issue of which
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combination of receptors contribute to the action spectrum for melatonin 
suppression.
In order to establish a contribution from the S-cones, colour blind subjects that have 
no functional blue cones (tritanopia) should be studied. Light-induced melatonin 
suppression in subjects lacking S-cones should be compared to those with normal 
colour vision. If there are no differences in melatonin suppression between the two 
subject groups it would be interpreted as the S-cones having no role. However, there 
is the possibility that redundancy could be occurring in tritanopic subjects and 
another known photoreceptor could take on the role of the S-cones. These issues will 
be clarified in future studies. The present action spectrum has short wavelength 
sensitivity and the only known short wavelength sensitive pigment in the retina is the 
S-cone. Thus if  S-cones are shown not to contribute to the response then it is more 
probable that a novel short wavelength sensitive photopigment is responsible for 
mediating melatonin suppression.
Many novel photopigments have recently been identified and been put forward as 
candidate circadian photopigments (Section 1.4.4.2). Pinopsin, an opsin isolated in 
the chicken pineal gland, has an absorption maximum near 470 nm (Okano et al., 
1994) and VA opsin localised from salmon forms a photopigment with a Àmax 451 nm 
(Soni and Foster, 1997). Both of these newly identified opsins show short 
wavelength sensitivity, however the functional properties of these have yet to be 
determined. Melanopsin is another newly identified photopigment found in the inner 
retina of mammals (Provencio et al., 2000) that has to yet be functionally 
characterised. The spectral sensitivity and absorbance of melanopsin have to be 
determined. The localisation of melanopsin in the inner retina makes it a likely 
candidate as evidence from studies on rodless coneless mice (Freedman et al., 1999; 
Lucas et al., 1999c) suggest that photopigments responsible for transmitting light 
information to the SCN are localised in the inner retinal layers.
Cryptochromes are non-opsin vitamin B2 based photoreceptors that have also been 
proposed as candidate circadian photoreceptors due to their localisation in the retinal 
ganglion cells in mice (Miyamoto and Sancar, 1998). The absorbance spectra of the
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cryptochromes (Hsu et al., 1996) have also been compared to our corrected 
melatonin action spectrum and do not provide good fits (R  ^ < 0.41). The two short 
wavelengths points (Xmax 424, 456 nm) of the corrected melatonin action spectrum lie 
on the absorbance curves of cryptochrome 1 and 2 , however, the other points of the 
action spectrum drop more sharply than the two cryptochrome curves resulting in a 
poor fit. One of the problems with fitting cryptochrome to action spectrum data is 
that there is no consensus on the absorption spectra of cryptochrome as it changes 
with different redox states (Lucas et al., 1999b). Although the cryptochromes clearly 
do not account solely for the observed response (Figure 5.24) it is too soon to say 
whether a combination of cryptochromes and known or novel opsins explain the 
shape of the action spectrum for melatonin suppression. Recent evidence suggests 
that the cryptochromes together with the visual opsins may have redundant roles in 
the transduction of light information for circadian responses (Selby et al., 2000).
6.4 Implications of Findings and Future Work
The current findings, in addition to identifying a novel photoreceptor mechanism in 
humans, will also allow the spectral composition of light to be optimised to 
manipulate (or not) the circadian axis. Recent correlation studies show that the acute 
light-induced alerting response is positively correlated with melatonin suppression 
using white light (Cajochen et al., 2000) in a dose-response manner. More recent 
studies investigating the effect of light wavelength on night-time alertness and 
performance showed that broad-band blue light (A a^x ~ 430 nm) is better than green 
(Amax ~ 5 4 5  nm) and red light (Xmax ~610 nm) at increasing alertness and improving 
performance (reduced serial choice reaction time) during the time of light exposure 
(1.00 to 5.00 h) (Hoppen et al., 2001b). Studies using monochromatic light and 
ideally construction of an action spectrum for this light-dependent response are now 
needed.
Whether or not other non-image forming light responses such as circadian phase 
resetting show a similar spectral sensitivity to melatonin suppression and are 
regulated by the same novel photopigment cannot be determined from the current 
data. However, at present there is no firm evidence to contradict the assumption that
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the photoreceptor system is the same. On the contrary, anatomical studies (Klein and 
Moore, 1979; Moore et al., 1995; Larsen et al., 1998) support the existence of a 
common neural circuit (type III retinal ganglion cells-RHT-SCN) for circadian 
resetting and melatonin suppression. The recent demonstration in humans of similar 
illuminance-response curves for circadian phase shifting and melatonin suppression 
(Zeitzer et al., 2000) adds further support for a common photoreceptor-mediated 
pathway.
This action spectrum for melatonin suppression illustrates the need for more research 
in the area of spectral sensitivity of circadian photoreception. Firstly the molecular 
and cellular identification of the photopigment responsible for the spectral sensitivity 
of melatonin suppression will need to be determined. Secondly it will be important to 
define clearly any contribution of the known photoreceptors to the melatonin action 
spectrum. Experiments in subjects with visual deficiencies will also be needed to 
investigate the effects of removing the known photoreceptors on the light-induced 
suppression of melatonin. Investigating subjects with no blue cones should be very 
informative (Section 6.3), however tritanopia is very rare and therefore subjects for 
these studies will be difficult to find.
Identifying additional novel photoreceptors and functional characterising them will 
also be required particularly if the known photoreceptors are shown not to contribute 
to the response in humans.
Construction of action spectra for circadian phase shifting will also be necessary to 
determine if  the same pathways regulate acute responses such as melatonin 
suppression. This, together with an action spectrum for the alerting effects of light, 
may have implications in the design and use of lights to treat circadian rhythm 
disorders. Presently bright white light is used to treat SAD (Terman and Terman, 
1999), sleep disorders (Dijk et al., 1995) adaptation to shift work (Eastman and 
Martin, 1999) and jet lag (Boulos et al., 1995). In addition to our present study these 
studies will provide knowledge to design optimal lighting for use in the treatment of 
certain types of sleep disorders (Czeisler et al., 1981; Terman et al., 1995), seasonal 
affective disorder (Rosenthal et al., 1988), adaptation to shift work (Czeisler et al..
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1990), jetlag (Samel and Wegmann, 1997), improving alertness and performance and 
reducing sleepiness and accidents during night work (Eastman et ah, 1995). There 
may also be broad applications for this ‘optimised’ light in, for example, factories, 
hospitals, and old age homes (Van Someren et ah, 1997). Once there is consensus 
from studies on the spectral composition of light that is the most effective at 
manipulating the various non-image forming light responses the practical 
applications of any newly developed light sources will have to be determined e.g. in 
people with circadian rhythm disorders. Identification of the most effective 
wavelengths of light is likely also to reduce the irradiance of light needed and the 
duration of light administration required to treat these patients effectively. This is 
particularly important in terms of ocular safety in subjects exposed to prolonged 
periods of bright light (Remé et ah, 1996).
In conclusion, the existence of a novel non-rod, non-cone photoreceptor system in 
the human retina has been demonstrated. This provides direct evidence that a non­
image forming light response (melatonin suppression) is distinct from image 
formation in humans. A novel short-wavelength opsin-based, photopigment has been 
shown to be the primary candidate involved in light-induced suppression of 
melatonin. Although it is likely also to be responsible for other non-image forming 
light responses such as circadian phase resetting, this remains to be proven. It is 
hoped that the current findings will allow the spectral composition of light to be 
optimised to manipulate (or to avoid manipulating) the human circadian axis. This 
knowledge will have broad applications in situations where light therapy is used to 
synchronise the circadian clock (such as treatment of circadian rhythm sleep 
disorders and adaptation to shift work, or transmeridian travel).
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Appendix 1 : Informed Consent Form
LIGHT SUPPRESSION OF MELATONIN 
IN SIGHTED, COLOUR BLIND 
AND BLIND SUBJECTS.
INFORMED CONSENT FORM
Patient Name:
Investigators: K. Thapan, Dr. S. Lockley, Dr. D. Skene, Prof. J. Arendt, 
Dr. J. Wright
The nature of this trial and treatment have been fully explained and understood by 
me and a copy of the written explanation given to me is attached. I am aware that 
there could also be unforeseen risks and I must assume that if  I suffer injury I will 
only receive compensation which I am entitled to receive under the law. In other 
words, I shall be in the same position I would be in if  I were receiving normal 
clinical management.
I agree to participate in the trial investigating melatonin suppression by moderately 
bright light.
I understand that I must inform the investigators of my involvement in any other 
trials or projects.
I have informed the investigators of all the medication I am taking.
I agree to allow the investigators to write to my GP requesting relevant details 
regarding medications or medical disorders that may affect the study.
I understand that all information about me will remain confidential.
I understand that I am free to withdraw from the study at anytime without 
explanation.
Patient Signature........................................................... Date..............
The explanation of the trial has been given in the presence o f .............................
Witness (who may be a member of the research team)
Witness Signature..........................................................Date..............
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Appendix 2: Pre-study Questionnaire
Name: D.O.B.
Address: Age
Sex
Tel:
GP’s Name 
GP’s Address
Any known eve conditions (glaucoma)
Visual Acuity Left Eve Right Eve - NO
GLASSES
Eve Colour 
Ishihara Test score
Medication Anti depressants(Prozac)
Beta-blockers (Atenolol) 
Tranquillisers(Benzodiazepines, Valium) 
Sleeping tablets (Tamazepam)
Health Psychiatric conditions
Migraine (Conditions suffered by subject or relative)
Epilepsy
Blood Pressure
Endocrine disorders
Smoker/Non Smoker 
Sleep disorders 
PSOI Score
Given more than 400ml blood in past 3 months
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Appendix 3: Ishihara Colour Blindness Plate Test
IS H IH A R A  T E S T  F O R  C O L O U R  B L IN D N E S S
S U B J E C T  N A M E D A T E
N u m b e r R E S P O N S E N o rm a l 'R e d /G r e e n  D e f ic ie n c ie s T o ta l C o lo u r
o f  p la te R e s p o n s e B lin d n e ss
1 12 1 2
2 8 3
3 6 5
4 2 9 7 0
5 5 7  . 3 5
6 5 2
7 3 5
8 15 1 7
9 7 4 21
• 10 2
11 6
1 2 9 7
1 3 4 5
14 5
15 7
16 16
1 7 7 3
18 * • 5
19 * 2
2 0 * 4 5
21 * 7 3
P r o ta n  D e u ta n
S tro n g  Mild S t r o n g  Mild
2 2 2 6 6  ( 2 ) 6  2  ( 2)6
2 3 4 2 2  ( 4 ) 2  4  (4 ) 2
2 4 3 5 5  ( 3 ) 5  3  (3 ) 5
2 5 9 6 6  ( 9 ) 6  9  ( 9 ) 6
T R A C IN G  B E T W E E N  X -X
P R O T A N D E U T A N
2 6 P u rp le R e d
2 7 P u rp le R e d
2 8 T r a c e T r a c e N orm al & T o ta l c o lo u r  B l in d n e s s  C a n ' t  T r a c e
2 9 T r a c e T r a c e N orm al & T o ta l c o lo u r  B l in d n e s s  C a n ' t  T r a c e
3 0 '^0 T r a c e N o  T r a c e N orm al T r a c e  B lu is h -G re e n  L ine
31 N o T r a c e N o  T ra c e N o rm a l T r a c e  O r a n g e  L ine
3 2 N o T r a c e N o  T r a c e N o rm al T r a c e  O r a n g e  L ine
3 3 N o T r a c e N o  T ra c e N o rm a l T r a c e  O r a n g e  L ine
3 4 B lu ish /G re e n  a n d  P u rp le N o rm a l T r a c e  B lu is h /G re e n  & Y e lo w /G re e n
3 5 B lu is h /G re e n  a n d  P u rp le N o rm a l T r a c e  B lu is h /G re e n  & Y e o w /G r e e n
3 6 P u rp le -B lu ish /G re e n N o rm a l T r a c e  P u r p le - O r a n g e
3 7 P u rp le -B lu ish /G re e n N o rm a l T r a c e  P u r p le - O r a n g e
3 8 No T r a c e  |N o  T ra c e N o rm a l N o  T r a c e  |
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Appendix 4: Pittsburgh Sleep Quality Index
Subject code: STUDY:
Date:
Instructions:
The following questions relate to your usual sleep habits during the past month only. Your answers 
should indicate the most accurate reply for the majority of days and nights in the past month. Please 
answer all the questions.
1) During the past month, when have you usually gone to bed at night?
Usual bed time
2) During the past month, how long (in minutes) has it usually take you to fall asleep each 
night?
Number of minutes
3) During the past month, when have you usually got up in the morning?
Usual getting up time
4) During the past month, how many hours of actual sleep did you get at night? (This may he 
different from the number of hours spent in bed.)
Hours of sleep per night
For each of the remaining questions, check the one best response. Please answer all questions.
5) During the past month, how often have you had trouble sleeping because you.....
a) Cannot get to sleep within 30 minutes
Not during the Less than
past month once a week_
h) Wake up in the middle of the night or early morning
Not during the Less than
past month once a week____
c) Have to get up to use the bathroom
Not during the Less than
past month once a week____
d) Cannot breathe comfortably
Not during the Less than
past month  once a week
e) Cough or snore loudly
Not during the Less than
past month  once a week
f) Feel too cold
Not during the Less than
past month  once a week
Three or more times 
a week
Three or more times 
a week
Three or more times 
a week
Three or more times 
a week
Three or more times 
a week
Three or more times 
a week
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g) Feel too hot
Not during the 
past month
h) Had bad dreams
Not during the 
past month
i) Have pain
Not during the 
past month
Less than 
once a week
Less than 
once a week
Less than 
once a week
j) Other reason(s), please describe
Three or more times 
a week
Three or more times 
a week
Three or more times 
a week
How often during the past month have you had trouble sleeping because of this?
Not during the 
past month
Less than 
once a week
Three or more times 
a week
6) During the past month, how would you rate your sleep quality overall?
Very good__________
Fairly good___________
Fairly bad___________
Very bad____________
7) During the past month, how often have you taken medicine (prescribed or “over the 
counter”) to help you sleep?
Not during the 
past month
Less than 
once a week
Three or more times 
a week
8) During the past month, how often have you had trouble staying awake while driving, eating 
meals, or engaging in social activity?
Not during the 
past month
Less than 
once a week
Three or more times 
a week
9) During the past month, how much of a problem has it been for you to show enthusiasm to 
get things done?
No problem at all_________
Only a very slight problem
Somewhat of a problem___
A very big problem______
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10) Do you have a bed partner or roommate?
No bed partner or roommate?
Partner/roommate in other room
Partner in same room, but not same bed 
Partner in same bed
If you have a roommate or bed partner, ask him/her how often in the past month you have 
had)...
a) Loud snoring
Not during the 
past month
Less than 
once a week
b) Long pauses between breaths while asleep
Not during the Less than
past month  once a week 
c) Legs twitching or jerking while you sleep
Not during the Less than
past month  once a week_
d) Episodes of disorientation or confusion during sleep?
Not during the Less than
past month  once a week___________
Three or more times 
a week
Three or more times 
a week
Three or more times 
a week
Three or more times 
a week
e) Other restlessness while you sleep; please describe
Not during the Less than
past month once a week  a week_
Three or more times
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Appendix 5 Sleep Diaries
SLEEP/NAP DIARY
IN S T R U C T IO N S; Y ou n e e d  to  k e e p  a  da ily  S L E E P  DIARY for 3  n ig h ts  p rio r to  e a c h  s tu d y  leg
Please answer the questions In the S L E E P  DIARY below once per day.
A ny n a p s  a t all o u ts id e  y o u r  n o rm a l n ig h ttim e  s le e p  p e r io d  n e e d s  to  b e  r e c o rd e d  in th e  NA P DIARY b e lo w . 
S L E E P  DIARY .
: NIGHT 1 NIGHT 2 NIGHT 3 1
DATE (D a te  y o u  w o k e  u p  o n ) ?  
1 (dd-M M M -yy) • • : , ,  . — , “  I • — ,
1 T im e  y o u  w e n t  to  b e d  l a s t  n ig h t?  
i (24 hr. c lo ck )
1 '  • •  ; • 1 1 ! •  :
1
I----------- :------------ .  1 ;
T im e  y o u  s t a r t e d  try in g  to  g o  to  
s l e e p  l a s t  n ig h t?
(24 hr. c lock ) 1 '  '  '  I 1 i  '  ■ •  1 1 1
!
H o w  lo n g  d o  y o u  th in k  It to o k  y o u  
to  fall a s l e e p ? I
H o w  m a n y  t im e s  d id  y o u  w a k e  u p  
d u r in g  th e  n ig h t?  * * i
H o w  m a n y  m in u te s  s l e e p  
d id  y o u  l o s e ?
W h a t t im e  d id  y o u  w a k e  u p ?  
(24  hr. c lo ck ) : 1 ( •  : 1 1 ! •  • ; : :  !1 : • •  '  I
W h at t im e  d id  y o u  g e t  u p ?  
(24 hr. c lo ck )
1 I • •  1 1 I 1 '  1 •  ! I : I .  i * :  1 I i
R a te  y o u r  s l e e p  q u a li ty .  ***
: !1
• ‘ N O T E : P le a s e  try  a n d  g iv e  th e  t im e  p e r io d s  y o u  w e r e  a w a k e ,  f o r  e a c h  t im e  y o u  w o k e  u p . 
N O T E : 1-9 s c a le ,  1 = th e  b e s t  s l e e p  e v e r , 5 = n e i th e r  th e  b e s t  n o r  w o r s t  s l e e p ,  9 = th e  w o r s t
NAP DIARY
s l e e p
DATE O F  NAP 
(dd-MfvlM-yy)
TIME NA P STA R TED  
(24  hr. clock)
TIM E NA P EN D ED  
(2 4  hr. c lo ck )
TO TA L NAP TIME 
(H R S/M IN .)
! t  ) • , . , 1----- >__!■: > 1
1 ' 1 •  ;  t  f ! '  1 •  . 1 1
• • 1 ”  I 1 • • *“  1 ,
1--- - - - - - !------- J  •  t  • . 1 '  I • ■ 1 1
, —. . , . — 1 ^
1 1 1 • : 1 1
,
L —  ■ ■■ '— '  1 I V  ' , • 1 • • . 1 1
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Appendix 6: Individual Light Summaries
Leg 1
Date Subject Light box Time (h) Wavelength Irradiance (|rW/cm'‘)
02.05.98 SI 0.30-1.00 Baseline
02.05.98 S2 0.30-1.00 Baseline
02.05.98 S3 1.15-1.45 Baseline
02.05.98 S4 1.15-1.45 Baseline
02.05.98 S5 2.00-2.30 Baseline
02.05.98 S6 2.00-2.30 Baseline
03.05.98 SI A 0.30-1.00 530 nm 1.8
03.05.98 S2 B 0.30-1.00 530 nm 0.7
03.05.98 S3 A 1.15-1.45 530 nm 1.8
03.05.98 S4 B 1.15-1.45 530 nm 0.7
03.05.98 S5 A 2.00-2.30 530 nm 1.8
03.05.98 S6 B 2.00-2.30 530 nm 0.7
04.05.98 SI A 0.30-1.00 530 nm 3.3
04.05.98 S2 B 0.30-1.00 530 nm 1.8
04.05.98 S3 A 1.15-1.45 530 nm 3.3
04.05.98 S4 B 1.15-1.45 530 nm 1.8
04.05.98 S5 A 2.00-2.30 530 nm 3.3
04.05.98 S6 B 2.00-2.30 530 nm 1.8
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm'')
26.05.98 SI 0.30-1.00 Baseline No pupil dilator
26.05.98 S2 0.30-1.00 Baseline No pupil dilator
26.05.98 S3 1.15-1.45 Baseline No pupil dilator
26.05.98 S4 1.15-1.45 Baseline No pupil dilator
26.05.98 S5 2.00-2.30 Baseline No pupil dilator
27.05.98 SI A 0.30-1.00 Baseline Pupil dilator
27.05.98 S2 B 0.30-1.00 Baseline Pupil dilator
27.05.98 S3 A 1.15-1.45 Baseline Pupil dilator
27.05.98 S4 B 1.15-1.45 Baseline Pupil dilator
27.05.98 S5 A 2.00-2.30 Baseline Pupil dilator
28.05.98 SI B 0.30-1.00 White 91
28.05.98 S2 A 0.30-1.00 530 nm 4.1
28.05.98 S3 B 1.15-1.45 White 91
28.05.98 S4 A 1.15-1.45 530 nm 4.1
28.05.98 S5 B 2.00-2.30 White 91
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm"‘)
16.06.98 SI 0.30-1.00 Baseline
16.06.98 S2 0.30-1.00 Baseline
16.06.98 S3 1.15-1.45 Baseline
16.06.98 S4 1.15-1.45 Baseline
16.06.98 S5 2.00-2.30 Baseline
16.06.98 S7 2.00-2.30 Baseline
17.06.98 SI B 0.30-1.00 530 nm 4.1
17.06.98 S2 A 0.30-1.00 White 3.7
17.06.98 S3 B 1.15-1.45 530 nm 4.1
17.06.98 S4 A 1.15-1.45 White 3.7
17.06.98 S5 B 2.00-2.30 530 nm 4.1
17.06.98 S7 A 2.00-2.30 White 3.7
18.06.98 SI A 0.30-1.00 White 3.9
18.06.98 S2 B 0.30-1.00 White 91
18.06.98 S3 A 1.15-1.45 White 3.9
18.06.98 S4 B 1.15-1.45 White 91
18.06.98 S5 A 2.00-2.30 White 3.9
18.06.98 S7 B 2.00-2.30 White 91
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Leg 4
Date Subject Light box Time (h) Wavelength Irradiance (p.W/cm )^
24.08.98 SI 0.30-1.00 Baseline
24.08.98 S2 0.30-1.00 Baseline
24.08.98 S9 1.15-1.45 Baseline
24.08.98 S4 1.15-1.45 Baseline
24.08.98 S7 23.45-0.15 Baseline
24.08.98 S8 23.45-0.15 Baseline
25.08.98 SI A 0.30-1.00 480 nm 2.8
25.08.98 S2 B 0.30-1.00 White 2.2
25.08.98 S9 A 1.15-1.45 480 nm 2.8
25.08.98 S4 B 1.15-1.45 White 2.2
25.08.98 S7 A 23.45-0.15 480 nm 2.8
25.08.98 S8 B 23.45-0.15 White 2.2
26.08.98 SI A 0.30-1.00 White 91
26.08.98 S2 B 0.30-1.00 White 91
26.08.98 S9 A 1.15-1.45 White 91
26.08.98 S4 B 1.15-1.45 White 91
26.08.98 S7 A 23.45-0.15 White 91
26.08.98 S8 B 23.45-0.15 White 91
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm"')
13.10.98 SIO 0.30-1.00 Baseline
13.10.98 S l l 0.30-1.00 Baseline
13.10.98 S12 1.15-1.45 Baseline
13.10.98 S13 1.15-1.45 Baseline
13.10.98 S14 23.45-0.15 Baseline
14.10.98 SIO B 0.30-1.00 White 6.6
14.10.98 S l l A 0.30-1.00 530 nm 7.0
14.10.98 S12 B 1.15-1.45 White 6.6
14.10.98 S13 A 1.15-1.45 530 nm 7.0
14.10.98 S14 23.45-0.15
15.10.98 SIO A 0.30-1.00 530 nm 7.0
15.10.98 S ll B 0.30-1.00 White 6.6
15.10.98 S12 A 1.15-1.45 530 nm 7.0
15.10.98 S13 B 1.15-1.45 White 6.6
15.10.98 S14 A 23.45-0.15 530 nm 7.0
Date Subject Light box Time (h) Wavelength Irradiance (nW/cm^)
27.10.98 SIO 0.30-1.00 Baseline
27.10.98 S ll 0.30-1.00 Baseline
27.10.98 S12 1.15-1.45 Baseline
27.10.98 S13 1.15-1.45 Baseline
27.10.98 S14 23.45-0.15 Baseline
27.10.98 S15 23.45-0.15 Baseline
28.10.98 SIO 0.30-1.00
28.10.98 S l l A 0.30-1.00 560 nm 7.2
28.10.98 S12 A 1.15-1.45 560 nm 7.2
28.10.98 S13 B 1.15-1.45 White 7.2
28.10.98 S14 A 23.45-0.15 560 nm 7.2
28.10.98 S15 B 23.45-0.15 White 7.2
29.10.98 SIO 0.30-1.00
29.10.98 S ll A 0.30-1.00 White 7.2
29.10.98 S12 B 1.15-1.45 White 7.2
29.10.98 S13 A 1.15-1.45 560 nm 7.2
29.10.98 S14 B 23.45-0.15 White 7.2
29.10.98 S15 A 23.45-0.15 560 nm 7.2
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Leg?
Date Subject Lightbox Time (h) Wavelength Irradiance (pW/cm' )^
10.11.98 SIO 0.30-1.00 Baseline
10.11.98 S l l 0.30-1.00 Baseline
10.11.98 S12 1.15-1.45 Baseline
10.11.98 S13 1.15-1.45 Baseline
10.11.98 S14 23.45-0.15 Baseline
10.11.98 S15 23.45-0.15 Baseline
28.10.98 SIO A 0.30-1.00 480 nm 4.1
28.10.98 S l l B 0.30-1.00 480 nm 1.8
28.10.98 S12 A 1.15-1.45 480 nm 4.1
28.10.98 S13 B 1.15-1.45 480 nm 1.8
28.10.98 S14 A 23.45-0.15 480 nm 4.1
28.10.98 S15 B 23.45-0.15 480 nm 1.8
29.10.98 SIO B 0.30-1.00 480 nm 1.8
29.10.98 S l l A 0.30-1.00 480 nm 4.1
29.10.98 S12 B 1.15-1.45 480 nm 1.8
29.10.98 S13 A 1.15-1.45 480 nm 4.1
29.10.98 S14 B 23.45-0.15 480 nm 1.8
29.10.98 S15 A 23.45-0.15 480 nm 4.1
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm^)
26.04.99 S12 0.15-0.45 Baseline
26.04.99 S13 1.00-1.30 Baseline
26.04.99 S14 23.30-0.00 Baseline
26.04.99 S15 23.30-0.00 Baseline
26.04.99 S16 0.15-0.45 Baseline
27.04.99 S12 A 0.15-0.45 530 nm 16
27.04.99 S13 A 1.00-1.30 530 nm 16
27.04.99 S14 A 23.30-0.00 530 nm 16
27.04.99 S15 B 23.30-0.00 530 nm 7.0
27.04.99 S16 B 0.15-0.45 530 nm 7.0
28.04.99 S12 B 0.15-0.45 480 nm 27
28.04.99 S13 B 1.00-1.30 480 nm 27
28.04.99 S14 B 23.30-0.00 480 nm 27
28.04.99 S15 A 23.30-0.00 480 nm 16
28.04.99 S16 A 0.15-0.45 480 nm 16
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm^)
02.05.99 S12 0.15-0.45 Baseline
02.05.99 S13 1.00-1.30 Baseline
02.05.99 S14 1.00-1.30 Baseline
02.05.99 S15 23.30-0.00 Baseline
02.05.99 S16 0.15-0.45 Baseline
02.05.99 S17 23.30-0.00 Baseline
03.05.99 S12 A 0.15-0.45 480 nm 9.0
03.05.99 S13 A 1.00-1.30 480 nm 9.0
03.05.99 S14 B 23.30-0.00 480 nm 14
03.05.99 S15 B 23.30-0.00 480 nm 14
03.05.99 S16 B 0.15-0.45 480 nm 14
03.05.99 S17 A 23.30-0.00 480 nm 9.0
04.05.99 S12 B 0.15-0.45 480 nm 14
04.05.99 S13 B 1.00-1.30 480 nm 14
04.05.99 S14 B 23.30-0.00 560 nm 14
04.05.99 S15 A 23.30-0.00 560 nm 14
04.05.99 S16 A 0.15-0.45 560 nm 14
04.05.99 S17 A 23.30-0.00 480 nm 14
245
Leg 10
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm^)
09.05.99 S12 0.15-0.45 Baseline
09.05.99 S13 1.00-1.30 Baseline
09.05.99 S14 1.00-1.30 Baseline
09.05.99 S15 23.30-0.00 Baseline
09.05.99 S16 0.15-0.45 Baseline
09.05.99 S17 23.30-0.00 Baseline
10.05.99 S12 A 0.15-0.45 480 nm 2.8
10.05.99 S13 A 1.00-1.30 480 nm 2.8
10.05.99 S14 B 23.30-0.00 480 nm 9.0
10.05.99 S15 B 23.30-0.00 480 nm 9.0
10.05.99 S16 B 0.15-0.45 480 nm 9.0
10.05.99 S17 A 23.30-0.00 480 nm 2.8
11.05.99 S12 B 0.15-0.45 560 nm 14
11.05.99 S13 B 1.00-1.30 560 nm 14
11.05.99 S14 B 23.30-0.00 480 nm 2.8
11.05.99 S15 A 23:30-0.00 530 nm 27
11.05.99 S16 A 0.15-0.45 530 nm 27
11.05.99 S17 A 23.30-0.00 530 nm 16
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm^)
24.08.99 S13 1.00-1.30 Baseline
24.08.99 S14 1.00-1.30 Baseline
24.08.99 S15 23.30-0.00 Baseline
24.08.99 S17 0.15-0.45 Baseline
24.08.99 S18 23.30-0.00 Baseline
24.08.99 S19 0.15-0.45 Baseline
25.08.99 S13 B 1.00-1.30 430 nm 2.8
25.08.99 S14 A 1.00-1.30 500 nm 13
25.08.99 S15 B 23.30-0.00 430 nm 2.8
25.08.99 S17 A 0.15-0.45 500 nm 13
25.08.99 S18 A 23.30-0.00 500 nm 13
25.08.99 S19 B 0.15-0.45 430 nm 2.8
26.08.99 S13 A 1.00-1.30 430 nm 1.9
26.08.99 S14 B 1.00-1.30 500 nm 18
26.08.99 S15 A 23.30-0.00 430 nm 1.9
26.08.99 S17 B 0.15-0.45 500 nm 18
26.08.99 S18 B 23.30-0.00 530 nm 27
26.08.99 S19 A 0.15-0.45 500 nm 18
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm" )^
31.08.99 S13 1.00-1.30 Baseline
31.08.99 S14 1.00-1.30 Baseline
31.08.99 S15 23.30-0.00 Baseline
31.08.99 S17 0.15-0.45 Baseline
31.08.99 S18 23.30-0.00 Baseline
31.08.99 S19 0.15-0.45 Baseline
01.09.99 S13 C 1.00-1.30 430 nm 2.8
01.09.99 S14 D 1.00-1.30 500 nm 6.5
01.09.99 S15 C 23.30-0.00 430 nm 2.8
01.09.99 S17 D 0.15-0.45 500 nm 6.5
01.09.99 S18 D 23.30-0.00 500 nm 13
01.09.99 S19 C 0.15-0.45 430 nm 6.5
02.09.99 S13 C 1.00-1.30 530 nm 41
02.09.99 S14 D 1.00-1.30 480 nm 22
02.09.99 S15 C 23.30-0.00 530 nm 41
02.09.99 S17 D 0.15-0.45 480 nm 22
02.09.99 S18 D 23.30-0.00 500 nm 26
02.09.99 S19 C 0.15-0.45 430 nm 9.0
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Leg 13
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm^)
07.09.99 S13 1.00-1.30 Baseline
07.09.99 S15 23.30-0.00 Baseline
07.09.99 S17 0.15-0.45 Baseline
07.09.99 S18 23.30-0.00 Baseline
07.09.99 S19 0.15-0.45 Baseline
07.09.99 S20 1.00-1.30 Baseline
08.09.99 S13 C 1.00-1.30 430 nm 9.0
08.09.99 S15 C 23.30-0.00 430 nm 9.0
08.09.99 S17 C 0.15-0.45 500 nm 26
08.09.99 S18 D 23.30-0.00 430 nm 1.9
08.09.99 S19 D 0.15-0.45 500 nm 6.5
08.09.99 S20 D 1.00-1.30 500 nm 6.5
09.09.99 S13 C 1.00-1.30 480 nm 22
09.09.99 S15 C 23.30-0.00 480 nm 22
09.09.99 S17 C 0.15-0.45 530 nm 41
09.09.99 S18 D 23.30-0.00 430 nm 2.8
09.09.99 S19 D 0.15-0.45 500 nm 13
09.09.99 S20 D 1.00-1.30 500 nm 13
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm^)
14.09.99 S13 1.00-1.30 Baseline
14.09.99 S15 23.30-0.00 Baseline
14.09.99 S17 0.15-0.45 Baseline
14.09.99 S18 23.30-0.00 Baseline
14.09.99 S19 0.15-0.45 Baseline
14.09.99 S20 1.00-1.30 Baseline
15.09.99 S13 D 1.00-1.30 560 nm 26
15.09.99 S15 D 23.30-0.00 560 nm 26
15.09.99 S17 D 0.15-0.45 560 nm 26
15.09.99 S18 C 23.30-0.00 430 nm 4.5
15.09.99 S19 C 0.15-0.45 500 nm 18
15.09.99 S20 C 1.00-1.30 500 nm 18
16.09.99 S13 D 1.00-1.30 560 nm 52
16.09.99 S15 D 23.30-0.00 560 nm 52
16.09.99 S17 D 0.15-0.45 560 nm 52
16.09.99 S18 C 23.30-0.00 530 nm 41
16.09.99 S19 C 0.15-0.45 500 nm 26
16.09.99 S20 C 1.00-1.30 500 nm 26
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm^)
21.09.99 S12 0.15-0.45 Baseline
21.09.99 S20 1.00-1.30 Baseline
21.09.99 S21 23.30-0.00 Baseline
21.09.99 S22 23.30-0.00 Baseline
22.09.99 S12 D 0.15-0.45 500 nm 26
22.09.99 S20 C 1.00-1.30 430 nm 1.9
22.09.99 S21 D 23.30-0.00 500 nm 6.5
22.09.99 S22 C 23.30-0.00 430 nm 1.9
23.09.99 S12 D 0.15-0.45 480 nm 22
23.09.99 S20 D 1.00-1.30 480 nm 22
23.09.99 S21 C 23.30-0.00 500 nm 13
23.09.99 S22 D 23.30-0.00 430 nm 2.8
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Leg 16
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm^)
28.09.99 S12 0.15-0.45 Baseline
28.09.99 S14 1.00-1.30 Baseline
28.09.99 S20 1.00-1.30 Baseline
28.09.99 S21 23.30-0.00 Baseline
28.09.99 S22 23.30-0.00 Baseline
29.09.99 S12 C 0.15-0.45 430 nm 2.8
29.09.99 S14 D 1.00-1.30 500 nm 26
29.09.99 S20 C 1.00-1.30 430 nm 4.5
29.09.99 S21 D 23.30-0.00 500 nm 18
29.09.99 S22 C 23.30-0.00 430 nm 4.5
30.09.99 S12 C 0.15-0.45 430 nm 9.0
30.09.99 S14 D 1.00-1.30 530 nm 41
30.09.99 S20 C 1.00-1.30 430 nm 9.0
30.09.99 S21 D 23.30-0.00 530 nm 41
30.09.99 S22 C 23.30-0.00 430 nm 9.0
Leg 17
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm^)
18.01.00 S13 1.00-1.30 Baseline
18.01.00 S15 23.30-0.00 Baseline
18.01.00 S18 23.30-0.00 Baseline
18.01.00 S19 0.15-0.45 Baseline
18.01.00 S20 1.00-1.30 Baseline
18.01.00 S22 0.15-0.45 Baseline
19.01.00 S13 C&D 1.00-1.30 530 nm 65
19.01.00 S15 C&D 23.30-0.00 530 nm 65
19.01.00 S18 A 23.30-0.00 460 nm 2.0
19.01.00 S19 A 0.15-0.45 460 nm 2.0
19.01.00 S20 A 1.00-1.30 500 nm 3.0
19.01.00 S22 C&D 0.15-0.45 530 nm 65
20.01.00 S13 C&D 1.00-1.30 430 nm 11
20.01.00 S15 C&D 23.30-0.00 460 nm 29
20.01.00 S18 A 23.30-0.00 500 nm 3.0
20.01.00 S19 A 0.15-0.45 460 nm 4.0
20.01.00 S20 A 1.00-1.30 460 nm 4.0
20.01.00 S22 C&D 0.15-0.45 430 nm 11
Leg 18
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm^)
25.01.00 S13 1.00-1.30 Baseline
25.01.00 S15 23.30-0.00 Baseline
25.01.00 S18 23.30-0.00 Baseline
25.01.00 S19 0.15-0.45 Baseline
25.01.00 S20 1.00-1.30 Baseline
25.01.00 S22 0.15-0.45 Baseline
26.01.00 S13 A 1.00-1.30 460 nm 2.0
26.01.00 S15 A 23.30-0.00 460 nm 2.0
26.01.00 S18 C&D 23.30-0.00 480 nm 31
26.01.00 S19 C&D 0.15-0.45 530 nm 65
26.01.00 S20 C&D 1.00-1.30 530 nm 65
26.01.00 S22 A 0.15-0.45 460 nm 2.0
27.01.00 S13 A 1.00-1.30 460 nm 4.0
27.01.00 S15 A 23.30-0.00 460 nm 4.0
27.01.00 S18 C&D 23.30-0.00 430 nm 11
27.01.00 S19 C&D 0.15-0.45 430 nm 11
27.01.00 S20 C&D 1.00-1.30 430 nm 11
27.01.00 S22 A 0.15-0.45 460 nm 4.0
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Date Subject Light box Time (h) Wavelength Irradiance (pW/cm" )^
01.02.00 S13 1.00-1.30 Baseline
01.02.00 S15 23.30-0.00 Baseline
01.02.00 S18 23.30-0.00 Baseline
01.02.00 S19 0.15-0.45 Baseline
01.02.00 S20 1.00-1.30 Baseline
01.02.00 S22 0.15-0.45 Baseline
02.02.00 S13 A 1.00-1.30 460 nm 4.0
02.02.00 S15 B&D 23.30-0.00 560 nm 65
02.02.00 S18 A&C 23.30-0.00 500 nm 30
02.02.00 S19 A&C 0.15-0.45 500 nm 30
02.02.00 S20 C&D 1.00-1.30 460 nm 29
02.02.00 S22 B&D 0.15-0.45 560 nm 65
03.02.00 S13 A 1.00-1.30 500 nm 3.0
03.02.00 S15 A 23.30-0.00 460 nm 8.0
03.02.00 S18 C&D 23.30-0.00 460 nm 29
03.02.00 S19 C&D 0.15-0.45 460 nm 29
03.02.00 S20 C&D 1.00-1.30 480 nm 31
03.02.00 S22 A 0.15-0.45 500 nm 3.0
Date Subject Light box Time (h) Wavelength Irradiance (pW/cm^)
01.02.00 S13 1.00-1.30 Baseline
01.02.00 S15 23.30-0.00 Baseline
01.02.00 S18 23.30-0.00 Baseline
01.02.00 S19 0.15-0.45 Baseline
01.02.00 S20 1.00-1.30 Baseline
01.02.00 S22 0.15-0.45 Baseline
02.02.00 S13 A&C 1.00-1.30 500 nm 30
02.02.00 S15 A&C 23.30-0.00 500 nm 30
02.02.00 S18 B&D 23.30-0.00 560 nm 65
02.02.00 S19 B&D 0.15-0.45 560 nm 65
02.02.00 S20 B&D 1.00-1.30 560 nm 65
02.02.00 S22 A&C 0.15-0.45 500 nm 30
03.02.00 S13 C&D 1.00-1.30 480 nm 31
03.02.00 S15 C&D 23.30-0.00 480 nm 31
03.02.00 S18 A 23.30-0.00 460 nm 8.0
03.02.00 S19 A 0.15-0.45 460 nm 8.0
03.02.00 S20 A 1.00-1.30 460 nm 8.0
03.02.00 S22 C&D 0.15-0.45 480 nm 31
Appendix 7: Real Versus Target Photon Number
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Wavelength (nm] Irradiance B xC SpA  BxC A SpA  B xA SpA  BxCDSpA BxCD SpB BxD SpB BxBDSpB BxBSnB Previous
430 1.9 7.29E+15 7.31 E+15 7.44E+15 7.32E+15 7.33 E+15 7.30E+15 7.34E+15 7.60E+15 7.40E+15
430 2.8 1.07E+16 1.08E+16 l.lOE+16 1.08E+16 1.08E+16 1.08E+16 1.08E+I6 1.12E+16 1.09E+16
430 4.5 1.73E+16 1.73 E+16 1.76E+16 1.73E+I6 1.74E+16 1.73E+16 1.74E+16 1.80E+16 1.75E+16
430 . 9.0 3.46E+16 3.46E+16 3.53 E+16 3.47E+16 3.47E+16 3.46E+16 3.48E+16 3.60E+16 3.51E+16
430 11.0 4.22E+16 4.23E+16 4.31 E+16 4.24E+16 4.24E+16 4.23E+16 4.25E+16 4.40E+16 4.29E+16
460 2.0 8.21 E+15 8.21E+15 8.30E+15 8.24E+15 8.26E+15 8.22E+15 8.24E+15 8.17E+15 8.33E+15
460 4.0 1.64E+16 1.64E+16 1.66E+16 1.65E+16 1.65E+16 1.64E+16 1.65E+16 1.63 E+16 1.67E+16
460 8.0 3.28E+16 3.28E+16 3.32E+16 3.30E+16 3.30E+16 3.29E+16 3.30E+16 3.27E+16 3.33E+16
460 29.0 1.19E+17 I.19E+17 1.20E+17 1.19E+17 1.20E+17 1.19E+17 1.19E+17 1.18E+17 1.21E+17
480 1.8 7.67E+15 7.72E+15 7.75E+15 7.70E+15 7.71 E+15 7.70E+15 7.71 E+15 7.66E+15 7.82E+15
480 2.8 1.19E+16 I.20E+16 1.21 E+16 1.20E+16 1.20E+16 1.20E+16 1.20E+16 I.19E+16 1.22E+16
480 4.1 1.75E+16 1.76E+16 1.77E+16 1.75E+16 1.76E+I6 1.75E+16 1.76E+16 1.74E+16 1.78 E+16
480 9.0 3.84E+16 3.86E+16 3.88E+16 3.85E+16 3.85E+16 3.85E+16 3.85E+16 3.83E+16 3.91 E+16
480 14.2 6.05E+16 6.09E+16 6.12E+16 6.08E+16 6.08E+16 6.07E+16 6.08E+16 6.04E+16 6.17E+16
480 22.0 9.38E+16 9.44E+16 9.48E+16 9.41 E+16 9.42 E+16 9.41 E+16 9.42E+16 9.36E+16 9.56E+I6
480 31.0 1.32E+17 1.33E+17 1.34E+17 1.33E+17 1.33 E+17 1.33E+17 1.33E+17 1.32E+17 1.35E+I7
500 3.0 1.34E+16 1.34E+16 1.35E+16 1.34E+16 1.34E+16 1.34E+16 1.34E+16 I.33E+16 1.36E+16
500 6.5 2.90E+16 2.91 E+16 2.92E+16 2.90E+16 2.91E+16 2.90E+16 2.91E+16 2.88E+16 2.94E+16
500 13.0 5.81E+16 5.82E+16 5.85E+16 5.81 E+16 5.82 E+16 5.80E+16 5.82E+16 5.76E+16 5.89E+16
500 18.0 8.04E+16 8.06E+16 8.10E+16 8.04E+I6 8.05E+16 8.03 E+16 8.05E+I6 7.98E+16 8.15E+16
500 26.0 1.16E+17 1.16E+17 1.17E+17 1.16E+I7 1.16E+17 1.16E+17 1.16E+17 1.15E+17 1.18E+17
500 30.0 1.34E+17 1.34E+17 1.35E+17 1.34E+17 1.34E+17 1.34E+17 1.34E+17 1.33E+17 1.36E+17
530 0.7 3.30E+15 3.32E+15 3.32E+15 3.31 E+15 3.30E+15 2.90E+15 3.25E+I5 3.78E+15 3.36E+15
530 1.8 8.49E+15 8.54E+15 8.55E+15 8.51 E+15 8.50E+15 7.45E+15 8.36E+15 9.72E+15 8.64E+15
530 3.3 1.53 E+16 1.54E+16 1.54E+16 1.54E+16 1.53E+16 1.35E+16 1.51E+16 1.76E+16 1.56E+16
530 4.1 1.93E+16 1.95E+16 1.95E+16 1.94E+16 1.94 E+16 1.70E+16 1.90E+16 2.21 E+16 1.97E+16
530 7.0 3.30E+16 3.32E+16 3.32E+16 3.31 E+16 3.30E+16 2.90E+16 3.25E+16 3.78E+16 3.36E+16
530 15.7 7.40E+16 7.45E+16 7.46E+16 7.42E+16 7.41 E+16 6.50E+16 7.29E+16 8.48E+16 7.54E+16
530 27.0 1.27E+17 1.28E+17 1.28E+17 1.28E+17 1.27E+17 1.12E+17 1.25E+17 1.46E+17 1.30E+17
530 41.0 1.93E+17 1.95E+17 1.95E+17 1.94E+17 1.94E+17 1.70E+17 1.90E+17 2.21 E+17 1.97E+17
530 65.0 3.06E+17 3.08E+17 3.09E+17 3.07E+17 3.07E+17 2.69E+17 3.02E+17 3.51E+17 3.12E+17
560 7.2 3.58E+16 3.57E+16 3.60E+16 3.58E+16 3.57E+16 3.57E+16 3.57E+16 3.57E+16 3.65E+16
560 13.6 6.76E+16 6.74E+16 6.80E+16 6.76E+16 6.75E+16 6.75E+16 6.75E+16 6.74E+16 6.90E+16
560 26.0 1.29E+17 1.29E+17 1.30E+17 1.29E+17 1.29E+17 1.29E+17 1.29E+17 1.29E+17 1.32E+17
560 52.0 2.58E+17 2.58E+17 2.60E+17 2.58E+17 2.58E+17 2.58E+17 2.58 E+17 2.58E+17 2.64E+17
560 65.0 3.23E+17 3.22E+17 3.25E+17 3.23E+17 3.23E+17 3.23E+17 3.23 E+17 3.22E+17 3.30E+17
The table shows all the possible combinations of light boxes and spheres (A-D for 
light boxes and A and B for spheres) together with the corresponding photons/cm^ 
for each irradiance at each wavelength. The photon number using the Ealing spectral 
transmission data are shown in the last column ‘previous’. The bold figures are the 
actual values used. _ . ^
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